assets/trials.csv

DOI,Journal,Year,Therapeutic Area,Phase,Paper Title
10.1056_nejmoa2511478,NEJM,2026,Cardiovascular,Phase 3,Randomized Trial of Adjunctive Prednisolone for Kawasaki Disease
10.1056_nejmoa2505665,NEJM,2026,Infectious Disease,Phase 2,"Immunogenicity and Safety of vYF, a Yellow Fever Vaccine - A Phase 2 Trial"
10.1056_nejmoa2513120,NEJM,2026,Hematology,Phase 2,A Phase 2 Randomized Trial of Mezagitamab in Primary Immune Thrombocytopenia
10.1056_nejmoa2507874,NEJM,2026,Oncology,Phase 3,Atezolizumab plus FOLFOX for Stage III Mismatch Repair-Deficient Colon Cancer
10.1056_nejmoa2511882,NEJM,2026,Oncology,Phase 3,Romiplostim versus Placebo for Chemotherapy-Induced Thrombocytopenia
10.1056_nejmoa2407326,NEJM,2026,Neurology,Phase 1/2,An Antibody-Oligonucleotide Conjugate for Myotonic Dystrophy Type 1
10.1056_nejmoa2511218,NEJM,2026,Oncology,Phase 3,"Palbociclib for Hormone-Receptor-Positive, HER2-Positive Advanced Breast Cancer"
10.1056_nejmoa2504546,NEJM,2026,Neurology,Phase 3,Fremanezumab in Children and Adolescents with Episodic Migraine
10.1056_nejmoa2511420,NEJM,2026,Respiratory,Phase 4,Ketamine or Etomidate for Tracheal Intubation of Critically Ill Adults
10.1056_nejmoa2509766,NEJM,2026,Cardiovascular,nan,Transcatheter or Surgical Aortic-Valve Replacement in Low-Risk Patients at 7 Years
10.1056_nejmoa2510310,NEJM,2026,Oncology,Phase 3,Improved Survival with Enzalutamide in Biochemically Recurrent Prostate Cancer
10.1056_nejmoa2504966,NEJM,2026,Oncology,Phase 3,Nivolumab for Resected Stage III or IV Melanoma at 9 Years
10.1056_nejmoa2510308,NEJM,2026,Oncology,Phase 3,Survival with Osimertinib plus Chemotherapy in <i>EGFR</i>-Mutated Advanced NSCLC
10.1056_nejmoa2501510,NEJM,2025,Nephrology/Urology,Phase 3,Trial of Pegcetacoplan in C3 Glomerulopathy and Immune-Complex MPGN
10.1056_nejmoa2500179,NEJM,2025,Infectious Disease,Phase 2,Daily Mosnodenvir as Dengue Prophylaxis in a Controlled Human Infection Model
10.1056_nejmoa2503385,NEJM,2025,Rheumatology/Immunology,nan,A Randomized Trial of Physical Therapy for Meniscal Tear and Knee Pain
10.1056_nejmoa2504644,NEJM,2025,Infectious Disease,Phase 3,Mass Administration of Azithromycin to Infants in Mali to Reduce Mortality
10.1056_nejmoa2501069,NEJM,2025,Infectious Disease,nan,Randomized Trial of Targeted Indoor Spraying to Prevent Aedes-Borne Diseases
10.1056_nejmoa2508170,NEJM,2025,Cardiovascular,Phase 3,Sotatercept for Pulmonary Arterial Hypertension within the First Year after Diagnosis
10.1056_nejmoa2502984,NEJM,2025,Infectious Disease,Phase 2/3,Clesrovimab for Prevention of RSV Disease in Healthy Infants
10.1056_nejmoa2504650,NEJM,2025,Oncology,Phase 3,Low-Dose Aspirin for PI3K-Altered Localized Colorectal Cancer
10.1056_nejmoa2500969,NEJM,2025,Endocrinology/Metabolism,Phase 3,Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity
10.1056_nejmoa2503001,NEJM,2025,Oncology,Phase 3,Overall Survival with Amivantamab-Lazertinib in <i>EGFR</i>-Mutated Advanced NSCLC
10.1056_nejmoa2509958,NEJM,2025,Cardiovascular,nan,Home-Based Care for Hypertension in Rural South Africa
10.1056_nejmoa2509426,NEJM,2025,Respiratory,Phase 4,Apixaban for Extended Treatment of Provoked Venous Thromboembolism
10.1056_nejmoa2410542,NEJM,2025,Respiratory,Phase 3,Phase 3 Trial of Inhaled Molgramostim in Autoimmune Pulmonary Alveolar Proteinosis
10.1056_nejmoa2505669,NEJM,2025,Endocrinology/Metabolism,Phase 3,"Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes"
10.1056_nejmoa2415434,NEJM,2025,Oncology,Phase 3,Neoadjuvant and Adjuvant Pembrolizumab in Locally Advanced Head and Neck Cancer
10.1056_nejmoa2505708,NEJM,2025,Respiratory,nan,Proportional-Assist Ventilation for Minimizing the Duration of Mechanical Ventilation
10.1056_nejmoa2502099,NEJM,2025,Oncology,Phase 3,Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy
10.1056_nejmoa2505725,NEJM,2025,Oncology,Phase 3,"Vepdegestrant, a PROTAC Estrogen Receptor Degrader, in Advanced Breast Cancer"
10.1056_nejmoa2502931,NEJM,2025,Oncology,Phase 3,Overall Survival with Neoadjuvant Nivolumab plus Chemotherapy in Lung Cancer
10.1056_nejmoa2501796,NEJM,2025,Oncology,Phase 2/3,Overall Survival with Inavolisib in <i>PIK3CA</i>-Mutated Advanced Breast Cancer
10.1056_nejmoa2415566,NEJM,2025,Oncology,Phase 3,Elinzanetant for Vasomotor Symptoms from Endocrine Therapy for Breast Cancer
10.1056_nejmoa2502760,NEJM,2025,Oncology,nan,Structured Exercise after Adjuvant Chemotherapy for Colon Cancer
10.1056_nejmoa2504544,NEJM,2025,Respiratory,Phase 3,As-Needed Albuterol-Budesonide in Mild Asthma
10.1056_nejmoa2503643,NEJM,2025,Respiratory,Phase 3,Nerandomilast in Patients with Progressive Pulmonary Fibrosis
10.1056_nejmoa2414108,NEJM,2025,Respiratory,Phase 3,Nerandomilast in Patients with Idiopathic Pulmonary Fibrosis
10.1056_nejmoa2405847,NEJM,2025,Rheumatology/Immunology,Phase 2,"Oveporexton, an Oral Orexin Receptor 2-Selective Agonist, in Narcolepsy Type 1"
10.1056_nejmoa2415820,NEJM,2025,Cardiovascular,Phase 3,Safety and Efficacy of Obicetrapib in Patients at High Cardiovascular Risk
10.1056_nejmoa2412381,NEJM,2025,Infectious Disease,Phase 2,BCG Revaccination for the Prevention of &lt;i&gt;Mycobacterium tuberculosis&lt;/i&gt; Infection
10.1056_nejmoa2413181,NEJM,2025,Respiratory,Phase 3,Mepolizumab to Prevent Exacerbations of COPD with an Eosinophilic Phenotype
10.1056_nejmoa2413156,NEJM,2025,Infectious Disease,Phase 3,Efficacy of Baloxavir Treatment in Preventing Transmission of Influenza
10.1056_nejmoa2411664,NEJM,2025,Respiratory,Phase 3,Phase 3 Trial of the DPP-1 Inhibitor Brensocatib in Bronchiectasis
10.1056_nejmoa2412439,NEJM,2025,Infectious Disease,Phase 2,Tecovirimat for Clade I MPXV Infection in the Democratic Republic of Congo
10.1056_nejmoa2415988,NEJM,2025,Neurology,Phase 3,Tolebrutinib in Nonrelapsing Secondary Progressive Multiple Sclerosis
10.1056_nejmoa2415985,NEJM,2025,Neurology,Phase 3,Tolebrutinib versus Teriflunomide in Relapsing Multiple Sclerosis
10.1056_nejmoa2501561,NEJM,2025,Other,Phase 3,A Phase 3 Trial of Inebilizumab in Generalized Myasthenia Gravis
10.1056_nejmoa2413449,NEJM,2025,Cardiovascular,Phase 3,A Phase 3 Trial of Upadacitinib for Giant-Cell Arteritis
10.1056_nejmoa2415160,NEJM,2025,Cardiovascular,Phase 3,Sotatercept in Patients with Pulmonary Arterial Hypertension at High Risk for Death
10.1056_nejmoa2415818,NEJM,2025,Cardiovascular,Phase 2,Lepodisiran - A Long-Duration Small Interfering RNA Targeting Lipoprotein(a)
10.1056_nejmoa2501006,NEJM,2025,Cardiovascular,Phase 3,Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes
10.1056_nejmoa2500366,NEJM,2025,Cardiovascular,Phase 4,Dapagliflozin in Patients Undergoing Transcatheter Aortic-Valve Implantation
10.1056_nejmoa2414482,NEJM,2025,Other,Phase 3,Tezepelumab in Adults with Severe Chronic Rhinosinusitis with Nasal Polyps
10.1056_nejmoa2415948,NEJM,2025,Endocrinology/Metabolism,nan,A Randomized Trial of Automated Insulin Delivery in Type 2 Diabetes
10.1056_nejmoa2408792,NEJM,2025,Dermatology,Phase 3,Remibrutinib in Chronic Spontaneous Urticaria
10.1056_nejmoa2410965,NEJM,2025,Infectious Disease,Phase 3,Efficacy and Safety of Obinutuzumab in Active Lupus Nephritis
10.1056_nejmoa2406674,NEJM,2025,Cardiovascular,Phase 2,Abelacimab versus Rivaroxaban in Patients with Atrial Fibrillation
10.1056_nejmoa2406070,NEJM,2025,Oncology,Phase 3,Survival with Trastuzumab Emtansine in Residual HER2-Positive Breast Cancer
10.1056_nejmoa2410858,NEJM,2025,Oncology,Phase 3,Imlunestrant with or without Abemaciclib in Advanced Breast Cancer
10.1056_nejmoa2409029,NEJM,2025,Oncology,Phase 3,Daratumumab or Active Monitoring for High-Risk Smoldering Multiple Myeloma
10.1056_nejmoa2411858,NEJM,2025,Infectious Disease,Phase 3,Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons
10.1056_nejmoa2410027,NEJM,2025,Cardiovascular,Phase 3,Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity
10.1056_nejmoa2409712,NEJM,2025,Other,Phase 3,Inebilizumab for Treatment of IgG4-Related Disease
10.1056_nejmoa2410819,NEJM,2025,Endocrinology/Metabolism,Phase 3,Tirzepatide for Obesity Treatment and Diabetes Prevention
10.1056_nejmoa2409183,NEJM,2025,Cardiovascular,Phase 3,Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease
10.1056_nejmoa2403991,NEJM,2025,Oncology,Phase 3,Phase 3 Trial of Cabozantinib to Treat Advanced Neuroendocrine Tumors
10.1056_nejmoa2409368,NEJM,2025,Gastroenterology/Hepatology,Phase 3,Plozasiran for Managing Persistent Chylomicronemia and Pancreatitis Risk
10.1056_nejmoa2409134,NEJM,2025,Cardiovascular,Phase 3,Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy
10.1056_nejmoa2405485,NEJM,2024,Infectious Disease,Phase 2,Xalnesiran with or without an Immunomodulator in Chronic Hepatitis B
10.1056_nejmoa2402141,NEJM,2024,Oncology,Phase 3,Nivolumab plus Ipilimumab in Microsatellite-Instability-High Metastatic Colorectal Cancer
10.1056_nejmoa2401497,NEJM,2024,Oncology,nan,Standard or Extended Lymphadenectomy for Muscle-Invasive Bladder Cancer
10.1056_nejmoa2401201,NEJM,2024,Other,nan,Middle Meningeal Artery Embolization for Nonacute Subdural Hematoma
10.1056_nejmoa2400141,NEJM,2024,Rheumatology/Immunology,nan,Total Hip Replacement or Resistance Training for Severe Hip Osteoarthritis
10.1056_nejmoa2404625,NEJM,2024,Oncology,Phase 2/3,Inavolisib-Based Therapy in &lt;i&gt;PIK3CA&lt;/i&gt;-Mutated Advanced Breast Cancer
10.1056_nejmoa2403664,NEJM,2024,Endocrinology/Metabolism,Phase 3,Once-Weekly Semaglutide in Persons with Obesity and Knee Osteoarthritis
10.1056_nejmoa2405888,NEJM,2024,Oncology,Phase 3,Nivolumab+AVD in Advanced-Stage Classic Hodgkin's Lymphoma
10.1056_nejmoa2314076,NEJM,2024,Oncology,Phase 2,Phase 2 Trial of Anti-TL1A Monoclonal Antibody Tulisokibart for Ulcerative Colitis
10.1056_nejmoa2312749,NEJM,2024,Other,Phase 2,Pomalidomide for Epistaxis in Hereditary Hemorrhagic Telangiectasia
10.1056_nejmoa2401537,NEJM,2024,Hematology,Phase 2,Axatilimab in Recurrent or Refractory Chronic Graft-versus-Host Disease
10.1056_nejmoa2408154,NEJM,2024,Oncology,Phase 3,Perioperative Durvalumab with Neoadjuvant Chemotherapy in Operable Bladder Cancer
10.1056_nejmoa2409515,NEJM,2024,Oncology,Phase 2,Ponsegromab for the Treatment of Cancer Cachexia
10.1056_nejmoa2407086,NEJM,2024,Oncology,Phase 3,Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer
10.1056_nejmoa2404873,NEJM,2024,Oncology,Phase 3,Durvalumab after Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer
10.1056_nejmoa2402638,NEJM,2024,Respiratory,Phase 4,Long-Term Oxygen Therapy for 24 or 15 Hours per Day in Severe Hypoxemia
10.1056_nejmoa2406673,NEJM,2024,Respiratory,Phase 3,Twice-Yearly Depemokimab in Severe Asthma with an Eosinophilic Phenotype
10.1056_nejmoa2314779,NEJM,2024,Cardiovascular,Phase 3,Adjunctive Intravenous Argatroban or Eptifibatide for Ischemic Stroke
10.1056_nejmoa2314577,NEJM,2024,Neurology,Phase 2,A Monoclonal Antibody to PACAP for Migraine Prevention
10.1056_nejmoa2407107,NEJM,2024,Cardiovascular,Phase 3,Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction
10.1056_nejmoa2313906,NEJM,2024,Oncology,Phase 3,Belzutifan versus Everolimus for Advanced Renal-Cell Carcinoma
10.1056_nejmoa2312093,NEJM,2024,Infectious Disease,Phase 4,Azithromycin to Reduce Mortality - An Adaptive Cluster-Randomized Trial
10.1056_nejmoa2312948,NEJM,2024,Oncology,Phase 3,Blinatumomab for MRD-Negative Acute Lymphoblastic Leukemia in Adults
10.1056_nejmoa2407001,NEJM,2024,Infectious Disease,Phase 3,Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women
10.1056_nejmoa2309002,NEJM,2024,Infectious Disease,Phase 2/3,Oral Nirmatrelvir-Ritonavir as Postexposure Prophylaxis for Covid-19
10.1056_nejmoa2313811,NEJM,2024,Oncology,Phase 3,Tisotumab Vedotin as Second- or Third-Line Therapy for Recurrent Cervical Cancer
10.1056_nejmoa2403614,NEJM,2024,Oncology,Phase 3,Amivantamab plus Lazertinib in Previously Untreated <i>EGFR</i>-Mutated Advanced NSCLC
10.1056_nejmoa2313318,NEJM,2024,Gastroenterology/Hepatology,Phase 3,Eosinophil Depletion with Benralizumab for Eosinophilic Esophagitis
10.1056_nejmoa2312282,NEJM,2024,Gastroenterology/Hepatology,Phase 3,Dupilumab for Eosinophilic Esophagitis in Patients 1 to 11 Years of Age
10.1056_nejmoa2404881,NEJM,2024,Respiratory,Phase 3,Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity
10.1056_nejmoa2404139,NEJM,2024,Oncology,Phase 3,Final Results for Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma
10.1056_nejmoa2401177,NEJM,2024,Infectious Disease,nan,Community-Based Cluster-Randomized Trial to Reduce Opioid Overdose Deaths
10.1056_nejmoa2404245,NEJM,2024,Infectious Disease,Phase 3,Stress Ulcer Prophylaxis during Invasive Mechanical Ventilation
10.1056_nejmoa2313680,NEJM,2024,Respiratory,nan,Noninvasive Ventilation for Preoxygenation during Emergency Intubation
10.1056_nejmoa2401943,NEJM,2024,Infectious Disease,Phase 2,Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis
10.1056_nejmoa2401755,NEJM,2024,Infectious Disease,Phase 2,A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis
10.1056_nejmoa2314134,NEJM,2024,Infectious Disease,Phase 2,Bulevirtide Combined with Pegylated Interferon for Chronic Hepatitis D
10.1056_nejmoa2404656,NEJM,2024,Neurology,Phase 3,Phase 3 Trial of Crinecerfont in Adult Congenital Adrenal Hyperplasia
10.1056_nejmoa2403407,NEJM,2024,Oncology,Phase 3,"Belantamab Mafodotin, Pomalidomide, and Dexamethasone in Multiple Myeloma"
10.1056_nejmoa2402614,NEJM,2024,Oncology,Phase 3,Osimertinib after Chemoradiotherapy in Stage III &lt;i&gt;EGFR&lt;/i&gt;-Mutated NSCLC
10.1056_nejmoa2404655,NEJM,2024,Neurology,Phase 3,Phase 3 Trial of Crinecerfont in Pediatric Congenital Adrenal Hyperplasia
10.1056_nejmoa2405090,NEJM,2024,Oncology,Phase 3,"Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma"
10.1056_nejmoa2400858,NEJM,2024,Oncology,Phase 3,Asciminib in Newly Diagnosed Chronic Myeloid Leukemia
10.1056_nejmoa2314192,NEJM,2024,Other,Phase 3,Oral Sebetralstat for On-Demand Treatment of Hereditary Angioedema Attacks
10.1056_nejmoa2402478,NEJM,2024,Pediatrics,Phase 3,Efficacy and Safety of Donidalorsen for Hereditary Angioedema
10.1056_nejmoa2404147,NEJM,2024,Endocrinology/Metabolism,Phase 2,"Zodasiran, an RNAi Therapeutic Targeting ANGPTL3, for Mixed Hyperlipidemia"
10.1056_nejmoa2404143,NEJM,2024,Endocrinology/Metabolism,Phase 2,"Plozasiran, an RNA Interference Agent Targeting APOC3, for Mixed Hyperlipidemia"
10.1056_nejmoa2403347,NEJM,2024,Cardiovascular,Phase 3,Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes
10.1056_nejmoa2401304,NEJM,2024,Respiratory,Phase 3,Dupilumab for COPD with Blood Eosinophil Evidence of Type 2 Inflammation
10.1056_nejmoa2311926,NEJM,2024,Oncology,Phase 3,Perioperative Nivolumab in Resectable Lung Cancer
10.1056_nejmoa2313040,NEJM,2024,Cardiovascular,Phase 4,Andexanet for Factor Xa Inhibitor-Associated Acute Intracerebral Hemorrhage
10.1056_nejmoa2401424,NEJM,2024,Cardiovascular,Phase 3,Aficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy
10.1056_nejmoa2314793,NEJM,2024,Pediatrics,Phase 3,Recombinant ADAMTS13 in Congenital Thrombotic Thrombocytopenic Purpura
10.1056_nejmoa2312775,NEJM,2024,Infectious Disease,Phase 2,Subcutaneous Administration of a Monoclonal Antibody to Prevent Malaria
10.1056_nejmoa2312695,NEJM,2024,Oncology,Phase 3,Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma
10.1056_nejmoa2310532,NEJM,2024,Oncology,Phase 3,Alectinib in Resected <i>ALK</i>-Positive Non-Small-Cell Lung Cancer
10.1056_nejmoa2311708,NEJM,2024,Cardiovascular,nan,Pragmatic Trial of Hospitalization Rate in Chronic Kidney Disease
10.1056_nejmoa2309003,NEJM,2024,Infectious Disease,Phase 2/3,Nirmatrelvir for Vaccinated or Unvaccinated Adult Outpatients with Covid-19
10.1056_nejmoa2312573,NEJM,2024,Cardiovascular,nan,Self-Expanding or Balloon-Expandable TAVR in Patients with a Small Aortic Annulus
10.1056_nejmoa2400969,NEJM,2024,Cardiovascular,Phase 3,Apolipoprotein A1 Infusions and Cardiovascular Outcomes after Acute Myocardial Infarction
10.1056_nejmoa2402309,NEJM,2024,Cardiovascular,Phase 2,Olezarsen for Hypertriglyceridemia in Patients at High Cardiovascular Risk
10.1056_nejmoa2400201,NEJM,2024,Gastroenterology/Hepatology,Phase 3,"Olezarsen, Acute Pancreatitis, and Familial Chylomicronemia Syndrome"
10.1056_nejmoa2314051,NEJM,2024,Cardiovascular,Phase 3,Empagliflozin after Acute Myocardial Infarction
10.1056_nejmoa2305478,NEJM,2024,Infectious Disease,Phase 3,RSV Prefusion F Protein-Based Maternal Vaccine - Preterm Birth and Other Outcomes
10.1056_nejmoa2312117,NEJM,2024,Oncology,Phase 3,Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer
10.1056_nejmoa2308900,NEJM,2024,Oncology,nan,Simple versus Radical Hysterectomy in Women with Low-Risk Cervical Cancer
10.1056_nejmoa2312382,NEJM,2024,Pediatrics,Phase 3,Omalizumab for the Treatment of Multiple Food Allergies
10.1056_nejmoa2311155,NEJM,2024,Rheumatology/Immunology,Phase 3,Benralizumab versus Mepolizumab for Eosinophilic Granulomatosis with Polyangiitis
10.1056_nejmoa2312100,NEJM,2024,Gastroenterology/Hepatology,Phase 3,A Phase 3 Trial of Seladelpar in Primary Biliary Cholangitis
10.1056_nejmoa2304748,NEJM,2024,Infectious Disease,Phase 3,Cefepime-Taniborbactam in Complicated Urinary Tract Infection
10.1056_nejmoa2309439,NEJM,2024,Neurology,Phase 2,Inhibition of CD40L with Frexalimab in Multiple Sclerosis
10.1056_nejmoa2310392,NEJM,2024,Cardiovascular,Phase 3,Tenecteplase for Stroke at 4.5 to 24 Hours with Perfusion-Imaging Selection
10.1056_nejmoa2308713,NEJM,2024,Dermatology,Phase 2,An Oral Interleukin-23-Receptor Antagonist Peptide for Plaque Psoriasis
10.1056_nejmoa2307679,NEJM,2024,Infectious Disease,Phase 4,Skin Antisepsis before Surgical Fixation of Extremity Fractures
10.1056_nejmoa2309495,NEJM,2024,Pediatrics,Phase 4,Azithromycin during Routine Well-Infant Visits to Prevent Death
10.1056_nejmoa2308836,NEJM,2024,Cardiovascular,Phase 4,Testosterone Treatment and Fractures in Men with Hypogonadism
10.1056_nejmoa2305434,NEJM,2024,Cardiovascular,Phase 3,Efficacy and Safety of Acoramidis in Transthyretin Amyloid Cardiomyopathy
10.1056_nejmoa2302687,NEJM,2024,Obstetrics/Gynecology,nan,Effects of Cooking with Liquefied Petroleum Gas or Biomass on Stunting in Infants
10.1056_nejmoa2305681,NEJM,2024,Infectious Disease,nan,Liquefied Petroleum Gas or Biomass Cooking and Severe Infant Pneumonia
10.1056_nejmoa2312054,NEJM,2024,Oncology,Phase 3,"Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma"
10.1056_nejmoa2306185,NEJM,2024,Gastroenterology/Hepatology,Phase 3,Efficacy and Safety of Elafibranor in Primary Biliary Cholangitis
10.1056_nejmoa2305635,NEJM,2024,Oncology,Phase 2,A Phase 2 Trial of Sibeprenlimab in Patients with IgA Nephropathy
10.1056_nejmoa2305637,NEJM,2024,Cardiovascular,nan,Drug-Eluting Resorbable Scaffold versus Angioplasty for Infrapopliteal Artery Disease
10.1056_nejmoa2309189,NEJM,2023,Infectious Disease,Phase 3,Nirsevimab for Prevention of Hospitalizations Due to RSV in Infants
10.1056_nejmoa2304007,NEJM,2023,Infectious Disease,Phase 4,Doxycycline Prophylaxis to Prevent Sexually Transmitted Infections in Women
10.1056_nejmoa2309169,NEJM,2023,Oncology,Phase 3,"Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer"
10.1056_nejmoa2305969,NEJM,2023,Cardiovascular,Phase 3,Intravenous Levothyroxine for Unstable Brain-Dead Heart Donors
10.1056_nejmoa2304430,NEJM,2023,Neurology,Phase 3,Two Phase 3 Trials of Gantenerumab in Early Alzheimer's Disease
10.1056_nejmoa2307983,NEJM,2023,Cardiovascular,Phase 3,Restrictive or Liberal Transfusion Strategy in Myocardial Infarction and Anemia
10.1056_nejmoa2307563,NEJM,2023,Cardiovascular,Phase 3,Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
10.1056_nejmoa2306434,NEJM,2023,Oncology,Phase 3,Osimertinib with or without Chemotherapy in <i>EGFR</i>-Mutated Advanced NSCLC
10.1056_nejmoa2308550,NEJM,2023,Pediatrics,Phase 3,Sparsentan versus Irbesartan in Focal Segmental Glomerulosclerosis
10.1056_nejmoa2301333,NEJM,2023,Dermatology,Phase 3,Phase 3 Trial of Nemolizumab in Patients with Prurigo Nodularis
10.1056_nejmoa2300757,NEJM,2023,Cardiovascular,Phase 3,Patisiran Treatment in Patients with Transthyretin Cardiac Amyloidosis
10.1056_nejmoa2307447,NEJM,2023,Cardiovascular,nan,Transcatheter Aortic-Valve Replacement in Low-Risk Patients at Five Years
10.1056_nejmoa2306441,NEJM,2023,Oncology,Phase 3,Amivantamab plus Chemotherapy in NSCLC with <i>EGFR</i> Exon 20 Insertions
10.1056_nejmoa2309457,NEJM,2023,Oncology,Phase 3,First-Line Selpercatinib or Chemotherapy and Pembrolizumab in <i>RET</i> Fusion-Positive NSCLC
10.1056_nejmoa2309719,NEJM,2023,Oncology,Phase 3,Phase 3 Trial of Selpercatinib in Advanced <i>RET</i>-Mutant Medullary Thyroid Cancer
10.1056_nejmoa2304753,NEJM,2023,Oncology,Phase 2,Three-Year Overall Survival with Tebentafusp in Metastatic Uveal Melanoma
10.1056_nejmoa2309863,NEJM,2023,Oncology,Phase 3,Nivolumab plus Gemcitabine-Cisplatin in Advanced Urothelial Carcinoma
10.1056_nejmoa2308849,NEJM,2023,Oncology,Phase 3,Erdafitinib or Chemotherapy in Advanced or Metastatic Urothelial Carcinoma
10.1056_nejmoa2308743,NEJM,2023,Endocrinology/Metabolism,Phase 3,Teplizumab and β-Cell Function in Newly Diagnosed Type 1 Diabetes
10.1056_nejmoa2303974,NEJM,2023,Oncology,Phase 3,Improved Outcomes with Enzalutamide in Biochemically Recurrent Prostate Cancer
10.1056_nejmoa2215254,NEJM,2023,Infectious Disease,Phase 4,Decolonization in Nursing Homes to Prevent Infection and Hospitalization
10.1056_nejmoa2304145,NEJM,2023,Psychiatry/Mental Health,Phase 3,Esketamine Nasal Spray versus Quetiapine for Treatment-Resistant Depression
10.1056_nejmoa2303452,NEJM,2023,Other,Phase 3,Sarilumab for Relapse of Polymyalgia Rheumatica during Glucocorticoid Taper
10.1056_nejmoa2300220,NEJM,2023,Infectious Disease,Phase 3,Ceftobiprole for Treatment of Complicated &lt;i&gt;Staphylococcus aureus&lt;/i&gt; Bacteremia
10.1056_nejmoa2303815,NEJM,2023,Oncology,Phase 2,Dabrafenib plus Trametinib in Pediatric Glioma with <i>BRAF</i> V600 Mutations
10.1056_nejmoa2209421,NEJM,2023,Infectious Disease,Phase 3,Inhaled Fluticasone Furoate for Outpatient Treatment of Covid-19
10.1056_nejmoa2216455,NEJM,2023,Hematology,Phase 3,Phase 3 Trial of Concizumab in Hemophilia with Inhibitors
10.1056_nejmoa2305861,NEJM,2023,Cardiovascular,nan,Optical Coherence Tomography-Guided versus Angiography-Guided PCI
10.1056_nejmoa2304968,NEJM,2023,Cardiovascular,Phase 3,Ferric Carboxymaltose in Heart Failure with Iron Deficiency
10.1056_nejmoa2306963,NEJM,2023,Cardiovascular,Phase 3,Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity
10.1056_nejmoa2303062,NEJM,2023,Cardiovascular,Phase 3,Anticoagulation with Edoxaban in Patients with Atrial High-Rate Episodes
10.1056_nejmoa2300184,NEJM,2023,Oncology,Phase 3,Duration of Adjunctive Antidepressant Maintenance in Bipolar I Depression
10.1056_nejmoa2209870,NEJM,2023,Surgery/Critical Care,Phase 2,Selective Inhibition of Na<sub>V</sub>1.8 with VX-548 for Acute Pain
10.1056_nejmoa2301940,NEJM,2023,Gastroenterology/Hepatology,Phase 2,Oral Orexin Receptor 2 Agonist in Narcolepsy Type 1
10.1056_nejmoa2304146,NEJM,2023,Cardiovascular,Phase 3,Pitavastatin to Prevent Cardiovascular Disease in HIV Infection
10.1056_nejmoa2305032,NEJM,2023,Neurology,Phase 3,Trial of Solanezumab in Preclinical Alzheimer's Disease
10.1056_nejmoa2207940,NEJM,2023,Infectious Disease,Phase 3,Mirikizumab as Induction and Maintenance Therapy for Ulcerative Colitis
10.1056_nejmoa2301972,NEJM,2023,Endocrinology/Metabolism,Phase 2,Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial
10.1056_nejmoa2303208,NEJM,2023,Endocrinology/Metabolism,Phase 3,Weekly Icodec versus Daily Glargine U100 in Type 2 Diabetes without Previous Insulin
10.1056_nejmoa2304286,NEJM,2023,Infectious Disease,Phase 2,"Randomized, Controlled Trial of the FGF21 Analogue Pegozafermin in NASH"
10.1056_nejmoa2302392,NEJM,2023,Endocrinology/Metabolism,Phase 2,Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity
10.1056_nejmoa2213429,NEJM,2023,Infectious Disease,Phase 3,"A Phase 3, Randomized Trial of Bulevirtide in Chronic Hepatitis D"
10.1056_nejmoa2215943,NEJM,2023,Oncology,Phase 3,Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis
10.1056_nejmoa2301601,NEJM,2023,Respiratory,nan,Video versus Direct Laryngoscopy for Tracheal Intubation of Critically Ill Adults
10.1056_nejmoa2215025,NEJM,2023,Cardiovascular,Phase 4,Cardiovascular Safety of Testosterone-Replacement Therapy
10.1056_nejmoa2212438,NEJM,2023,Other,nan,Transplantation Outcomes with Donor Hearts after Circulatory Death
10.1056_nejmoa2304594,NEJM,2023,Oncology,Phase 3,Overall Survival with Osimertinib in Resected <i>EGFR</i>-Mutated NSCLC
10.1056_nejmoa2303269,NEJM,2023,Oncology,Phase 2/3,Preoperative Treatment of Locally Advanced Rectal Cancer
10.1056_nejmoa2301665,NEJM,2023,Oncology,Phase 3,Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma
10.1056_nejmoa2303951,NEJM,2023,Respiratory,Phase 3,Dupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil Counts
10.1056_nejmoa2304194,NEJM,2023,Oncology,Phase 3,Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma
10.1056_nejmoa2302983,NEJM,2023,Oncology,Phase 3,Perioperative Pembrolizumab for Early-Stage Non-Small-Cell Lung Cancer
10.1056_nejmoa2303379,NEJM,2023,Oncology,Phase 3,Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma
10.1056_nejmoa2214131,NEJM,2023,Oncology,Phase 3,Capivasertib in Hormone Receptor-Positive Advanced Breast Cancer
10.1056_nejmoa2302399,NEJM,2023,Psychiatry/Mental Health,Phase 2/3,Ketamine versus ECT for Nonpsychotic Treatment-Resistant Major Depression
10.1056_nejmoa2212728,NEJM,2023,Gastroenterology/Hepatology,Phase 3,Upadacitinib Induction and Maintenance Therapy for Crohn's Disease
10.1056_nejmoa2209856,NEJM,2023,Rheumatology/Immunology,Phase 2,A Phase 2 Trial of Peresolimab for Adults with Rheumatoid Arthritis
10.1056_nejmoa2212851,NEJM,2023,Oncology,Phase 3,Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma
10.1056_nejmoa2212895,NEJM,2023,Pediatrics,Phase 3,Phase 3 Trial of Epicutaneous Immunotherapy in Toddlers with Peanut Allergy
10.1056_nejmoa2303966,NEJM,2023,Obstetrics/Gynecology,nan,Randomized Trial of Early Detection and Treatment of Postpartum Hemorrhage
10.1056_nejmoa2214963,NEJM,2023,Oncology,Phase 3,Trifluridine-Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer
10.1056_nejmoa2214470,NEJM,2023,Rheumatology/Immunology,nan,"Eat, Sleep, Console Approach or Usual Care for Neonatal Opioid Withdrawal"
10.1056_nejmoa2208754,NEJM,2023,Dermatology,Phase 2,Dersimelagon in Erythropoietic Protoporphyrias
10.1056_nejmoa2207419,NEJM,2023,Gastroenterology/Hepatology,Phase 3,Tranexamic Acid to Prevent Obstetrical Hemorrhage after Cesarean Delivery
10.1056_nejmoa2211934,NEJM,2023,Infectious Disease,Phase 4,Postexposure Doxycycline to Prevent Bacterial Sexually Transmitted Infections
10.1056_nejmoa2216480,NEJM,2023,Infectious Disease,Phase 3,Bivalent Prefusion F Vaccine in Pregnancy to Prevent RSV Illness in Infants
10.1056_nejmoa2208450,NEJM,2023,Infectious Disease,Phase 4,Vedolizumab for the Treatment of Chronic Pouchitis
10.1056_nejmoa2302312,NEJM,2023,Oncology,Phase 3,Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer
10.1056_nejmoa2215145,NEJM,2023,Infectious Disease,Phase 3,Hydrocortisone in Severe Community-Acquired Pneumonia
10.1056_nejmoa2206714,NEJM,2023,Dermatology,Phase 3,Two Phase 3 Trials of Lebrikizumab for Moderate-to-Severe Atopic Dermatitis
10.1056_nejmoa2210834,NEJM,2023,Endocrinology/Metabolism,nan,Trial of Hybrid Closed-Loop Control in Young Children with Type 1 Diabetes
10.1056_nejmoa2210140,NEJM,2023,Oncology,Phase 3,"Nirogacestat, a γ-Secretase Inhibitor for Desmoid Tumors"
10.1056_nejmoa2213558,NEJM,2023,Cardiovascular,Phase 3,Phase 3 Trial of Sotatercept for Treatment of Pulmonary Arterial Hypertension
10.1056_nejmoa2300213,NEJM,2023,Cardiovascular,nan,Five-Year Follow-up after Transcatheter Repair of Secondary Mitral Regurgitation
10.1056_nejmoa2300525,NEJM,2023,Cardiovascular,nan,Transcatheter Repair for Patients with Tricuspid Regurgitation
10.1056_nejmoa2215024,NEJM,2023,Cardiovascular,Phase 3,Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients
10.1056_nejmoa2204462,NEJM,2023,Psychiatry/Mental Health,Phase 4,Antidepressant Augmentation versus Switch in Treatment-Resistant Geriatric Depression
10.1056_nejmoa2211437,NEJM,2023,Oncology,Phase 2,Neoadjuvant-Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma
10.1056_nejmoa2209275,NEJM,2023,Nephrology/Urology,Phase 3,Hydrochlorothiazide and Prevention of Kidney-Stone Recurrence
10.1056_nejmoa2214676,NEJM,2023,Oncology,Phase 3,Rucaparib or Physician's Choice in Metastatic Prostate Cancer
10.1056_nejmoa2207566,NEJM,2023,Infectious Disease,Phase 2,Efficacy and Safety of an Ad26.RSV.preF-RSV preF Protein Vaccine in Older Adults
10.1056_nejmoa2209604,NEJM,2023,Infectious Disease,Phase 3,Respiratory Syncytial Virus Prefusion F Protein Vaccine in Older Adults
10.1056_nejmoa2214403,NEJM,2023,Cardiovascular,nan,Trial of Endovascular Thrombectomy for Large Ischemic Strokes
10.1056_nejmoa2212111,NEJM,2023,Infectious Disease,Phase 3,Azithromycin to Prevent Sepsis or Death in Women Planning a Vaginal Birth
10.1056_nejmoa2212663,NEJM,2023,Infectious Disease,Phase 3,Early Restrictive or Liberal Fluid Management for Sepsis-Induced Hypotension
10.1056_nejmoa2213082,NEJM,2023,Infectious Disease,Phase 3,Bivalent Omicron BA.1-Adapted BNT162b2 Booster in Adults Older than 55 Years
10.1056_nejmoa2205973,NEJM,2023,Respiratory,Phase 3,Aspirin or Low-Molecular-Weight Heparin for Thromboprophylaxis after a Fracture
10.1056_nejmoa2211582,NEJM,2023,Oncology,Phase 3,Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia
10.1056_nejmoa2213169,NEJM,2023,Cardiovascular,Phase 2,Phase 2 Trial of Baxdrostat for Treatment-Resistant Hypertension
10.1056_nejmoa2204233,NEJM,2023,Cardiovascular,Phase 3,Empagliflozin in Patients with Chronic Kidney Disease
10.1056_nejmoa2206663,NEJM,2022,Other,Phase 3,Trial of Beremagene Geperpavec (B-VEC) for Dystrophic Epidermolysis Bullosa
10.1056_nejmoa2200072,NEJM,2022,Infectious Disease,Phase 2,Randomized Trial of Vaccines for Zaire Ebola Virus Disease
10.1056_nejmoa2212270,NEJM,2022,Cardiovascular,Phase 3,Chlorthalidone vs. Hydrochlorothiazide for Hypertension-Cardiovascular Events
10.1056_nejmoa2204783,NEJM,2022,Psychiatry/Mental Health,nan,Trial of Training to Reduce Driver Inattention in Teens with ADHD
10.1056_nejmoa2210027,NEJM,2022,Infectious Disease,Phase 2,Efficacy and Safety of Bepirovirsen in Chronic Hepatitis B Infection
10.1056_nejmoa2211023,NEJM,2022,Cardiovascular,Phase 2,Small Interfering RNA to Reduce Lipoprotein(a) in Cardiovascular Disease
10.1056_nejmoa2207304,NEJM,2022,Surgery/Critical Care,nan,Defibrillation Strategies for Refractory Ventricular Fibrillation
10.1056_nejmoa2212667,NEJM,2022,Pediatrics,Phase 3,"Methylprednisolone for Heart Surgery in Infants - A Randomized, Controlled Trial"
10.1056_nejmoa2210645,NEJM,2022,Cardiovascular,Phase 3,Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk
10.1056_nejmoa2206660,NEJM,2022,Oncology,Phase 3,Brentuximab Vedotin with Chemotherapy in Pediatric High-Risk Hodgkin's Lymphoma
10.1056_nejmoa2206443,NEJM,2022,Psychiatry/Mental Health,Phase 2,Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression
10.1056_nejmoa2208601,NEJM,2022,Endocrinology/Metabolism,Phase 3,Once-Weekly Semaglutide in Adolescents with Obesity
10.1056_nejmoa2206966,NEJM,2022,Infectious Disease,Phase 2,Safety and Efficacy of a Monoclonal Antibody against Malaria in Mali
10.1056_nejmoa2208415,NEJM,2022,Respiratory,nan,Oxygen-Saturation Targets for Critically Ill Adults Receiving Mechanical Ventilation
10.1056_nejmoa2209367,NEJM,2022,Infectious Disease,Phase 2/3,Evaluation of mRNA-1273 Vaccine in Children 6 Months to 5 Years of Age
10.1056_nejmoa2206734,NEJM,2022,Obstetrics/Gynecology,nan,Liquefied Petroleum Gas or Biomass for Cooking and Effects on Birth Weight
10.1056_nejmoa2117912,NEJM,2022,Other,Phase 3,Trial of Intravenous Immune Globulin in Dermatomyositis
10.1056_nejmoa2205650,NEJM,2022,Endocrinology/Metabolism,nan,Intermittently Scanned Continuous Glucose Monitoring for Type 1 Diabetes
10.1056_nejmoa2205225,NEJM,2022,Endocrinology/Metabolism,nan,"Multicenter, Randomized Trial of a Bionic Pancreas in Type 1 Diabetes"
10.1056_nejmoa2204705,NEJM,2022,Neurology,Phase 3,Trial of Antisense Oligonucleotide Tofersen for <i>SOD1</i> ALS
10.1056_nejmoa2200436,NEJM,2022,Cardiovascular,Phase 3,Glycemia Reduction in Type 2 Diabetes - Microvascular and Cardiovascular Outcomes
10.1056_nejmoa2200433,NEJM,2022,Endocrinology/Metabolism,Phase 3,Glycemia Reduction in Type 2 Diabetes - Glycemic Outcomes
10.1056_nejmoa2204961,NEJM,2022,Cardiovascular,nan,Cerebral Embolic Protection during Transcatheter Aortic-Valve Replacement
10.1056_nejmoa2202884,NEJM,2022,Gastroenterology/Hepatology,Phase 3,Aggressive or Moderate Fluid Resuscitation in Acute Pancreatitis
10.1056_nejmoa2203364,NEJM,2022,Other,Phase 3,A Randomized Trial of Enteral Glutamine for Treatment of Burn Injuries
10.1056_nejmoa2201662,NEJM,2022,Infectious Disease,Phase 3,"Randomized Trial of Metformin, Ivermectin, and Fluvoxamine for Covid-19"
10.1056_nejmoa2118025,NEJM,2022,Rheumatology/Immunology,Phase 2,Trial of Anti-BDCA2 Antibody Litifilimab for Systemic Lupus Erythematosus
10.1056_nejmoa2204752,NEJM,2022,Infectious Disease,Phase 3,Bronchodilators in Tobacco-Exposed Persons with Symptoms and Preserved Lung Function
10.1056_nejmoa2119430,NEJM,2022,Infectious Disease,Phase 3,Bedaquiline-Pretomanid-Linezolid Regimens for Drug-Resistant Tuberculosis
10.1056_nejmoa2206286,NEJM,2022,Cardiovascular,Phase 3,Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction
10.1056_nejmoa2203094,NEJM,2022,Cardiovascular,Phase 4,Acetazolamide in Acute Decompensated Heart Failure with Volume Overload
10.1056_nejmoa2208275,NEJM,2022,Cardiovascular,Phase 3,Polypill Strategy in Secondary Cardiovascular Prevention
10.1056_nejmoa2201302,NEJM,2022,Oncology,Phase 3,Olokizumab versus Placebo or Adalimumab in Rheumatoid Arthritis
10.1056_nejmoa2201904,NEJM,2022,Neurology,Phase 3,Ublituximab versus Teriflunomide in Relapsing Multiple Sclerosis
10.1056_nejmoa2118024,NEJM,2022,Rheumatology/Immunology,Phase 2,Trial of Anti-BDCA2 Antibody Litifilimab for Cutaneous Lupus Erythematosus
10.1056_nejmoa2202867,NEJM,2022,Neurology,Phase 2,Trial of Prasinezumab in Early-Stage Parkinson's Disease
10.1056_nejmoa2203395,NEJM,2022,Neurology,Phase 2,Trial of Cinpanemab in Early Parkinson's Disease
10.1056_nejmoa2202809,NEJM,2022,Oncology,Phase 3,Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer
10.1056_nejmoa2204225,NEJM,2022,Endocrinology/Metabolism,Phase 3,Aflibercept Monotherapy or Bevacizumab First for Diabetic Macular Edema
10.1056_nejmoa2206125,NEJM,2022,Oncology,Phase 3,Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin's Lymphoma
10.1056_nejmoa2119660,NEJM,2022,Neurology,Phase 3,Trial of Erythropoietin for Hypoxic-Ischemic Encephalopathy in Newborns
10.1056_nejmoa2116154,NEJM,2022,Infectious Disease,Phase 2,Vaccine Efficacy in Adults in a Respiratory Syncytial Virus Challenge Study
10.1056_nejmoa2202707,NEJM,2022,Surgery/Critical Care,Phase 4,Restriction of Intravenous Fluid in ICU Patients with Septic Shock
10.1056_nejmoa2201048,NEJM,2022,Oncology,Phase 3,Treatment of Anal High-Grade Squamous Intraepithelial Lesions to Prevent Anal Cancer
10.1056_nejmoa2200644,NEJM,2022,Infectious Disease,Phase 3,Intravenous Vitamin C in Adults with Sepsis in the Intensive Care Unit
10.1056_nejmoa2203690,NEJM,2022,Oncology,Phase 3,Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
10.1056_nejmoa2204925,NEJM,2022,Oncology,Phase 3,"Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma"
10.1056_nejmoa2206038,NEJM,2022,Endocrinology/Metabolism,Phase 3,Tirzepatide Once Weekly for the Treatment of Obesity
10.1056_nejmoa2204601,NEJM,2022,Endocrinology/Metabolism,Phase 3,Once-Weekly Dulaglutide for the Treatment of Youths with Type 2 Diabetes
10.1056_nejmoa2201817,NEJM,2022,Oncology,Phase 3,Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell Lymphoma
10.1056_nejmoa2201737,NEJM,2022,Respiratory,Phase 2,Trial of a Preferential Phosphodiesterase 4B Inhibitor for Idiopathic Pulmonary Fibrosis
10.1056_nejmoa2203163,NEJM,2022,Respiratory,Phase 3,Albuterol-Budesonide Fixed-Dose Combination Rescue Inhaler for Asthma
10.1056_nejmoa2115542,NEJM,2022,Infectious Disease,Phase 2/3,Capsid Inhibition with Lenacapavir in Multidrug-Resistant HIV-1 Infection
10.1056_nejmoa2203315,NEJM,2022,Infectious Disease,Phase 2/3,Evaluation of mRNA-1273 Covid-19 Vaccine in Children 6 to 11 Years of Age
10.1056_nejmoa2106062,NEJM,2022,Infectious Disease,Phase 2,Prefusion F Protein-Based Respiratory Syncytial Virus Immunization in Pregnancy
10.1056_nejmoa2117344,NEJM,2022,Oncology,Phase 3,Ivosidenib and Azacitidine in <i>IDH1</i>-Mutated Acute Myeloid Leukemia
10.1056_nejmoa2116620,NEJM,2022,Infectious Disease,Phase 3,Intramuscular AZD7442 (Tixagevimab-Cilgavimab) for Prevention of Covid-19
10.1056_nejmoa2116634,NEJM,2022,Hematology,Phase 3,Mitapivat versus Placebo for Pyruvate Kinase Deficiency
10.1056_nejmoa2108447,NEJM,2022,Other,nan,Nonoperative or Surgical Treatment of Acute Achilles' Tendon Rupture
10.1056_nejmoa2202170,NEJM,2022,Oncology,Phase 3,Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer
10.1056_nejmoa2105462,NEJM,2022,Infectious Disease,Phase 3,Oral Tebipenem Pivoxil Hydrobromide in Complicated Urinary Tract Infection
10.1056_nejmoa2201295,NEJM,2022,Cardiovascular,Phase 4,Treatment for Mild Chronic Hypertension during Pregnancy
10.1056_nejmoa2119657,NEJM,2022,Infectious Disease,Phase 2,Early Outpatient Treatment for Covid-19 with Convalescent Plasma
10.1056_nejmoa2110343,NEJM,2022,Dermatology,Phase 2/3,Two Phase 3 Trials of Baricitinib for Alopecia Areata
10.1056_nejmoa2200674,NEJM,2022,Infectious Disease,Phase 3,Safety and Efficacy of a Third Dose of BNT162b2 Covid-19 Vaccine
10.1056_nejmoa2115022,NEJM,2022,Oncology,Phase 3,Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer
10.1056_nejmoa2114897,NEJM,2022,Respiratory,Phase 3,Hydrocortisone to Improve Survival without Bronchopulmonary Dysplasia
10.1056_nejmoa2106535,NEJM,2022,Rheumatology/Immunology,Phase 2,Phase 2 Trial of Iberdomide in Systemic Lupus Erythematosus
10.1056_nejmoa2109329,NEJM,2022,Other,Phase 2,Inhibition of Prekallikrein for Hereditary Angioedema
10.1056_nejmc2112186,NEJM,2022,Infectious Disease,Phase 2/3,Safety of Nirsevimab for RSV in Infants with Heart or Lung Disease or Prematurity
10.1056_nejmoa2110275,NEJM,2022,Infectious Disease,Phase 3,Nirsevimab for Prevention of RSV in Healthy Late-Preterm and Term Infants
10.1056_nejmoa2118813,NEJM,2022,Respiratory,Phase 4,Reliever-Triggered Inhaled Glucocorticoid in Black and Latinx Adults with Asthma
10.1056_nejmoa2119115,NEJM,2022,Oncology,Phase 3,"Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer"
10.1056_nejmoa2108903,NEJM,2022,Infectious Disease,Phase 2,"EDP-938, a Respiratory Syncytial Virus Inhibitor, in a Human Virus Challenge"
10.1056_nejmoa2118542,NEJM,2022,Infectious Disease,Phase 2/3,"Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19"
10.1056_nejmoa2112187,NEJM,2022,Oncology,Phase 3,Survival with Cemiplimab in Recurrent Cervical Cancer
10.1056_nejmoa2117608,NEJM,2022,Infectious Disease,Phase 3,Final Analysis of Efficacy and Safety of Single-Dose Ad26.COV2.S
10.1056_nejmoa2111380,NEJM,2022,Oncology,Phase 3,Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma
10.1056_nejmoa2109927,NEJM,2022,Oncology,Phase 4,Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis
10.1056_nejmoa2106516,NEJM,2022,Infectious Disease,Phase 3,"SER-109, an Oral Microbiome Therapy for Recurrent <i>Clostridioides difficile</i> Infection"
10.1056_nejmoa2111673,NEJM,2022,Endocrinology/Metabolism,nan,Randomized Trial of Closed-Loop Control in Very Young Children with Type 1 Diabetes
10.1056_nejmoa2108330,NEJM,2022,Oncology,Phase 3,Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer
10.1056_nejmoa2109970,NEJM,2022,Oncology,Phase 2/3,Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma
10.1056_nejmoa2116846,NEJM,2022,Infectious Disease,Phase 3,Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients
10.1056_nejmoa2116044,NEJM,2022,Infectious Disease,Phase 2/3,Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients
10.1056_nejmoa2116596,NEJM,2022,Oncology,Phase 3,Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma
10.1056_nejmoa2116133,NEJM,2022,Oncology,Phase 3,Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma
10.1056_nejmoa2115961,NEJM,2022,Surgery/Critical Care,nan,Concomitant Tricuspid Repair in Patients with Degenerative Mitral Regurgitation
10.1056_nejmoa2112299,NEJM,2022,Cardiovascular,nan,Fractional Flow Reserve-Guided PCI as Compared with Coronary Bypass Surgery
10.1056_nejmoa2108793,NEJM,2021,Infectious Disease,Phase 2/3,Dolutegravir as First- or Second-Line Treatment for HIV-1 Infection in Children
10.1056_nejmoa2105470,NEJM,2021,Infectious Disease,nan,Multicomponent Strategy with Decentralized Molecular Testing for Tuberculosis
10.1056_nejmoa2111563,NEJM,2021,Dermatology,Phase 2,Trial of Spesolimab for Generalized Pustular Psoriasis
10.1056_nejmoa2108873,NEJM,2021,Oncology,Phase 3,21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer
10.1056_nejmoa2106567,NEJM,2021,Respiratory,Phase 3,Dupilumab in Children with Uncontrolled Moderate-to-Severe Asthma
10.1056_nejmoa2103629,NEJM,2021,Neurology,Phase 3,Phase 3 Trials of Tapinarof Cream for Plaque Psoriasis
10.1056_nejmoa2104508,NEJM,2021,Cardiovascular,Phase 3,Angiotensin Receptor-Neprilysin Inhibition in Acute Myocardial Infarction
10.1056_nejmoa2110730,NEJM,2021,Cardiovascular,Phase 2,Chlorthalidone for Hypertension in Advanced Chronic Kidney Disease
10.1056_nejmoa2113380,NEJM,2021,Cardiovascular,Phase 3,Daprodustat for the Treatment of Anemia in Patients Not Undergoing Dialysis
10.1056_nejmoa2113379,NEJM,2021,Cardiovascular,Phase 3,Daprodustat for the Treatment of Anemia in Patients Undergoing Dialysis
10.1056_nejmoa2107934,NEJM,2021,Infectious Disease,Phase 2/3,Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab
10.1056_nejmoa2030880,NEJM,2021,Respiratory,Phase 2,"Risankizumab in Severe Asthma - A Phase 2a, Placebo-Controlled Trial"
10.1056_nejmoa2024257,NEJM,2021,Respiratory,Phase 2,Efficacy and Safety of Itepekimab in Patients with Moderate-to-Severe Asthma
10.1056_nejmoa2036205,NEJM,2021,Infectious Disease,Phase 2,"A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH"
10.1056_nejmoa2024848,NEJM,2021,Infectious Disease,Phase 3,Efficacy of a Cell-Culture-Derived Quadrivalent Influenza Vaccine in Children
10.1056_nejmoa2103583,NEJM,2021,Psychiatry/Mental Health,Phase 2,Intranasal Oxytocin in Children and Adolescents with Autism Spectrum Disorder
10.1056_nejmoa2113514,NEJM,2021,Surgery/Critical Care,nan,Spinal Anesthesia or General Anesthesia for Hip Surgery in Older Adults
10.1056_nejmoa2033617,NEJM,2021,Cardiovascular,Phase 3,Ozanimod as Induction and Maintenance Therapy for Ulcerative Colitis
10.1056_nejmoa2108163,NEJM,2021,Infectious Disease,Phase 3,REGEN-COV Antibody Combination and Outcomes in Outpatients with Covid-19
10.1056_nejmoa2105290,NEJM,2021,Infectious Disease,Phase 3,Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine
10.1056_nejmoa2103485,NEJM,2021,Oncology,Phase 2,Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma
10.1056_nejmoa2113017,NEJM,2021,Infectious Disease,Phase 3,Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase
10.1056_nejmoa2112435,NEJM,2021,Oncology,Phase 3,"Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer"
10.1056_nejmoa2110345,NEJM,2021,Infectious Disease,Phase 2/3,Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months
10.1056_nejmoa2107038,NEJM,2021,Cardiovascular,Phase 3,Empagliflozin in Heart Failure with a Preserved Ejection Fraction
10.1056_nejmoa2111016,NEJM,2021,Cardiovascular,Phase 3,Edoxaban versus Vitamin K Antagonist for Atrial Fibrillation after TAVR
10.1056_nejmoa2110956,NEJM,2021,Cardiovascular,Phase 3,Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes
10.1056_nejmoa2100665,NEJM,2021,Respiratory,Phase 3,Triple Therapy for Cystic Fibrosis <i>Phe508del</i>-Gating and -Residual Function Genotypes
10.1056_nejmoa2026330,NEJM,2021,Infectious Disease,Phase 3,Seasonal Malaria Vaccination with or without Seasonal Malaria Chemoprevention
10.1056_nejmoa2035908,NEJM,2021,Neurology,Phase 3,Atogepant for the Preventive Treatment of Migraine
10.1056_nejmoa2106391,NEJM,2021,Oncology,Phase 3,Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma
10.1056_nejmoa2103784,NEJM,2021,Infectious Disease,Phase 3,Early Convalescent Plasma for High-Risk Outpatients with Covid-19
10.1056_nejmoa2101016,NEJM,2021,Infectious Disease,Phase 2/3,Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women
10.1056_nejmoa2109522,NEJM,2021,Infectious Disease,Phase 2/3,Evaluation of mRNA-1273 SARS-CoV-2 Vaccine in Adolescents
10.1056_nejmoa2103417,NEJM,2021,Infectious Disease,Phase 4,Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19
10.1056_nejmoa2105911,NEJM,2021,Infectious Disease,Phase 4,Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19
10.1056_nejmoa2100990,NEJM,2021,Rheumatology/Immunology,nan,Decompression with or without Fusion in Degenerative Lumbar Spondylolisthesis
10.1056_nejmoa2109682,NEJM,2021,Infectious Disease,Phase 3,Subcutaneous REGEN-COV Antibody Combination to Prevent Covid-19
10.1056_nejmoa1913569,NEJM,2021,Infectious Disease,Phase 3,A Trial of Hyperimmune Globulin to Prevent Congenital Cytomegalovirus Infection
10.1056_nejmoa2104162,NEJM,2021,Oncology,Phase 3,Duration of Adjuvant Aromatase-Inhibitor Therapy in Postmenopausal Breast Cancer
10.1056_nejmoa2034634,NEJM,2021,Neurology,Phase 3,Trial of Pimavanserin in Dementia-Related Psychosis
10.1056_nejmoa2102685,NEJM,2021,Infectious Disease,Phase 2/3,Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19
10.1056_nejmoa2033122,NEJM,2021,Infectious Disease,Phase 3,Ruxolitinib for Glucocorticoid-Refractory Chronic Graft-versus-Host Disease
10.1056_nejmoa2108269,NEJM,2021,Cardiovascular,Phase 3,Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes
10.1056_nejmoa2028631,NEJM,2021,Other,Phase 3,Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis
10.1056_nejmoa2107519,NEJM,2021,Endocrinology/Metabolism,Phase 3,Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
10.1056_nejmoa2107322,NEJM,2021,Oncology,Phase 3,Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer
10.1056_nejmoa2030243,NEJM,2021,Infectious Disease,nan,Efficacy of Wolbachia-Infected Mosquito Deployments for the Control of Dengue
10.1056_nejmoa2028564,NEJM,2021,Other,Phase 3,Rituximab versus Mycophenolate Mofetil in Patients with Pemphigus Vulgaris
10.1056_nejmoa2105215,NEJM,2021,Oncology,Phase 3,Adjuvant Olaparib for Patients with <i>BRCA1</i>- or <i>BRCA2</i>-Mutated Breast Cancer
10.1056_nejmoa2013615,NEJM,2021,Infectious Disease,Phase 2,Meningococcal Serogroup ACWYX Conjugate Vaccine in Malian Toddlers
10.1056_nejmoa2034442,NEJM,2021,Oncology,Phase 3,Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma
10.1056_nejmoa2107456,NEJM,2021,Infectious Disease,Phase 2/3,"Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents"
10.1056_nejmoa1901281,NEJM,2021,Cardiovascular,nan,Final Report of a Trial of Intensive versus Standard Blood-Pressure Control
10.1056_nejmoa2102137,NEJM,2021,Cardiovascular,nan,Comparative Effectiveness of Aspirin Dosing in Cardiovascular Disease
10.1056_nejmoa2026141,NEJM,2021,Cardiovascular,nan,Physical Rehabilitation for Older Patients Hospitalized for Heart Failure
10.1056_nejmoa2034975,NEJM,2021,Respiratory,Phase 3,"Tezepelumab in Adults and Adolescents with Severe, Uncontrolled Asthma"
10.1056_nejmoa2027278,NEJM,2021,Infectious Disease,nan,Tympanostomy Tubes or Medical Management for Recurrent Acute Otitis Media
10.1056_nejmoa2028198,NEJM,2021,Endocrinology/Metabolism,Phase 4,"Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined"
10.1056_nejmoa2033400,NEJM,2021,Infectious Disease,Phase 3,Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis
10.1056_nejmoa2025956,NEJM,2021,Cardiovascular,Phase 3,Safety and Efficacy of Vadadustat for Anemia in Patients Undergoing Dialysis
10.1056_nejmoa2035938,NEJM,2021,Cardiovascular,Phase 3,Vadadustat in Patients with Anemia and Non-Dialysis-Dependent CKD
10.1056_nejmoa2102383,NEJM,2021,Dermatology,Phase 3,Bimekizumab versus Secukinumab in Plaque Psoriasis
10.1056_nejmoa2102388,NEJM,2021,Dermatology,Phase 3,Bimekizumab versus Adalimumab in Plaque Psoriasis
10.1056_nejmoa2101544,NEJM,2021,Infectious Disease,Phase 3,Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19
10.1056_nejmoa2028485,NEJM,2021,Oncology,Phase 3,Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer
10.1056_nejmoa2032994,NEJM,2021,Psychiatry/Mental Health,Phase 2,Trial of Psilocybin versus Escitalopram for Depression
10.1056_nejmoa2022516,NEJM,2021,Gastroenterology/Hepatology,Phase 3,Trial of Upadacitinib and Adalimumab for Psoriatic Arthritis
10.1056_nejmoa2021712,NEJM,2021,Nephrology/Urology,Phase 3,"Lumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1"
10.1056_nejmoa2024277,NEJM,2021,Cardiovascular,Phase 2,Sotatercept for the Treatment of Pulmonary Arterial Hypertension
10.1056_nejmoa2032125,NEJM,2021,Oncology,Phase 3,Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer
10.1056_nejmoa2019380,NEJM,2021,Dermatology,Phase 3,Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis
10.1056_nejmoa2031499,NEJM,2021,Infectious Disease,Phase 2/3,Vaccine Efficacy of ALVAC-HIV and Bivalent Subtype C gp120-MF59 in Adults
10.1056_nejmoa2029073,NEJM,2021,Hematology,Phase 3,Pegcetacoplan versus Eculizumab in Paroxysmal Nocturnal Hemoglobinuria
10.1056_nejmoa2031738,NEJM,2021,Infectious Disease,Phase 2,Two Randomized Trials of Neutralizing Antibodies to Prevent HIV-1 Acquisition
10.1056_nejmoa2100708,NEJM,2021,Neurology,Phase 2,Donanemab in Early Alzheimer's Disease
10.1056_nejmoa2026982,NEJM,2021,Oncology,Phase 3,Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma
10.1056_nejmoa2008290,NEJM,2021,Respiratory,Phase 3,Terlipressin plus Albumin for the Treatment of Type 1 Hepatorenal Syndrome
10.1056_nejmoa2028700,NEJM,2021,Infectious Disease,Phase 3,Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia
10.1056_nejmoa2017015,NEJM,2021,Psychiatry/Mental Health,Phase 2,Muscarinic Cholinergic Receptor Agonist and Peripheral Antagonist for Schizophrenia
10.1056_nejmoa2035716,NEJM,2021,Oncology,Phase 3,Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma
10.1056_nejmoa2008283,NEJM,2021,Oncology,Phase 3,Treatment of Uterine Fibroid Symptoms with Relugolix Combination Therapy
10.1056_nejmoa2023386,NEJM,2021,Rheumatology/Immunology,Phase 3,Avacopan for the Treatment of ANCA-Associated Vasculitis
10.1056_nejmoa2035807,NEJM,2021,Oncology,Phase 3,Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma
10.1056_nejmoa2023345,NEJM,2021,Infectious Disease,Phase 1/2,Randomized Trial of a Vaccine Regimen to Prevent Chronic HCV Infection
10.1056_nejmoa2024040,NEJM,2021,Dermatology,Phase 3,Phase 3 Trials of Tirbanibulin Ointment for Actinic Keratosis
10.1056_nejmoa2032183,NEJM,2021,Endocrinology/Metabolism,Phase 3,Once-Weekly Semaglutide in Adults with Overweight or Obesity
10.1056_nejmoa2024922,NEJM,2021,Infectious Disease,Phase 3,Dexmedetomidine or Propofol for Sedation in Mechanically Ventilated Adults with Sepsis
10.1056_nejmoa2022141,NEJM,2021,Obstetrics/Gynecology,Phase 4,Levonorgestrel vs. Copper Intrauterine Devices for Emergency Contraception
10.1056_nejmoa2020214,NEJM,2021,Other,Phase 3,Bupropion and Naltrexone in Methamphetamine Use Disorder
10.1056_nejmoa2034201,NEJM,2021,Infectious Disease,Phase 1/2,Interim Results of a Phase 1-2a Trial of Ad26.COV2.S Covid-19 Vaccine
10.1056_nejmoa2008470,NEJM,2021,Cardiovascular,Phase 2/3,Inhaled Treprostinil in Pulmonary Hypertension Due to Interstitial Lung Disease
10.1056_nejmoa2035389,NEJM,2021,Infectious Disease,Phase 3,Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
10.1056_nejmoa2030340,NEJM,2021,Infectious Disease,Phase 3,Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia
10.1056_nejmoa2035002,NEJM,2021,Infectious Disease,Phase 3,"REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19"
10.1056_nejmoa2031994,NEJM,2021,Infectious Disease,Phase 3,Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19
10.1056_nejmoa2030183,NEJM,2021,Cardiovascular,Phase 3,Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure
10.1056_nejmoa2030186,NEJM,2021,Cardiovascular,Phase 3,Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease
10.1056_nejmoa2027892,NEJM,2021,Infectious Disease,Phase 3,Phase 3 Trial of Interleukin-1 Trap Rilonacept in Recurrent Pericarditis
10.1056_nejmoa2029554,NEJM,2021,Cardiovascular,nan,Cryoballoon Ablation as Initial Therapy for Atrial Fibrillation
10.1056_nejmoa2025797,NEJM,2021,Cardiovascular,Phase 3,Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure
10.1056_nejmoa2028395,NEJM,2021,Infectious Disease,Phase 2,A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis
10.1056_nejmoa2029849,NEJM,2021,Infectious Disease,Phase 2/3,SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19
10.1056_nejmoa2020248,NEJM,2020,Respiratory,nan,Higher or Lower Hemoglobin Transfusion Thresholds for Preterm Infants
10.1056_nejmoa2004444,NEJM,2020,Oncology,Phase 3,Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission
10.1056_nejmoa2034577,NEJM,2020,Infectious Disease,Phase 2/3,Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
10.1056_nejmoa2025845,NEJM,2020,Endocrinology/Metabolism,Phase 3,Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes
10.1056_nejmoa2017699,NEJM,2020,Oncology,Phase 3,Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer
10.1056_nejmoa2027187,NEJM,2020,Oncology,Phase 3,First-Line Lorlatinib or Crizotinib in Advanced &lt;i&gt;ALK&lt;/i&gt;-Positive Lung Cancer
10.1056_nejmoa2006136,NEJM,2020,Oncology,Phase 2,Golimumab and Beta-Cell Function in Youth with New-Onset Type 1 Diabetes
10.1056_nejmoa2031049,NEJM,2020,Other,Phase 2,Evinacumab in Patients with Refractory Hypercholesterolemia
10.1056_nejmoa2002606,NEJM,2020,Infectious Disease,Phase 4,Macrolide and Nonmacrolide Resistance with Mass Azithromycin Distribution
10.1056_nejmoa2012047,NEJM,2020,Other,Phase 2,Anti-Siglec-8 Antibody for Eosinophilic Gastritis and Duodenitis
10.1056_nejmoa2028836,NEJM,2020,Infectious Disease,Phase 3,Efficacy of Tocilizumab in Patients Hospitalized with Covid-19
10.1056_nejmoa2008250,NEJM,2020,Rheumatology/Immunology,Phase 3,Trial of Upadacitinib or Abatacept in Rheumatoid Arthritis
10.1056_nejmoa2027906,NEJM,2020,Infectious Disease,Phase 2/3,Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates
10.1056_nejmoa2014320,NEJM,2020,Infectious Disease,nan,A Randomized Trial Comparing Antibiotics with Appendectomy for Appendicitis
10.1056_nejmoa1917346,NEJM,2020,Oncology,Phase 3,Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC
10.1056_nejmoa2024816,NEJM,2020,Cardiovascular,Phase 3,Dapagliflozin in Patients with Chronic Kidney Disease
10.1056_nejmoa2004967,NEJM,2020,Cardiovascular,Phase 3,Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes
10.1056_nejmoa2022474,NEJM,2020,Endocrinology/Metabolism,Phase 2,Once-Weekly Insulin for Type 2 Diabetes without Previous Insulin Treatment
10.1056_nejmoa2027071,NEJM,2020,Oncology,Phase 3,Osimertinib in Resected <i>EGFR</i>-Mutated Non-Small-Cell Lung Cancer
10.1056_nejmoa2022485,NEJM,2020,Oncology,Phase 3,Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer
10.1056_nejmoa2002788,NEJM,2020,Oncology,Phase 3,Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma
10.1056_nejmoa2013219,NEJM,2020,Respiratory,nan,Randomized Trial of Nocturnal Oxygen in Chronic Obstructive Pulmonary Disease
10.1056_nejmoa2001180,NEJM,2020,Nephrology/Urology,Phase 3,"Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis"
10.1056_nejmoa2001342,NEJM,2020,Oncology,Phase 3,"Nonmetastatic, Castration-Resistant Prostate Cancer and Survival with Darolutamide"
10.1056_nejmoa1916063,NEJM,2020,Other,Phase 3,Eflornithine plus Sulindac for Prevention of Progression in Familial Adenomatous Polyposis
10.1056_nejmoa1913590,NEJM,2020,Respiratory,Phase 2,Inhaled Molgramostim Therapy in Autoimmune Pulmonary Alveolar Proteinosis
10.1056_nejmoa2021713,NEJM,2020,Respiratory,Phase 2,Phase 2 Trial of the DPP-1 Inhibitor Brensocatib in Bronchiectasis
10.1056_nejmoa2005493,NEJM,2020,Oncology,Phase 3,Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma
10.1056_nejmoa1916945,NEJM,2020,Neurology,Phase 2,Trial of Sodium Phenylbutyrate-Taurursodiol for Amyotrophic Lateral Sclerosis
10.1056_nejmoa2007448,NEJM,2020,Endocrinology/Metabolism,nan,Weight Loss in Underserved Patients - A Cluster-Randomized Trial
10.1056_nejmoa2022190,NEJM,2020,Cardiovascular,Phase 3,Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure
10.1056_nejmoa2012883,NEJM,2020,Cardiovascular,Phase 3,Low-Dose Edoxaban in Very Elderly Patients with Atrial Fibrillation
10.1056_nejmoa2019910,NEJM,2020,Pediatrics,Phase 3,Evolocumab in Pediatric Heterozygous Familial Hypercholesterolemia
10.1056_nejmoa2004736,NEJM,2020,Endocrinology/Metabolism,nan,A Randomized Trial of Closed-Loop Control in Children with Type 1 Diabetes
10.1056_nejmoa1914617,NEJM,2020,Cardiovascular,nan,Drug-Coated Balloons for Dysfunctional Dialysis Arteriovenous Fistulas
10.1056_nejmoa2004215,NEJM,2020,Pediatrics,Phase 3,Evinacumab for Homozygous Familial Hypercholesterolemia
10.1056_nejmoa2012971,NEJM,2020,Oncology,Phase 3,Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia
10.1056_nejmoa1917246,NEJM,2020,Neurology,Phase 3,Ofatumumab versus Teriflunomide in Multiple Sclerosis
10.1056_nejmoa1908380,NEJM,2020,Infectious Disease,Phase 3,Respiratory Syncytial Virus Vaccination during Pregnancy and Effects in Infants
10.1056_nejmoa1913556,NEJM,2020,Infectious Disease,Phase 2,Single-Dose Nirsevimab for Prevention of RSV in Preterm Infants
10.1056_nejmoa1915176,NEJM,2020,Infectious Disease,Phase 3,Vitamin D Supplements for Prevention of Tuberculosis Infection and Disease
10.1056_nejmoa2000741,NEJM,2020,Nephrology/Urology,nan,Timing of Initiation of Renal-Replacement Therapy in Acute Kidney Injury
10.1056_nejmoa2000073,NEJM,2020,Dermatology,Phase 2,Trial of Roflumilast Cream for Chronic Plaque Psoriasis
10.1056_nejmoa1916870,NEJM,2020,Cardiovascular,Phase 3,Ticagrelor and Aspirin or Aspirin Alone in Acute Ischemic Stroke or TIA
10.1056_nejmoa2002183,NEJM,2020,Other,Phase 3,A Randomized Trial of a Multifactorial Strategy to Prevent Serious Fall Injuries
10.1056_nejmoa2003715,NEJM,2020,Neurology,Phase 3,Phase 1-2 Trial of Antisense Oligonucleotide Tofersen for <i>SOD1</i> ALS
10.1056_nejmoa1900669,NEJM,2020,Rheumatology/Immunology,nan,Effect on Patient Safety of a Resident Physician Schedule without 24-Hour Shifts
10.1056_nejmoa1916624,NEJM,2020,Cardiovascular,Phase 3,Serum Urate Lowering with Allopurinol and Kidney Function in Type 1 Diabetes
10.1056_nejmoa1916046,NEJM,2020,Respiratory,Phase 3,Triple Inhaled Therapy at Two Glucocorticoid Doses in Moderate-to-Very-Severe COPD
10.1056_nejmoa1910708,NEJM,2020,Infectious Disease,Phase 4,Systematic or Test-Guided Treatment for Tuberculosis in HIV-Infected Adults
10.1056_nejmoa1913147,NEJM,2020,Gastroenterology/Hepatology,Phase 3,Phase 3 Trial of RNAi Therapeutic Givosiran for Acute Intermittent Porphyria
10.1056_nejmoa2016638,NEJM,2020,Infectious Disease,Phase 3,A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19
10.1056_nejmoa2003892,NEJM,2020,Oncology,Phase 3,"Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer"
10.1056_nejmoa2004325,NEJM,2020,Oncology,Phase 3,Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer
10.1056_nejmoa2004413,NEJM,2020,Oncology,Phase 2,Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer
10.1056_nejmoa2015301,NEJM,2020,Infectious Disease,Phase 3,Remdesivir for 5 or 10 Days in Patients with Severe Covid-19
10.1056_nejmoa2007764,NEJM,2020,Infectious Disease,Phase 3,Remdesivir for the Treatment of Covid-19 - Final Report
10.1056_nejmoa1915254,NEJM,2020,Infectious Disease,Phase 2,Randomized Trial of Lactin-V to Prevent Recurrence of Bacterial Vaginosis
10.1056_nejmoa1915745,NEJM,2020,Oncology,Phase 3,Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
10.1056_nejmoa2001123,NEJM,2020,Cardiovascular,nan,Endovascular Thrombectomy with or without Intravenous Alteplase in Acute Stroke
10.1056_nejmoa1911440,NEJM,2020,Oncology,Phase 3,Olaparib for Metastatic Castration-Resistant Prostate Cancer
10.1056_nejmoa1917635,NEJM,2020,Hematology,Phase 3,Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease
10.1056_nejmoa1911772,NEJM,2020,Psychiatry/Mental Health,Phase 2,A Non-D2-Receptor-Binding Drug for the Treatment of Schizophrenia
10.1056_nejmoa1916038,NEJM,2020,Endocrinology/Metabolism,Phase 3,"A Randomized, Controlled Trial of Liraglutide for Adolescents with Obesity"
10.1056_nejmoa1915925,NEJM,2020,Cardiovascular,Phase 4,Management of Coronary Disease in Patients with Advanced Kidney Disease
10.1056_nejmoa1915922,NEJM,2020,Cardiovascular,nan,Initial Invasive or Conservative Strategy for Stable Coronary Disease
10.1056_nejmoa1916374,NEJM,2020,Cardiovascular,Phase 4,Health Status after Invasive or Conservative Care in Coronary and Advanced Kidney Disease
10.1056_nejmoa1916370,NEJM,2020,Cardiovascular,nan,Health-Status Outcomes with Invasive or Conservative Care in Coronary Disease
10.1056_nejmoa1915103,NEJM,2020,Oncology,Phase 3,Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer
10.1056_nejmoa2000052,NEJM,2020,Cardiovascular,Phase 3,Rivaroxaban in Peripheral Artery Disease after Revascularization
10.1056_nejmoa1915928,NEJM,2020,Cardiovascular,Phase 3,Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction
10.1056_nejmoa1910182,NEJM,2020,Hematology,Phase 3,A Phase 3 Trial of Luspatercept in Patients with Transfusion-Dependent β-Thalassemia
10.1056_nejmoa1913805,NEJM,2020,Other,Phase 3,Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia
10.1056_nejmoa1912387,NEJM,2020,Cardiovascular,Phase 3,Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol
10.1056_nejmoa1904398,NEJM,2020,Infectious Disease,Phase 3,Long-Acting Cabotegravir and Rilpivirine for Maintenance of HIV-1 Suppression
10.1056_nejmoa1909512,NEJM,2020,Infectious Disease,Phase 3,Long-Acting Cabotegravir and Rilpivirine after Oral Induction for HIV-1 Infection
10.1056_nejmoa1908316,NEJM,2020,Other,Phase 2,Trial of Nemolizumab in Moderate-to-Severe Prurigo Nodularis
10.1056_nejmoa1803537,NEJM,2020,Nephrology/Urology,Phase 3,Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis
10.1056_nejmoa1910434,NEJM,2020,Endocrinology/Metabolism,Phase 3,Teprotumumab for the Treatment of Active Thyroid Eye Disease
10.1056_nejmoa1904351,NEJM,2020,Obstetrics/Gynecology,Phase 3,Elagolix for Heavy Menstrual Bleeding in Women with Uterine Fibroids
10.1056_nejmoa1907423,NEJM,2020,Pediatrics,Phase 3,A Randomized Trial of Erythropoietin for Neuroprotection in Preterm Infants
10.1056_nejmsa1906848,NEJM,2020,Musculoskeletal/Pain,nan,"Health Care Hotspotting - A Randomized, Controlled Trial"
10.1056_nejmoa1908892,NEJM,2020,Oncology,Phase 3,Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes
10.1056_nejmoa1905239,NEJM,2020,Cardiovascular,Phase 2,Lipoprotein(a) Reduction in Persons with Cardiovascular Disease
10.1056_nejmoa1912196,NEJM,2020,Rheumatology/Immunology,Phase 3,Trial of Anifrolumab in Active Systemic Lupus Erythematosus
10.1056_nejmoa1911149,NEJM,2020,Oncology,Phase 3,Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer
10.1056_nejmoa1914609,NEJM,2020,Oncology,Phase 2,"Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer"
10.1056_nejmoa1914510,NEJM,2020,Oncology,Phase 2,Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer
10.1056_nejmoa1913662,NEJM,2020,Oncology,Phase 3,"Overall Survival with Osimertinib in Untreated, <i>EGFR</i>-Mutated Advanced NSCLC"
10.1056_nejmoa1911426,NEJM,2020,Cardiovascular,Phase 3,Reduced Leaflet Motion after Transcatheter Aortic-Valve Replacement
10.1056_nejmoa1911425,NEJM,2020,Cardiovascular,Phase 3,A Controlled Trial of Rivaroxaban after Transcatheter Aortic-Valve Replacement
10.1056_nejmoa1912770,NEJM,2020,Nephrology/Urology,Phase 3,A Phase 3 Trial of Difelikefalin in Hemodialysis Patients with Pruritus
10.1056_nejmoa1911124,NEJM,2019,Respiratory,Phase 3,"Early High-Dose Vitamin D<sub>3</sub> for Critically Ill, Vitamin D-Deficient Patients"
10.1056_nejmoa1813049,NEJM,2019,Neurology,Phase 3,Ubrogepant for the Treatment of Migraine
10.1056_nejmoa1901747,NEJM,2019,Infectious Disease,Phase 3,Trial of Satralizumab in Neuromyelitis Optica Spectrum Disorder
10.1056_nejmoa1905795,NEJM,2019,Cardiovascular,Phase 3,Randomized Trial of Three Anticonvulsant Medications for Status Epilepticus
10.1056_nejmoa1903986,NEJM,2019,Oncology,nan,Supplemental MRI Screening for Women with Extremely Dense Breast Tissue
10.1056_nejmoa1910993,NEJM,2019,Infectious Disease,Phase 2/3,"A Randomized, Controlled Trial of Ebola Virus Disease Therapeutics"
10.1056_nejmoa1912388,NEJM,2019,Cardiovascular,Phase 3,Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction
10.1056_nejmoa1902626,NEJM,2019,Oncology,Phase 3,Secondary Surgical Cytoreduction for Recurrent Ovarian Cancer
10.1056_nejmoa1816594,NEJM,2019,Other,Phase 3,Trial of Apremilast for Oral Ulcers in Behçet's Syndrome
10.1056_nejmoa1817307,NEJM,2019,Infectious Disease,Phase 3,Phase 3 Efficacy Trial of Modified Vaccinia Ankara as a Vaccine against Smallpox
10.1056_nejmoa1908639,NEJM,2019,Respiratory,Phase 3,Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele
10.1056_nejmoa1903869,NEJM,2019,Infectious Disease,Phase 3,Efficacy of a Tetravalent Dengue Vaccine in Healthy Children and Adolescents
10.1056_nejmoa1902688,NEJM,2019,Oncology,Phase 3,Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i>-Mutated AML
10.1056_nejmoa1909953,NEJM,2019,Respiratory,Phase 2,Final Analysis of a Trial of M72/AS01<sub>E</sub> Vaccine to Prevent Tuberculosis
10.1056_nejmoa1908142,NEJM,2019,Respiratory,Phase 3,Metoprolol for the Prevention of Acute Exacerbations of COPD
10.1056_nejmoa1907863,NEJM,2019,Endocrinology / Metabolism,nan,"Six-Month Randomized, Multicenter Trial of Closed-Loop Control in Type 1 Diabetes"
10.1056_nejmoa1813060,NEJM,2019,Infectious Disease,Phase 4,Isoniazid Preventive Therapy in HIV-Infected Pregnant and Postpartum Women
10.1056_nejmoa1911206,NEJM,2019,Oncology,Phase 4,Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer
10.1056_nejmoa1908075,NEJM,2019,Oncology,Phase 3,"Encorafenib, Binimetinib, and Cetuximab in <i>BRAF</i> V600E-Mutated Colorectal Cancer"
10.1056_nejmoa1908681,NEJM,2019,Respiratory,Phase 3,Nintedanib in Progressive Fibrosing Interstitial Lung Diseases
10.1056_nejmoa1909707,NEJM,2019,Oncology,Phase 3,Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer
10.1056_nejmoa1910962,NEJM,2019,Oncology,Phase 3,Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
10.1056_nejmoa1909406,NEJM,2019,Hematology,nan,Five-Year Outcomes after PCI or CABG for Left Main Coronary Disease
10.1056_nejmoa1910231,NEJM,2019,Oncology,Phase 3,Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer
10.1056_nejmoa1906190,NEJM,2019,Musculoskeletal / Pain,nan,Total Hip Arthroplasty or Hemiarthroplasty for Hip Fracture
10.1056_nejmoa1908419,NEJM,2019,Hematology,Phase 4,Ticagrelor with or without Aspirin in High-Risk Patients after PCI
10.1056_nejmoa1905560,NEJM,2019,Cardiovascular,Phase 3,Step-Up Therapy in Black Children and Adults with Poorly Controlled Asthma
10.1056_nejmoa1905725,NEJM,2019,Oncology,Phase 3,Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis
10.1056_nejmoa1900750,NEJM,2019,Oncology,Phase 3,Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis
10.1056_nejmoa1911303,NEJM,2019,Cardiovascular,Phase 3,Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
10.1056_nejmoa1815359,NEJM,2019,Cardiovascular,Phase 2,Polypill for Cardiovascular Disease Prevention in an Underserved Population
10.1056_nejmoa1815981,NEJM,2019,Psychiatry / Mental Health,Phase 2,Trial of SAGE-217 in Patients with Major Depressive Disorder
10.1056_nejmoa1908077,NEJM,2019,Hematology,Phase 3,Ticagrelor in Patients with Stable Coronary Disease and Diabetes
10.1056_nejmoa1908655,NEJM,2019,Cardiovascular,Phase 3,Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction
10.1056_nejmoa1801291,NEJM,2019,Cardiovascular,Phase 3,Effects of Serelaxin in Patients with Acute Heart Failure
10.1056_nejmoa1817073,NEJM,2019,Oncology,Phase 3,Ibrutinib-Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia
10.1056_nejmoa1817323,NEJM,2019,Oncology,Phase 2,Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma
10.1056_nejmoa1812281,NEJM,2019,Infectious Disease,Phase 4,"Universal Testing, Expanded Treatment, and Incidence of HIV Infection in Botswana"
10.1056_nejmoa1809866,NEJM,2019,Cardiovascular,nan,HIV Testing and Treatment with the Use of a Community Health Approach in Rural Africa
10.1056_nejmoa1814556,NEJM,2019,Infectious Disease,nan,Effect of Universal Testing and Treatment on HIV Incidence - HPTN 071 (PopART)
10.1056_nejmoa1811090,NEJM,2019,Infectious Disease,Phase 3,"Rimegepant, an Oral Calcitonin Gene-Related Peptide Receptor Antagonist, for Migraine"
10.1056_nejmoa1813440,NEJM,2019,Neurology,Phase 3,Trial of Galcanezumab in Prevention of Episodic Cluster Headache
10.1056_nejmoa1814427,NEJM,2019,Nephrology / Urology,Phase 2/3,Rituximab or Cyclosporine in the Treatment of Membranous Nephropathy
10.1056_nejmoa1903212,NEJM,2019,Hematology,Phase 3,A Phase 3 Randomized Trial of Voxelotor in Sickle Cell Disease
10.1056_nejmoa1813181,NEJM,2019,Oncology,Phase 3,Adjuvant Chemotherapy plus Radiation for Locally Advanced Endometrial Cancer
10.1056_nejmoa1901118,NEJM,2019,Cardiovascular,Phase 3,Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
10.1056_nejmoa1902226,NEJM,2019,Endocrinology / Metabolism,Phase 2,"An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes"
10.1056_nejmoa1900906,NEJM,2019,Endocrinology / Metabolism,nan,Vitamin D Supplementation and Prevention of Type 2 Diabetes
10.1056_nejmoa1903765,NEJM,2019,Oncology,Phase 3,Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer
10.1056_nejmoa1903387,NEJM,2019,Oncology,Phase 3,Maintenance Olaparib for Germline <i>BRCA</i>-Mutated Metastatic Pancreatic Cancer
10.1056_nejmoa1904819,NEJM,2019,Oncology,Phase 3,Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer
10.1056_nejmoa1903307,NEJM,2019,Oncology,Phase 3,"Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer"
10.1056_nejmoa1817249,NEJM,2019,Oncology,Phase 3,Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma
10.1056_nejmoa1905248,NEJM,2019,Respiratory,Phase 3,Benralizumab for the Prevention of COPD Exacerbations
10.1056_nejmoa1814917,NEJM,2019,Cardiovascular,Phase 3,Mometasone or Tiotropium in Mild Asthma with a Low Sputum Eosinophil Level
10.1056_nejmoa1901686,NEJM,2019,Cardiovascular,Phase 3,Early Neuromuscular Blockade in the Acute Respiratory Distress Syndrome
10.1056_nejmoa1903076,NEJM,2019,Respiratory,Phase 3,Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease
10.1056_nejmoa1813904,NEJM,2019,Oncology,Phase 3,"Alpelisib for <i>PIK3CA</i>-Mutated, Hormone Receptor-Positive Advanced Breast Cancer"
10.1056_nejmoa1813959,NEJM,2019,Hematology,Phase 3,Dabigatran for Prevention of Stroke after Embolic Stroke of Undetermined Source
10.1056_nejmoa1901981,NEJM,2019,Neurology,Phase 2,Placebo-Controlled Trial of an Oral BTK Inhibitor in Multiple Sclerosis
10.1056_nejmoa1900907,NEJM,2019,Neurology,Phase 1/2,Targeting Huntingtin Expression in Patients with Huntington's Disease
10.1056_nejmoa1900866,NEJM,2019,Respiratory,Phase 3,Eculizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder
10.1056_nejmoa1903822,NEJM,2019,Endocrinology / Metabolism,Phase 3,Liraglutide in Children and Adolescents with Type 2 Diabetes
10.1056_nejmoa1811744,NEJM,2019,Cardiovascular,Phase 3,Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
10.1056_nejmoa1812840,NEJM,2019,Neurology,Phase 3,Randomized Trial of Verubecestat for Prodromal Alzheimer's Disease
10.1056_nejmoa1812185,NEJM,2019,Hematology,Phase 2/3,Benralizumab for &lt;i&gt;PDGFRA&lt;/i&gt;-Negative Hypereosinophilic Syndrome
10.1056_nejmoa1814052,NEJM,2019,Cardiovascular,nan,Transcatheter Aortic-Valve Replacement with a Balloon-Expandable Valve in Low-Risk Patients
10.1056_nejmoa1901111,NEJM,2019,Cardiovascular,Phase 4,Antibacterial Envelope to Prevent Cardiac Implantable Device Infection
10.1056_nejmoa1817083,NEJM,2019,Hematology,Phase 4,Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation
10.1056_nejmoa1816885,NEJM,2019,Hematology,nan,Transcatheter Aortic-Valve Replacement with a Self-Expanding Valve in Low-Risk Patients
10.1056_nejmoa1900486,NEJM,2019,Hematology,nan,A Fully Magnetically Levitated Left Ventricular Assist Device - Final Report
10.1056_nejmoa1901778,NEJM,2019,Other,Phase 1,Antibody-Based Ticagrelor Reversal Agent in Healthy Volunteers
10.1056_nejmoa1803917,NEJM,2019,Cardiovascular,Phase 3,Safety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol
10.1056_nejmoa1806808,NEJM,2019,Infectious Disease,Phase 3,One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis
10.1056_nejmoa1811867,NEJM,2019,Respiratory,Phase 3,A Trial of a Shorter Regimen for Rifampin-Resistant Tuberculosis
10.1056_nejmoa1810641,NEJM,2019,Cardiovascular,nan,Sleep and Alertness in a Duty-Hour Flexibility Trial in Internal Medicine
10.1056_nejmoa1810642,NEJM,2019,Cardiovascular,nan,Patient Safety Outcomes under Flexible and Standard Resident Duty-Hour Rules
10.1056_nejmoa1814630,NEJM,2019,Oncology,Phase 3,Rivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients with Cancer
10.1056_nejmoa1816047,NEJM,2019,Oncology,Phase 3,Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
10.1056_nejmoa1816714,NEJM,2019,Oncology,Phase 3,Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
10.1056_nejmoa1716771,NEJM,2019,Infectious Disease,nan,Decolonization to Reduce Postdischarge Infection Risk among MRSA Carriers
10.1056_nejmoa1815671,NEJM,2019,Oncology,Phase 3,"Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer"
10.1056_nejmoa1800201,NEJM,2019,Respiratory,Phase 3,Omadacycline for Community-Acquired Bacterial Pneumonia
10.1056_nejmoa1806311,NEJM,2019,Hematology,Phase 3,Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura
10.1056_nejmoa1814017,NEJM,2019,Oncology,Phase 3,Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer
10.1056_nejmoa1812390,NEJM,2019,Cardiovascular,nan,Randomized Trial of Endoscopic or Open Vein-Graft Harvesting for Coronary-Artery Bypass
10.1056_nejmoa1811403,NEJM,2019,Oncology,Phase 3,Marine n-3 Fatty Acids and Prevention of Cardiovascular Disease and Cancer
10.1056_nejmoa1809944,NEJM,2019,Oncology,Phase 3,Vitamin D Supplements and Prevention of Cancer and Cardiovascular Disease
10.1056_nejmoa1812792,NEJM,2019,Hematology,Phase 3,Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia
10.1056_nejmoa1809798,NEJM,2019,Oncology,Phase 3,Low-Dose Methotrexate for the Prevention of Atherosclerotic Events
10.1056_nejmoa1812389,NEJM,2019,Cardiovascular,Phase 3,Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
10.1056_nejmoa1812851,NEJM,2019,Cardiovascular,Phase 4,Angiotensin-Neprilysin Inhibition in Acute Decompensated Heart Failure
10.1056_nejmoa1805052,NEJM,2018,Oncology,Phase 3,Sorafenib for Advanced and Refractory Desmoid Tumors
10.1056_nejmoa1812836,NEJM,2018,Oncology,Phase 3,Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL
10.1056_nejmoa1802598,NEJM,2018,Pediatrics,Phase 2/3,Lactobacillus rhamnosus GG versus Placebo for Acute Gastroenteritis in Children
10.1056_nejmoa1812856,NEJM,2018,Gastroenterology / Hepatology,Phase 3,AR101 Oral Immunotherapy for Peanut Allergy
10.1056_nejmoa1805762,NEJM,2018,Oncology,Phase 2,Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma
10.1056_nejmoa1801174,NEJM,2018,Cardiovascular,Phase 3,Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
10.1056_nejmoa1714919,NEJM,2018,Hematology,Phase 4,Pantoprazole in Patients at Risk for Gastrointestinal Bleeding in the ICU
10.1056_nejmoa1808217,NEJM,2018,Respiratory,Phase 3,Haloperidol and Ziprasidone for Treatment of Delirium in Critical Illness
10.1056_nejmoa1809615,NEJM,2018,Oncology,Phase 3,Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
10.1056_nejmoa1810527,NEJM,2018,Oncology,Phase 3,Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer
10.1056_nejmoa1810858,NEJM,2018,Oncology,Phase 3,Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
10.1056_nejmoa1807119,NEJM,2018,Respiratory,Phase 2,VX-659-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles
10.1056_nejmoa1807120,NEJM,2018,Respiratory,Phase 1/2,VX-445-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles
10.1056_nejmoa1809697,NEJM,2018,Oncology,Phase 3,Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC
10.1056_nejmoa1810171,NEJM,2018,Oncology,Phase 3,Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer
10.1056_nejmoa1800781,NEJM,2018,Cardiovascular,nan,Wearable Cardioverter-Defibrillator after Myocardial Infarction
10.1056_nejmoa1803484,NEJM,2018,Infectious Disease,Phase 2,Phase 2b Controlled Trial of M72/AS01<sub>E</sub> Vaccine to Prevent Tuberculosis
10.1056_nejmoa1809064,NEJM,2018,Oncology,Phase 3,First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
10.1056_nejmoa1806640,NEJM,2018,Cardiovascular,nan,Transcatheter Mitral-Valve Repair in Patients with Heart Failure
10.1056_nejmoa1810865,NEJM,2018,Oncology,Phase 3,Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer
10.1056_nejmoa1811737,NEJM,2018,Respiratory,Phase 3,Nintedanib plus Sildenafil in Patients with Idiopathic Pulmonary Fibrosis
10.1056_nejmoa1800149,NEJM,2018,Infectious Disease,Phase 3,Trial of Fingolimod versus Interferon Beta-1a in Pediatric Multiple Sclerosis
10.1056_nejmoa1806382,NEJM,2018,Oncology,Phase 2,Phase 2 Trial of Selective Tyrosine Kinase 2 Inhibition in Psoriasis
10.1056_nejmoa1716197,NEJM,2018,Infectious Disease,Phase 3,Baloxavir Marboxil for Uncomplicated Influenza in Adults and Adolescents
10.1056_nejmoa1805104,NEJM,2018,Oncology,Phase 3,Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma
10.1056_nejmoa1803550,NEJM,2018,Hematology,Phase 3,Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors
10.1056_nejmoa1803583,NEJM,2018,Cardiovascular,Phase 2,Phase 2 Trial of Ibudilast in Progressive Multiple Sclerosis
10.1056_nejmoa1808848,NEJM,2018,Hematology,Phase 3,"Rivaroxaban in Patients with Heart Failure, Sinus Rhythm, and Coronary Disease"
10.1056_nejmoa1804989,NEJM,2018,Cardiovascular,Phase 4,Effects of n-3 Fatty Acid Supplements in Diabetes Mellitus
10.1056_nejmoa1804988,NEJM,2018,Oncology,Phase 4,Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus
10.1056_nejmoa1805090,NEJM,2018,Hematology,Phase 3,Rivaroxaban for Thromboprophylaxis after Hospitalization for Medical Illness
10.1056_nejmoa1808721,NEJM,2018,Cardiovascular,Phase 4,Cardiovascular Safety of Lorcaserin in Overweight or Obese Patients
10.1056_nejmoa1805689,NEJM,2018,Cardiovascular,Phase 3,Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy
10.1056_nejmoa1802905,NEJM,2018,Oncology,Phase 3,Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation
10.1056_nejmoa1800566,NEJM,2018,Obstetrics / Gynecology,nan,Labor Induction versus Expectant Management in Low-Risk Nulliparous Women
10.1056_nejmoa1716995,NEJM,2018,Gastroenterology / Hepatology,Phase 2,Oral Plasma Kallikrein Inhibitor for Prophylaxis in Hereditary Angioedema
10.1056_nejmoa1802345,NEJM,2018,Respiratory,Phase 3,Prehospital Plasma during Air Medical Transport in Trauma Patients at Risk for Hemorrhagic Shock
10.1056_nejmoa1714021,NEJM,2018,Infectious Disease,Phase 2,Prevention of M. tuberculosis Infection with H4:IC31 Vaccine or BCG Revaccination
10.1056_nejmoa1717002,NEJM,2018,Oncology,Phase 3,Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma
10.1056_nejmoa1716793,NEJM,2018,Hematology,Phase 2/3,Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis
10.1056_nejmoa1716153,NEJM,2018,Endocrinology / Metabolism,Phase 3,"Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis"
10.1056_nejmoa1800536,NEJM,2018,Oncology,Phase 3,"Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer"
10.1056_nejmoa1715726,NEJM,2018,Hematology,Phase 3,Mifepristone Pretreatment for the Medical Management of Early Pregnancy Loss
10.1056_nejmoa1716948,NEJM,2018,Oncology,Phase 3,Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
10.1056_nejmoa1803164,NEJM,2018,Oncology,Phase 3,Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer
10.1056_nejmoa1804710,NEJM,2018,Oncology,Phase 3,Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer
10.1056_nejmoa1802917,NEJM,2018,Oncology,Phase 3,Phase 3 Trial of Ibrutinib plus Rituximab in Waldenström's Macroglobulinemia
10.1056_nejmoa1714641,NEJM,2018,Nephrology / Urology,Phase 2,Burosumab Therapy in Children with X-Linked Hypophosphatemia
10.1056_nejmoa1804093,NEJM,2018,Respiratory,Phase 3,Efficacy and Safety of Dupilumab in Glucocorticoid-Dependent Severe Asthma
10.1056_nejmoa1804092,NEJM,2018,Respiratory,Phase 3,Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma
10.1056_nejmoa1802670,NEJM,2018,Respiratory,nan,Procalcitonin-Guided Use of Antibiotics for Lower Respiratory Tract Infection
10.1056_nejmoa1715274,NEJM,2018,Oncology,Phase 3,Inhaled Combined Budesonide-Formoterol as Needed in Mild Asthma
10.1056_nejmoa1715275,NEJM,2018,Oncology,Phase 3,As-Needed Budesonide-Formoterol versus Maintenance Budesonide in Mild Asthma
10.1056_nejmoa1706314,NEJM,2018,Oncology,Phase 3,Canakinumab for the Treatment of Autoinflammatory Recurrent Fever Syndromes
10.1056_nejmoa1802686,NEJM,2018,Hematology,Phase 3,Rivaroxaban for Stroke Prevention after Embolic Stroke of Undetermined Source
10.1056_nejmoa1800410,NEJM,2018,Cardiovascular,Phase 3,Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA
10.1056_nejmoa1801601,NEJM,2018,Infectious Disease,nan,Restrictive versus Liberal Fluid Therapy for Major Abdominal Surgery
10.1056_nejmoa1706441,NEJM,2018,Endocrinology / Metabolism,Phase 2/3,Randomized Trial of Verubecestat for Mild-to-Moderate Alzheimer's Disease
10.1056_nejmoa1715474,NEJM,2018,Infectious Disease,Phase 4,Azithromycin to Reduce Childhood Mortality in Sub-Saharan Africa
10.1056_nejmoa1713901,NEJM,2018,Respiratory,Phase 3,Once-Daily Single-Inhaler Triple versus Dual Therapy in Patients with COPD
10.1056_nejmoa1801005,NEJM,2018,Oncology,Phase 3,Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer
10.1056_nejmoa1801946,NEJM,2018,Oncology,Phase 3,Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden
10.1056_nejmoa1802357,NEJM,2018,Oncology,Phase 3,Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
10.1056_nejmoa1709691,NEJM,2018,Ophthalmology,Phase 3,n-3 Fatty Acid Supplementation for the Treatment of Dry Eye Disease
10.1056_nejmoa1713976,NEJM,2018,Oncology,Phase 3,Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia
10.1056_nejmoa1712126,NEJM,2018,Oncology,Phase 3,Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
10.1056_nejmoa1800965,NEJM,2018,Cardiovascular,nan,Education Outcomes in a Duty-Hour Flexibility Trial in Internal Medicine
10.1056_nejmoa1710895,NEJM,2018,Cardiovascular,Phase 3,Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout
10.1056_nejmoa1800866,NEJM,2018,Hematology,nan,Two-Year Outcomes with a Magnetically Levitated Cardiac Pump in Heart Failure
10.1056_nejmoa1708131,NEJM,2018,Infectious Disease,Phase 3,Tenofovir versus Placebo to Prevent Perinatal Transmission of Hepatitis B
10.1056_nejmoa1710988,NEJM,2018,Cardiovascular,Phase 3,Quintupling Inhaled Glucocorticoids to Prevent Childhood Asthma Exacerbations
10.1056_nejmoa1711584,NEJM,2018,Nephrology / Urology,nan,Balanced Crystalloids versus Saline in Critically Ill Adults
10.1056_nejmoa1710504,NEJM,2018,Pediatrics,Phase 3,Nusinersen versus Sham Control in Later-Onset Spinal Muscular Atrophy
10.1056_nejmoa1715546,NEJM,2018,Oncology,Phase 3,Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer
10.1056_nejmoa1713973,NEJM,2018,Cardiovascular,nan,Thrombectomy for Stroke at 6 to 16 Hours with Selection by Perfusion Imaging
10.1056_nejmoa1714678,NEJM,2018,Oncology,Phase 3,"Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma"
10.1056_nejmoa1711948,NEJM,2018,Oncology,Phase 3,Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism
10.1056_nejmoa1708984,NEJM,2018,Oncology,Phase 3,Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma
10.1056_nejmoa1713137,NEJM,2018,Oncology,Phase 3,Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer
10.1056_nejmoa1710933,NEJM,2018,Cardiovascular,Phase 3,Outcomes after Angiography with Sodium Bicarbonate and Acetylcysteine
10.1056_nejmoa1706442,NEJM,2018,Cardiovascular,nan,Thrombectomy 6 to 24 Hours after Stroke with a Mismatch between Deficit and Infarct
10.1056_nejmoa1701075,NEJM,2017,Obstetrics / Gynecology,nan,Outcomes of a Coaching-Based WHO Safe Childbirth Checklist Program in India
10.1056_nejmoa1709038,NEJM,2017,Neurology,Phase 3,Fremanezumab for the Preventive Treatment of Chronic Migraine
10.1056_nejmoa1710030,NEJM,2017,Nephrology / Urology,Phase 3,Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease
10.1056_nejmoa1709846,NEJM,2017,Respiratory,Phase 3,Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del
10.1056_nejmoa1709847,NEJM,2017,Respiratory,Phase 3,Tezacaftor-Ivacaftor in Residual-Function Heterozygotes with Cystic Fibrosis
10.1056_nejmoa1614598,NEJM,2017,Oncology,Phase 3,Obinutuzumab for the First-Line Treatment of Follicular Lymphoma
10.1056_nejmoa1707572,NEJM,2017,Surgery / Critical Care,Phase 3,Age of Red Cells for Transfusion and Outcomes in Critically Ill Adults
10.1056_nejmoa1612917,NEJM,2017,Oncology,Phase 3,Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes
10.1056_nejmoa1707404,NEJM,2017,Cardiovascular,nan,Patent Foramen Ovale Closure or Antiplatelet Therapy for Cryptogenic Stroke
10.1056_nejmoa1708337,NEJM,2017,Endocrinology / Metabolism,Phase 3,Effects of Sotagliflozin Added to Insulin in Patients with Type 1 Diabetes
10.1056_nejmoa1708322,NEJM,2017,Cardiovascular,Phase 3,Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis
10.1056_nejmoa1709030,NEJM,2017,Oncology,Phase 3,Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
10.1056_nejmoa1708539,NEJM,2017,Oncology,Phase 3,Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma
10.1056_nejmoa1709937,NEJM,2017,Oncology,Phase 3,Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer
10.1056_nejmoa1706444,NEJM,2017,Oncology,Phase 3,Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease
10.1056_nejmoa1707914,NEJM,2017,Cardiovascular,Phase 3,Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
10.1056_nejmoa1708454,NEJM,2017,Hematology,Phase 3,Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation
10.1056_nejmoa1709118,NEJM,2017,Hematology,Phase 3,Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease
10.1056_nejmoa1611179,NEJM,2017,Cardiovascular,nan,Effect of Intensive Blood-Pressure Treatment on Patient-Reported Outcomes
10.1056_nejmoa1611925,NEJM,2017,Cardiovascular,Phase 3,Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
10.1056_nejmoa1704795,NEJM,2017,Oncology,Phase 3,Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer
10.1056_nejmoa1701067,NEJM,2017,Cardiovascular,nan,Fractional Flow Reserve-Guided Multivessel Angioplasty in Myocardial Infarction
10.1056_nejmoa1615758,NEJM,2017,Cardiovascular,Phase 2,Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol
10.1056_nejmoa1701488,NEJM,2017,Cardiovascular,Phase 3,Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients
10.1056_nejmoa1700456,NEJM,2017,Cardiovascular,nan,Surgical or Transcatheter Aortic-Valve Replacement in Intermediate-Risk Patients
10.1056_nejmoa1613683,NEJM,2017,Oncology,Phase 3,Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
10.1056_nejmoa1606468,NEJM,2017,Neurology,Phase 3,Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis
10.1056_nejmoa1601277,NEJM,2017,Neurology,Phase 3,Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis
10.1056_nejmoa1610426,NEJM,2017,Hematology,nan,A Fully Magnetically Levitated Circulatory Pump for Advanced Heart Failure
10.1056_nejmoa1612674,NEJM,2017,Oncology,Phase 3,Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer
10.1056_nejmoa1607303,NEJM,2016,Oncology,Phase 3,Palbociclib and Letrozole in Advanced Breast Cancer
10.1056_nejmoa1610227,NEJM,2016,Hematology,nan,Everolimus-Eluting Stents or Bypass Surgery for Left Main Coronary Artery Disease
10.1056_nejmoa1604330,NEJM,2016,Infectious Disease,Phase 1/2,"A Randomized, Controlled Trial of ZMapp for Ebola Virus Infection"
10.1056_nejmoa1606774,NEJM,2016,Oncology,Phase 3,Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
10.1056_nejmoa1611310,NEJM,2016,Oncology,Phase 3,"Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer"
10.1056_nejmoa1600159,NEJM,2016,Neurology,nan,A Randomized Trial of Focused Ultrasound Thalamotomy for Essential Tremor
10.1056_nejmoa1515510,NEJM,2016,Cardiovascular,Phase 3,Low-Dose versus Standard-Dose Intravenous Alteplase in Acute Ischemic Stroke
10.1056_nejmoa1513248,NEJM,2016,Oncology,Phase 2,Ozanimod Induction and Maintenance Treatment for Ulcerative Colitis
10.1056_nejmoa1516282,NEJM,2016,Oncology,Phase 3,"Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma"
10.1056_nejmoa1509150,NEJM,2016,Infectious Disease,Phase 3,Dihydroartemisinin-Piperaquine for the Prevention of Malaria in Pregnancy
10.1056_nejmoa1505533,NEJM,2016,Hematology,Phase 2,Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura
10.1056_nejmoa1511939,NEJM,2015,Cardiovascular,nan,A Randomized Trial of Intensive versus Standard Blood-Pressure Control
10.1056_nejmoa1509233,NEJM,2015,Hematology,nan,Possible Subclinical Leaflet Thrombosis in Bioprosthetic Aortic Valves
10.1056_nejmoa1510764,NEJM,2015,Oncology,Phase 3,Prospective Validation of a 21-Gene Expression Assay in Breast Cancer
10.1056_nejmoa1506816,NEJM,2015,Infectious Disease,Phase 4,Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection
10.1056_nejmoa1406235,NEJM,2015,Hematology,nan,Trial of a Paclitaxel-Coated Balloon for Femoropopliteal Artery Disease
10.1056_nejmoa1505270,NEJM,2015,Oncology,Phase 3,Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer
10.1056_nejmoa1413654,NEJM,2015,Oncology,Phase 1/2,Rociletinib in EGFR-mutated non-small-cell lung cancer
10.1056_nejmoa1500858,NEJM,2015,Cardiovascular,Phase 2,Efficacy and safety of evolocumab in reducing lipids and cardiovascular events
10.1056_nejmoa1412096,NEJM,2015,Oncology,Phase 3,Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma
10.1056_nejmoa1412379,NEJM,2015,Oncology,Phase 3,Adjuvant ovarian suppression in premenopausal breast cancer
10.1016_s0140-6736(26)00258-8,LANC,2026,Infectious Disease,Phase 2,"Safety and efficacy of the monoclonal antibody L9LS for malaria prevention in children exposed to perennial malaria transmission in Kenya: a randomised, double-blind, placebo-controlled, phase 2 trial"
10.1016_s0140-6736(26)00602-1,LANC,2026,Oncology,Phase 3,"Pembrolizumab plus weekly paclitaxel in platinum-resistant recurrent ovarian cancer (ENGOT-ov65/KEYNOTE-B96): a multicentre, randomised, double-blind, phase 3 study"
10.1016_s0140-6736(26)00131-5,LANC,2026,Rheumatology/Immunology,Phase 2,"Efficacy and safety of LEVI-04 in patients with osteoarthritis of the knee: a randomised, double-blind, placebo-controlled, phase 2 trial"
10.1016_s0140-6736(25)02637-6,LANC,2026,Nephrology/Urology,nan,Prevention of urinary stones with hydration: a randomised clinical trial of an adherence intervention
10.1016_s0140-6736(25)02602-9,LANC,2026,Oncology,Phase 3,"Pimicotinib versus placebo for tenosynovial giant cell tumour (MANEUVER): an international, randomised, placebo-controlled, phase 3 trial"
10.1016_s0140-6736(25)01948-8,LANC,2026,Infectious Disease,Phase 3,"Switch to fixed-dose doravirine (100 mg) and islatravir (0·25 mg) once daily in virologically suppressed adults with HIV-1 on bictegravir, emtricitabine, and tenofovir alafenamide: 48-week results of a phase 3, multicentre, randomised, controlled, double-blind, non-inferiority trial"
10.1016_s0140-6736(25)01945-2,LANC,2026,Infectious Disease,Phase 3,"Switch to fixed-dose doravirine (100 mg) and islatravir (0·25 mg) once daily in virologically suppressed adults with HIV-1 on oral antiretroviral therapy: 48-week results of a phase 3, multicentre, randomised, open-label, non-inferiority trial"
10.1016_s0140-6736(25)02255-x,LANC,2026,Nephrology/Urology,Phase 2,"TRPC6 inhibition for the treatment of focal segmental glomerulosclerosis: a randomised, placebo-controlled, phase 2 trial of BI 764198"
10.1016_s0140-6736(25)01953-1,LANC,2026,Infectious Disease,Phase 3,"Zoliflodacin versus ceftriaxone plus azithromycin for treatment of uncomplicated urogenital gonorrhoea: an international, randomised, controlled, open-label, phase 3, non-inferiority clinical trial"
10.1016_s0140-6736(25)01778-7,LANC,2026,Oncology,Phase 3,"Tafasitamab, lenalidomide, and rituximab in relapsed or refractory follicular lymphoma (inMIND): a global, phase 3, randomised controlled trial"
10.1016_s0140-6736(25)01717-9,LANC,2025,Nephrology/Urology,nan,"A preventive care strategy to reduce moderate or severe acute kidney injury after major surgery (BigpAK-2); a multinational, randomised clinical trial"
10.1016_s0140-6736(25)02097-5,LANC,2025,Hematology,Phase 2,"Efficacy and safety of REGN9933<sup>A2</sup> and REGN7508<sup>Cat</sup> for preventing postoperative venous thromboembolism (ROXI-VTE-I and ROXI-VTE-II): two randomised, open-label, phase 2 trials"
10.1016_s0140-6736(25)01375-3,LANC,2025,Cardiovascular,Phase 3,Semaglutide and cardiovascular outcomes by baseline and changes in adiposity measurements: a prespecified analysis of the SELECT trial
10.1016_s0140-6736(25)01239-5,LANC,2025,Infectious Disease,nan,"A clinical decision tool including a decision tree, point-of-care testing of CRP, and safety-netting advice to guide antibiotic prescribing in acutely ill children in primary care in Belgium (ARON): a pragmatic, cluster-randomised, controlled trial"
10.1016_s0140-6736(25)01774-x,LANC,2025,Endocrinology/Metabolism,Phase 3,"Efficacy and safety of tirzepatide in children and adolescents with type 2 diabetes (SURPASS-PEDS): a randomised, double-blind, placebo-controlled, phase 3 trial"
10.1016_s0140-6736(25)01665-4,LANC,2025,Cardiovascular,Phase 3,"Vericiguat in patients with chronic heart failure and reduced ejection fraction (VICTOR): a double-blind, placebo-controlled, randomised, phase 3 trial"
10.1016_s0140-6736(25)00859-1,LANC,2025,Psychiatry/Mental Health,nan,Building community capacity in mental health care with the Strong Minds-Strong Communities programme: a randomised controlled trial in the USA
10.1016_s0140-6736(25)01073-6,LANC,2025,Infectious Disease,Phase 2,"Safety and efficacy of once-weekly efruxifermin versus placebo in metabolic dysfunction-associated steatohepatitis (HARMONY): 96-week results from a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial"
10.1016_s0140-6736(25)00866-9,LANC,2025,Oncology,Phase 3,"Adagrasib versus docetaxel in KRAS<sup>G12C</sup>-mutated non-small-cell lung cancer (KRYSTAL-12): a randomised, open-label, phase 3 trial"
10.1016_s0140-6736(25)00766-4,LANC,2025,Infectious Disease,Phase 3,"Feasibility of interrupting the transmission of soil-transmitted helminths: the DeWorm3 community cluster-randomised controlled trial in Benin, India, and Malawi"
10.1016_s0140-6736(25)00681-6,LANC,2025,Gastroenterology/Hepatology,Phase 2/3,"Efficacy and safety of intravenous induction and subcutaneous maintenance therapy with guselkumab for patients with Crohn's disease (GALAXI-2 and GALAXI-3): 48-week results from two phase 3, randomised, placebo and active comparator-controlled, double-blind, triple-dummy trials"
10.1016_s0140-6736(25)00684-1,LANC,2025,Oncology,Phase 3,"Talazoparib plus enzalutamide in men with metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial"
10.1016_s0140-6736(25)00683-x,LANC,2025,Oncology,Phase 3,"Talazoparib plus enzalutamide in men with HRR-deficient metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial"
10.1016_s0140-6736(25)01069-4,LANC,2025,Endocrinology/Metabolism,Phase 3,"Once-weekly insulin efsitora alfa versus once-daily insulin glargine U100 in adults with type 2 diabetes treated with basal and prandial insulin (QWINT-4): a phase 3, randomised, non-inferiority trial"
10.1016_s0140-6736(25)01044-x,LANC,2025,Endocrinology/Metabolism,Phase 3,"Once-weekly insulin efsitora alfa versus once-daily insulin degludec in adults with type 2 diabetes currently treated with basal insulin (QWINT-3): a phase 3, randomised, non-inferiority trial"
10.1016_s0140-6736(25)00635-x,LANC,2025,Hematology,Phase 3,"Mitapivat in adults with non-transfusion-dependent α-thalassaemia or β-thalassaemia (ENERGIZE): a phase 3, international, randomised, double-blind, placebo-controlled trial"
10.1016_s0140-6736(25)00631-2,LANC,2025,Oncology,Phase 3,"Retifanlimab with carboplatin and paclitaxel for locally recurrent or metastatic squamous cell carcinoma of the anal canal (POD1UM-303/InterAACT-2): a global, phase 3 randomised controlled trial"
10.1016_s0140-6736(25)00986-9,LANC,2025,Other,Phase 3,"Efficacy and safety of selumetinib in adults with neurofibromatosis type 1 and symptomatic, inoperable plexiform neurofibromas (KOMET): a multicentre, international, randomised, placebo-controlled, parallel, double-blind, phase 3 study"
10.1016_s0140-6736(25)01011-6,LANC,2025,Oncology,Phase 3,"Efficacy and safety of first-line maintenance therapy with lurbinectedin plus atezolizumab in extensive-stage small-cell lung cancer (IMforte): a randomised, multicentre, open-label, phase 3 trial"
10.1016_s0140-6736(25)00319-8,LANC,2025,Cardiovascular,nan,"ACURATE neo2 valve versus commercially available transcatheter heart valves in patients with severe aortic stenosis (ACURATE IDE): a multicentre, randomised, controlled, non-inferiority trial"
10.1016_s0140-6736(25)00721-4,LANC,2025,Other,Phase 3,"Fixed-dose combination of obicetrapib and ezetimibe for LDL cholesterol reduction (TANDEM): a phase 3, randomised, double-blind, placebo-controlled trial"
10.1016_s0140-6736(25)00001-7,LANC,2025,Dermatology,Phase 3,"Efficacy and safety of topical delgocitinib cream versus oral alitretinoin capsules in adults with severe chronic hand eczema (DELTA FORCE): a 24-week, randomised, head-to-head, phase 3 trial"
10.1016_s0140-6736(25)00628-2,LANC,2025,Infectious Disease,Phase 3,"Oral gepotidacin for the treatment of uncomplicated urogenital gonorrhoea (EAGLE-1): a phase 3 randomised, open-label, non-inferiority, multicentre study"
10.1016_s0140-6736(25)00106-0,LANC,2025,Cardiovascular,nan,"SAPIEN 3 versus Myval transcatheter heart valves for transcatheter aortic valve implantation (COMPARE-TAVI 1): a multicentre, randomised, non-inferiority trial"
10.1016_s0140-6736(25)00507-0,LANC,2025,Other,Phase 2,"Durability and efficacy of solbinsiran, a GalNAc-conjugated siRNA targeting ANGPTL3, in adults with mixed dyslipidaemia (PROLONG-ANG3): a double-blind, randomised, placebo-controlled, phase 2 trial"
10.1016_s0140-6736(25)00505-7,LANC,2025,Cardiovascular,nan,"Outcomes after fractional flow reserve-guided percutaneous coronary intervention versus coronary artery bypass grafting (FAME 3): 5-year follow-up of a multicentre, open-label, randomised trial"
10.1016_s0140-6736(25)00509-4,LANC,2025,Endocrinology/Metabolism,Phase 3,"Semaglutide and walking capacity in people with symptomatic peripheral artery disease and type 2 diabetes (STRIDE): a phase 3b, double-blind, randomised, placebo-controlled trial"
10.1016_s0140-6736(25)00345-9,LANC,2025,Infectious Disease,Phase 3,"Chikungunya virus virus-like particle vaccine safety and immunogenicity in adolescents and adults in the USA: a phase 3, randomised, double-blind, placebo-controlled trial"
10.1016_s0140-6736(25)00145-x,LANC,2025,Oncology,nan,"Effect of invitation to colonoscopy versus faecal immunochemical test screening on colorectal cancer mortality (COLONPREV): a pragmatic, randomised, controlled, non-inferiority trial"
10.1016_s0140-6736(25)00372-1,LANC,2025,Infectious Disease,Phase 3,"Chikungunya virus virus-like particle vaccine safety and immunogenicity in adults older than 65 years: a phase 3, randomised, double-blind, placebo-controlled trial"
10.1016_s0140-6736(25)00046-7,LANC,2025,Infectious Disease,Phase 3,"Safety and immunogenicity of a pentavalent meningococcal conjugate vaccine targeting serogroups A, C, W, Y, and X when co-administered with routine childhood vaccines at ages 9 months and 15 months in Mali: a single-centre, double-blind, randomised, controlled, phase 3, non-inferiority trial"
10.1016_s0140-6736(25)00197-7,LANC,2025,Other,Phase 3,"Efficacy and safety of twice per year depemokimab in chronic rhinosinusitis with nasal polyps (ANCHOR-1 and ANCHOR-2): phase 3, randomised, double-blind, parallel trials"
10.1016_s0140-6736(25)00194-1,LANC,2025,Cardiovascular,Phase 3,"Efficacy and safety of nerinetide in acute ischaemic stroke in patients undergoing endovascular thrombectomy without previous thrombolysis (ESCAPE-NEXT): a multicentre, double-blind, randomised controlled trial"
10.1016_s0140-6736(24)02848-4,LANC,2025,Oncology,Phase 3,"Nivolumab plus ipilimumab versus nivolumab in microsatellite instability-high metastatic colorectal cancer (CheckMate 8HW): a randomised, open-label, phase 3 trial"
10.1016_s0140-6736(24)02468-1,LANC,2025,Rheumatology/Immunology,Phase 4,"Stopping of adalimumab in juvenile idiopathic arthritis-associated uveitis (ADJUST): a multicentre, double-masked, randomised controlled trial"
10.1016_s0140-6736(24)02071-3,LANC,2025,Other,Phase 2,"Efficacy, safety, and target engagement of dazukibart, an IFNβ specific monoclonal antibody, in adults with dermatomyositis: a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial"
10.1016_s0140-6736(24)01927-5,LANC,2025,Gastroenterology/Hepatology,Phase 2/3,"Guselkumab in patients with moderately to severely active ulcerative colitis (QUASAR): phase 3 double-blind, randomised, placebo-controlled induction and maintenance studies"
10.1016_s0140-6736(24)01762-8,LANC,2024,Gastroenterology/Hepatology,Phase 3,"Efficacy and safety of mirikizumab in patients with moderately-to-severely active Crohn's disease: a phase 3, multicentre, randomised, double-blind, placebo-controlled and active-controlled, treat-through study"
10.1016_s0140-6736(24)02315-8,LANC,2024,Cardiovascular,nan,"Balloon guide catheters for endovascular thrombectomy in patients with acute ischaemic stroke due to large-vessel occlusion in China (PROTECT-MT): a multicentre, open-label, blinded-endpoint, randomised controlled trial"
10.1016_s0140-6736(24)01809-9,LANC,2024,Psychiatry/Mental Health,Phase 4,"Effectiveness, cost-effectiveness, and positive externalities of integrated chronic care for adults with major depressive disorder in Malawi (IC3D): a stepped-wedge, cluster-randomised, controlled trial"
10.1016_s0140-6736(24)01744-6,LANC,2024,Cardiovascular,Phase 3,"Efficacy and safety of a novel low-dose triple single-pill combination of telmisartan, amlodipine and indapamide, compared with dual combinations for treatment of hypertension: a randomised, double-blind, active-controlled, international clinical trial"
10.1016_s0140-6736(24)01556-3,LANC,2024,Pediatrics,Phase 3,"Effects of oral sepiapterin on blood Phe concentration in a broad range of patients with phenylketonuria (APHENITY): results of an international, phase 3, randomised, double-blind, placebo-controlled trial"
10.1016_s0140-6736(24)01595-2,LANC,2024,Oncology,nan,"Liver transplantation plus chemotherapy versus chemotherapy alone in patients with permanently unresectable colorectal liver metastases (TransMet): results from a multicentre, open-label, prospective, randomised controlled trial"
10.1016_s0140-6736(24)01653-2,LANC,2024,Oncology,Phase 3,"&lt;sup&gt;177&lt;/sup&gt;Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial"
10.1016_s0140-6736(24)01756-2,LANC,2024,Oncology,Phase 3,"Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial"
10.1016_s0140-6736(24)01808-7,LANC,2024,Oncology,Phase 3,"Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 trial"
10.1016_s0140-6736(24)01804-x,LANC,2024,Endocrinology/Metabolism,Phase 3,Once-weekly insulin efsitora alfa versus once-daily insulin degludec in adults with type 1 diabetes (QWINT-5): a phase 3 randomised non-inferiority trial
10.1016_s0140-6736(24)01643-x,LANC,2024,Cardiovascular,Phase 3,"Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: a pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trials"
10.1016_s0140-6736(24)01498-3,LANC,2024,Cardiovascular,Phase 3,Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial
10.1016_s0140-6736(24)01304-7,LANC,2024,Surgery/Critical Care,nan,"Effect of high versus standard protein provision on functional recovery in people with critical illness (PRECISe): an investigator-initiated, double-blinded, multicentre, parallel-group, randomised controlled trial in Belgium and the Netherlands"
10.1016_s0140-6736(24)00814-6,LANC,2024,Oncology,Phase 2,"Molecularly guided therapy versus chemotherapy after disease control in unfavourable cancer of unknown primary (CUPISCO): an open-label, randomised, phase 2 study"
10.1016_s0140-6736(24)01203-0,LANC,2024,Nephrology/Urology,Phase 3,"Nemolizumab with concomitant topical therapy in adolescents and adults with moderate-to-severe atopic dermatitis (ARCADIA 1 and ARCADIA 2): results from two replicate, double-blind, randomised controlled phase 3 trials"
10.1016_s0140-6736(24)01027-4,LANC,2024,Dermatology,Phase 3,"Efficacy and safety of delgocitinib cream in adults with moderate to severe chronic hand eczema (DELTA 1 and DELTA 2): results from multicentre, randomised, controlled, double-blind, phase 3 trials"
10.1016_s0140-6736(24)00701-3,LANC,2024,Oncology,Phase 3,"[<sup>177</sup>Lu]Lu-DOTA-TATE plus long-acting octreotide versus high‑dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2-3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study"
10.1016_s0140-6736(24)00885-7,LANC,2024,Oncology,Phase 3,"Vimseltinib versus placebo for tenosynovial giant cell tumour (MOTION): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial"
10.1016_s0140-6736(24)00101-6,LANC,2024,Dermatology,Phase 3,"Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): two 48-week, randomised, double-blind, placebo-controlled, multicentre phase 3 trials"
10.1016_s0140-6736(24)00921-8,LANC,2024,Cardiovascular,Phase 3,"Tenecteplase versus standard of care for minor ischaemic stroke with proven occlusion (TEMPO-2): a randomised, open label, phase 3 superiority trial"
10.1016_s0140-6736(24)00064-3,LANC,2024,Obstetrics/Gynecology,nan,"Effectiveness of kangaroo mother care before clinical stabilisation versus standard care among neonates at five hospitals in Uganda (OMWaNA): a parallel-group, individually randomised controlled trial and economic evaluation"
10.1016_s0140-6736(24)00469-0,LANC,2024,Cardiovascular,Phase 3,Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials
10.1016_s0140-6736(24)00317-9,LANC,2024,Oncology,Phase 3,"Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trial"
10.1016_s0140-6736(23)02577-1,LANC,2024,Endocrinology/Metabolism,Phase 2/3,"Intravitreal aflibercept 8 mg in diabetic macular oedema (PHOTON): 48-week results from a randomised, double-masked, non-inferiority, phase 2/3 trial"
10.1016_s0140-6736(24)00063-1,LANC,2024,Ophthalmology,Phase 3,"Intravitreal aflibercept 8 mg in neovascular age-related macular degeneration (PULSAR): 48-week results from a randomised, double-masked, non-inferiority, phase 3 trial"
10.1016_s0140-6736(24)00050-3,LANC,2024,Cardiovascular,nan,Endovascular thrombectomy plus medical care versus medical care alone for large ischaemic stroke: 1-year outcomes of the SELECT2 trial
10.1016_s0140-6736(23)02196-7,LANC,2024,Infectious Disease,Phase 3,"Oral gepotidacin versus nitrofurantoin in patients with uncomplicated urinary tract infection (EAGLE-2 and EAGLE-3): two randomised, controlled, double-blind, double-dummy, phase 3, non-inferiority trials"
10.1016_s0140-6736(23)02631-4,LANC,2024,Infectious Disease,Phase 3,"Chemoprevention for malaria with monthly intermittent preventive treatment with dihydroartemisinin-piperaquine in pregnant women living with HIV on daily co-trimoxazole in Kenya and Malawi: a randomised, double-blind, placebo-controlled trial"
10.1016_s0140-6736(23)02356-5,LANC,2024,Cardiovascular,Phase 3,Indomethacin with or without prophylactic pancreatic stent placement to prevent pancreatitis after ERCP: a randomised non-inferiority trial
10.1016_s0140-6736(23)02408-x,LANC,2024,Nephrology/Urology,Phase 2,"Efficacy and safety of aldosterone synthase inhibition with and without empagliflozin for chronic kidney disease: a randomised, controlled, phase 2 trial"
10.1016_s0140-6736(23)02190-6,LANC,2024,Psychiatry/Mental Health,Phase 3,"Efficacy and safety of the muscarinic receptor agonist KarXT (xanomeline-trospium) in schizophrenia (EMERGENT-2) in the USA: results from a randomised, double-blind, placebo-controlled, flexible-dose phase 3 trial"
10.1016_s0140-6736(23)02284-5,LANC,2024,Respiratory,Phase 4,"Reduction of daily maintenance inhaled corticosteroids in patients with severe eosinophilic asthma treated with benralizumab (SHAMAL): a randomised, multicentre, open-label, phase 4 study"
10.1016_s0140-6736(23)01724-5,LANC,2024,Oncology,Phase 2/3,"Imetelstat in patients with lower-risk myelodysplastic syndromes who have relapsed or are refractory to erythropoiesis-stimulating agents (IMerge): a multinational, randomised, double-blind, placebo-controlled, phase 3 trial"
10.1016_s0140-6736(23)01684-7,LANC,2024,Dermatology,Phase 3,Efficacy and safety of ligelizumab in adults and adolescents with chronic spontaneous urticaria: results of two phase 3 randomised controlled trials
10.1016_s0140-6736(23)02133-5,LANC,2023,Oncology,nan,An SMS and animated video intervention to increase uptake of breast cancer screening: a randomised controlled trial
10.1016_s0140-6736(23)01683-5,LANC,2023,Neurology,Phase 3,"Ubrogepant for the treatment of migraine attacks during the prodrome: a phase 3, multicentre, randomised, double-blind, placebo-controlled, crossover trial in the USA"
10.1016_s0140-6736(23)02302-4,LANC,2023,Nephrology/Urology,Phase 3,"Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial"
10.1016_s0140-6736(23)01613-6,LANC,2023,Oncology,Phase 2/3,"Pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma in Canada, Italy, and France: a phase 3, open-label, randomised controlled trial"
10.1016_s0140-6736(23)02230-4,LANC,2023,Cardiovascular,Phase 2,"Zibotentan in combination with dapagliflozin compared with dapagliflozin in patients with chronic kidney disease (ZENITH-CKD): a multicentre, randomised, active-controlled, phase 2b, clinical trial"
10.1016_s0140-6736(23)01796-8,LANC,2023,Oncology,Phase 3,"Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial"
10.1016_s0140-6736(23)02033-0,LANC,2023,Oncology,Phase 3,Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial
10.1016_s0140-6736(23)01520-9,LANC,2023,Ophthalmology,Phase 3,"Pegcetacoplan for the treatment of geographic atrophy secondary to age-related macular degeneration (OAKS and DERBY): two multicentre, randomised, double-masked, sham-controlled, phase 3 trials"
10.1016_s0140-6736(23)02179-7,LANC,2023,Endocrinology/Metabolism,Phase 3,"Once-weekly insulin icodec versus once-daily insulin degludec as part of a basal-bolus regimen in individuals with type 1 diabetes (ONWARDS 6): a phase 3a, randomised, open-label, treat-to-target trial"
10.1016_s0140-6736(23)01460-5,LANC,2023,Hematology,Phase 3,"Efficacy and safety of the neonatal Fc receptor inhibitor efgartigimod in adults with primary immune thrombocytopenia (ADVANCE IV): a multicentre, randomised, placebo-controlled, phase 3 trial"
10.1016_s0140-6736(23)01366-1,LANC,2023,Oncology,Phase 3,"NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial"
10.1016_s0140-6736(23)00912-1,LANC,2023,Cardiovascular,nan,"Adaptive versus conventional cardiac resynchronisation therapy in patients with heart failure (AdaptResponse): a global, prospective, randomised controlled trial"
10.1016_s0140-6736(23)01245-x,LANC,2023,Oncology,Phase 3,"Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial"
10.1016_s0140-6736(23)01240-0,LANC,2023,Obstetrics/Gynecology,Phase 2/3,Oral emergency contraception with levonorgestrel plus piroxicam: a randomised double-blind placebo-controlled trial
10.1016_s0140-6736(23)01554-4,LANC,2023,Nephrology/Urology,Phase 3,Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial
10.1016_s0140-6736(23)00913-3,LANC,2023,Oncology,Phase 3,"Adjuvant everolimus after surgery for renal cell carcinoma (EVEREST): a double-blind, placebo-controlled, randomised, phase 3 trial"
10.1016_s0140-6736(23)01049-8,LANC,2023,Neurology,Phase 3,"Atogepant for the preventive treatment of chronic migraine (PROGRESS): a randomised, double-blind, placebo-controlled, phase 3 trial"
10.1016_s0140-6736(23)00961-3,LANC,2023,Oncology,Phase 3,"Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study"
10.1016_s0140-6736(23)01406-x,LANC,2023,Cardiovascular,nan,"Hearing intervention versus health education control to reduce cognitive decline in older adults with hearing loss in the USA (ACHIEVE): a multicentre, randomised controlled trial"
10.1016_s0140-6736(23)00921-2,LANC,2023,Rheumatology/Immunology,Phase 3,"Baricitinib in juvenile idiopathic arthritis: an international, phase 3, randomised, double-blind, placebo-controlled, withdrawal, efficacy, and safety trial"
10.1016_s0140-6736(23)00774-2,LANC,2023,Oncology,Phase 3,"First-line atezolizumab monotherapy versus single-agent chemotherapy in patients with non-small-cell lung cancer ineligible for treatment with a platinum-containing regimen (IPSOS): a phase 3, global, multicentre, open-label, randomised controlled study"
10.1016_s0140-6736(23)01053-x,LANC,2023,Endocrinology/Metabolism,Phase 2,"Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA"
10.1016_s0140-6736(23)01127-3,LANC,2023,Endocrinology/Metabolism,Phase 3,"Efficacy and safety of once-daily oral semaglutide 25 mg and 50 mg compared with 14 mg in adults with type 2 diabetes (PIONEER PLUS): a multicentre, randomised, phase 3b trial"
10.1016_s0140-6736(23)01185-6,LANC,2023,Endocrinology/Metabolism,Phase 3,"Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial"
10.1016_s0140-6736(23)01200-x,LANC,2023,Endocrinology/Metabolism,Phase 3,"Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial"
10.1016_s0140-6736(23)01302-8,LANC,2023,Endocrinology/Metabolism,Phase 2,"Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a multicentre, randomised, dose-response, phase 2 study"
10.1016_s0140-6736(23)01163-7,LANC,2023,Endocrinology/Metabolism,Phase 2,"Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial"
10.1016_s0140-6736(23)00772-9,LANC,2023,Oncology,Phase 3,"Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study"
10.1016_s0140-6736(23)00776-6,LANC,2023,Surgery/Critical Care,Phase 3,"Self-administered intranasal etripamil using a symptom-prompted, repeat-dose regimen for atrioventricular-nodal-dependent supraventricular tachycardia (RAPID): a multicentre, randomised trial"
10.1016_s0140-6736(23)00641-4,LANC,2023,Infectious Disease,Phase 3,"Safety and immunogenicity of a single-shot live-attenuated chikungunya vaccine: a double-blind, multicentre, randomised, placebo-controlled, phase 3 trial"
10.1016_s0140-6736(23)00874-7,LANC,2023,Oncology,Phase 3,"Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial"
10.1016_s0140-6736(23)00922-4,LANC,2023,Oncology,Phase 3,"Atezolizumab plus cabozantinib versus cabozantinib monotherapy for patients with renal cell carcinoma after progression with previous immune checkpoint inhibitor treatment (CONTACT-03): a multicentre, randomised, open-label, phase 3 trial"
10.1016_s0140-6736(23)01055-3,LANC,2023,Oncology,Phase 3,"Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial"
10.1016_s0140-6736(23)00520-2,LANC,2023,Endocrinology/Metabolism,Phase 3,"Switching to once-weekly insulin icodec versus once-daily insulin glargine U100 in individuals with basal-bolus insulin-treated type 2 diabetes (ONWARDS 4): a phase 3a, randomised, open-label, multicentre, treat-to-target, non-inferiority trial"
10.1016_s0140-6736(23)00464-6,LANC,2023,Oncology,Phase 3,"Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial"
10.1016_s0140-6736(23)00725-0,LANC,2023,Oncology,Phase 3,"Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial"
10.1016_s0140-6736(23)00727-4,LANC,2023,Oncology,Phase 3,"Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial"
10.1016_s0140-6736(23)00620-7,LANC,2023,Oncology,Phase 3,"Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial"
10.1016_s0140-6736(23)00222-2,LANC,2023,Infectious Disease,Phase 2/3,"Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b-3 trial"
10.1016_s0140-6736(23)00346-x,LANC,2023,Hematology,Phase 2/3,"The effect of vitamin B12 supplementation during pregnancy on infant growth and development in Nepal: a community-based, double-blind, randomised, placebo-controlled trial"
10.1016_s0140-6736(23)00569-x,LANC,2023,Nephrology/Urology,Phase 3,"Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial"
10.1016_s0140-6736(23)00284-2,LANC,2023,Hematology,Phase 3,"Efficacy and safety of fitusiran prophylaxis in people with haemophilia A or haemophilia B with inhibitors (ATLAS-INH): a multicentre, open-label, randomised phase 3 trial"
10.1016_s0140-6736(23)00085-5,LANC,2023,Obstetrics/Gynecology,Phase 3,Fezolinetant for treatment of moderate-to-severe vasomotor symptoms associated with menopause (SKYLIGHT 1): a phase 3 randomised controlled study
10.1016_s0140-6736(22)02644-7,LANC,2023,Other,Phase 2,"Immunogenicity and safety of BPZE1, an intranasal live attenuated pertussis vaccine, versus tetanus-diphtheria-acellular pertussis vaccine: a randomised, double-blind, phase 2b trial"
10.1016_s0140-6736(23)00061-2,LANC,2023,Gastroenterology/Hepatology,Phase 3,"Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies"
10.1016_s0140-6736(23)00350-1,LANC,2023,Other,Phase 3,"Efficacy and safety of garadacimab, a factor XIIa inhibitor for hereditary angioedema prevention (VANGUARD): a global, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial"
10.1016_s0140-6736(22)02546-6,LANC,2023,Rheumatology/Immunology,Phase 3,"Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-II)"
10.1016_s0140-6736(22)02607-1,LANC,2023,Rheumatology/Immunology,Phase 3,"Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-I)"
10.1016_s0140-6736(22)02574-0,LANC,2023,Oncology,Phase 3,"Adjuvant nivolumab plus ipilimumab versus placebo for localised renal cell carcinoma after nephrectomy (CheckMate 914): a double-blind, randomised, phase 3 trial"
10.1016_s0140-6736(22)02406-0,LANC,2023,Other,Phase 3,"An investigational oral plasma kallikrein inhibitor for on-demand treatment of hereditary angioedema: a two-part, randomised, double-blind, placebo-controlled, crossover phase 2 trial"
10.1016_s0140-6736(23)00221-0,LANC,2023,Oncology,Phase 3,"Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRAS<sup>G12C</sup> mutation: a randomised, open-label, phase 3 trial"
10.1016_s0140-6736(23)00022-3,LANC,2023,Dermatology,Phase 3,"Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials"
10.1016_s0140-6736(22)01841-4,LANC,2023,Other,nan,"A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study"
10.1016_s0140-6736(22)02036-0,LANC,2023,Hematology,Phase 3,"Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study"
10.1016_s0140-6736(22)02469-2,LANC,2023,Surgery/Critical Care,nan,"The effect of higher protein dosing in critically ill patients with high nutritional risk (EFFORT Protein): an international, multicentre, pragmatic, registry-based randomised trial"
10.1016_s0140-6736(22)02037-2,LANC,2023,Dermatology,Phase 2,"An anti-OX40 antibody to treat moderate-to-severe atopic dermatitis: a multicentre, double-blind, placebo-controlled phase 2b study"
10.1016_s0140-6736(22)02303-0,LANC,2023,Oncology,Phase 3,"Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-α inhibitors: a randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE)"
10.1016_s0140-6736(22)02420-5,LANC,2023,Oncology,Phase 3,"Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial"
10.1016_s0140-6736(22)02302-9,LANC,2023,Rheumatology/Immunology,Phase 3,"Bimekizumab in patients with psoriatic arthritis, naive to biologic treatment: a randomised, double-blind, placebo-controlled, phase 3 trial (BE OPTIMAL)"
10.1016_s0140-6736(22)02324-8,LANC,2023,Infectious Disease,Phase 3,"Rezafungin versus caspofungin for treatment of candidaemia and invasive candidiasis (ReSTORE): a multicentre, double-blind, double-dummy, randomised phase 3 trial"
10.1016_s0140-6736(22)01883-9,LANC,2022,Infectious Disease,Phase 2,"9 months of delamanid, linezolid, levofloxacin, and pyrazinamide versus conventional therapy for treatment of fluoroquinolone-sensitive multidrug-resistant tuberculosis (MDR-END): a multicentre, randomised, open-label phase 2/3 non-inferiority trial in South Korea"
10.1016_s0140-6736(22)02034-7,LANC,2022,Cardiovascular,Phase 3,"Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicentre, blinded, randomised, parallel-group, phase 3 trial"
10.1016_s0140-6736(22)01805-0,LANC,2022,Nephrology/Urology,nan,"Personalised cooler dialysate for patients receiving maintenance haemodialysis (MyTEMP): a pragmatic, cluster-randomised trial"
10.1016_s0140-6736(22)01882-7,LANC,2022,Cardiovascular,nan,"Intensive blood pressure control after endovascular thrombectomy for acute ischaemic stroke (ENCHANTED2/MT): a multicentre, open-label, blinded-endpoint, randomised controlled trial"
10.1016_s0140-6736(22)01652-x,LANC,2022,Infectious Disease,Phase 4,"Aqueous skin antisepsis before surgical fixation of open fractures (Aqueous-PREP): a multiple-period, cluster-randomised, crossover trial"
10.1016_s0140-6736(22)01539-2,LANC,2022,Dermatology,Phase 2/3,"Dupilumab in children aged 6 months to younger than 6 years with uncontrolled atopic dermatitis: a randomised, double-blind, placebo-controlled, phase 3 trial"
10.1016_s0140-6736(22)01659-2,LANC,2022,Oncology,Phase 2,"Combined nivolumab and ipilimumab with or without stereotactic body radiation therapy for advanced Merkel cell carcinoma: a randomised, open label, phase 2 trial"
10.1016_s0140-6736(22)01658-0,LANC,2022,Oncology,Phase 3,"Adjuvant atezolizumab versus placebo for patients with renal cell carcinoma at increased risk of recurrence following resection (IMmotion010): a multicentre, randomised, double-blind, phase 3 trial"
10.1016_s0140-6736(22)01588-4,LANC,2022,Cardiovascular,Phase 2,"Factor XIa inhibition with asundexian after acute non-cardioembolic ischaemic stroke (PACIFIC-Stroke): an international, randomised, double-blind, placebo-controlled, phase 2b trial"
10.1016_s0140-6736(22)01198-9,LANC,2022,Respiratory,Phase 2,"Mepolizumab for urban children with exacerbation-prone eosinophilic asthma in the USA (MUPPITS-2): a randomised, double-blind, placebo-controlled, parallel-group trial"
10.1016_s0140-6736(22)01212-0,LANC,2022,Rheumatology/Immunology,Phase 3,"Upadacitinib for the treatment of active non-radiographic axial spondyloarthritis (SELECT-AXIS 2): a randomised, double-blind, placebo-controlled, phase 3 trial"
10.1016_s0140-6736(22)01280-6,LANC,2022,Cardiovascular,nan,"Endoscopic sleeve gastroplasty for treatment of class 1 and 2 obesity (MERIT): a prospective, multicentre, randomised trial"
10.1016_s0140-6736(22)01199-0,LANC,2022,Dermatology,Phase 3,"Efficacy and safety of abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: a randomised, double-blind, multicentre phase 3 trial"
10.1016_s0140-6736(22)00662-6,LANC,2022,Oncology,Phase 3,"Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial"
10.1016_s0140-6736(22)00688-2,LANC,2022,Gastroenterology/Hepatology,Phase 3,"Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial"
10.1016_s0140-6736(22)00581-5,LANC,2022,Gastroenterology/Hepatology,Phase 2/3,"Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials"
10.1016_s0140-6736(22)00467-6,LANC,2022,Gastroenterology/Hepatology,Phase 3,Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials
10.1016_s0140-6736(21)01790-6,LANC,2022,Oncology,Phase 3,"The addition of androgen deprivation therapy and pelvic lymph node treatment to prostate bed salvage radiotherapy (NRG Oncology/RTOG 0534 SPPORT): an international, multicentre, randomised phase 3 trial"
10.1016_s0140-6736(22)00560-8,LANC,2022,Cardiovascular,nan,"Aggressive intraoperative warming versus routine thermal management during non-cardiac surgery (PROTECT): a multicentre, parallel group, superiority trial"
10.1016_s0140-6736(22)00455-x,LANC,2022,Cardiovascular,nan,"Long-term efficacy and safety of renal denervation in the presence of antihypertensive drugs (SPYRAL HTN-ON MED): a randomised, sham-controlled trial"
10.1016_s0140-6736(22)00456-1,LANC,2022,Cardiovascular,Phase 2,"Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study"
10.1016_s0140-6736(22)00538-4,LANC,2022,Infectious Disease,Phase 3,"Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial"
10.1016_s0140-6736(22)00562-1,LANC,2022,Oncology,Phase 3,"Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial"
10.1016_s0140-6736(22)00012-5,LANC,2022,Cardiovascular,Phase 2,"Repeated intravenous cardiosphere-derived cell therapy in late-stage Duchenne muscular dystrophy (HOPE-2): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial"
10.1016_s0140-6736(21)02348-5,LANC,2022,Other,Phase 3,"Efficacy and safety of gefapixant, a P2X<sub>3</sub> receptor antagonist, in refractory chronic cough and unexplained chronic cough (COUGH-1 and COUGH-2): results from two double-blind, randomised, parallel-group, placebo-controlled, phase 3 trials"
10.1016_s0140-6736(21)02175-9,LANC,2022,Oncology,Phase 2/3,"Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281/LOGS): an international, randomised, open-label, multicentre, phase 2/3 trial"
10.1016_s0140-6736(22)00101-5,LANC,2022,Infectious Disease,Phase 3,"Hyperimmune immunoglobulin for hospitalised patients with COVID-19 (ITAC): a double-blind, placebo-controlled, phase 3, randomised trial"
10.1016_s0140-6736(22)00018-6,LANC,2022,Endocrinology/Metabolism,Phase 3,"Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials"
10.1016_s0140-6736(22)00010-1,LANC,2022,Ophthalmology,Phase 3,"Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials"
10.1016_s0140-6736(21)02390-4,LANC,2022,Pediatrics,Phase 2,Efficacy and safety of oral immunotherapy in children aged 1-3 years with peanut allergy (the Immune Tolerance Network IMPACT trial): a randomised placebo-controlled study
10.1016_s0140-6736(21)02251-0,LANC,2022,Rheumatology/Immunology,Phase 2,"Safety and efficacy of subcutaneous ianalumab (VAY736) in patients with primary Sjögren's syndrome: a randomised, double-blind, placebo-controlled, phase 2b dose-finding trial"
10.1016_s0140-6736(21)01751-7,LANC,2021,Endocrinology/Metabolism,Phase 2,"Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial"
10.1016_s0140-6736(21)02394-1,LANC,2021,Endocrinology/Metabolism,nan,"Adjustable intragastric balloon for treatment of obesity: a multicentre, open-label, randomised clinical trial"
10.1016_s0140-6736(21)01255-1,LANC,2021,Rheumatology/Immunology,Phase 3,"Tofacitinib in juvenile idiopathic arthritis: a double-blind, placebo-controlled, withdrawal phase 3 randomised trial"
10.1016_s0140-6736(21)01256-3,LANC,2021,Pediatrics,Phase 2,Efficacy and safety of maralixibat treatment in patients with Alagille syndrome and cholestatic pruritus (ICONIC): a randomised phase 2 study
10.1016_s0140-6736(21)01789-x,LANC,2021,Oncology,nan,Evaluation of geriatric assessment and management on the toxic effects of cancer treatment (GAP70+): a cluster-randomised study
10.1016_s0140-6736(21)01754-2,LANC,2021,Cardiovascular,nan,Haemodynamic-guided management of heart failure (GUIDE-HF): a randomised controlled trial
10.1016_s0140-6736(21)01234-4,LANC,2021,Oncology,Phase 3,"Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study"
10.1016_s0140-6736(21)01443-4,LANC,2021,Endocrinology/Metabolism,Phase 3,"Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial"
10.1016_s0140-6736(21)00580-8,LANC,2021,Oncology,Phase 3,"Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial"
10.1016_s0140-6736(21)01324-6,LANC,2021,Endocrinology/Metabolism,Phase 3,"Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial"
10.1016_s0140-6736(21)00797-2,LANC,2021,Oncology,Phase 3,"First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial"
10.1016_s0140-6736(21)00592-4,LANC,2021,Oncology,Phase 3,"Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial"
10.1016_s0140-6736(21)00666-8,LANC,2021,Gastroenterology/Hepatology,Phase 3,"Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trial"
10.1016_s0140-6736(21)00589-4,LANC,2021,Nephrology/Urology,Phase 3,"Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial"
10.1016_s0140-6736(21)00588-2,LANC,2021,Dermatology,Phase 3,"Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials"
10.1016_s0140-6736(21)00520-1,LANC,2021,Cardiovascular,Phase 2,"IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial"
10.1016_s0140-6736(21)00788-1,LANC,2021,Cardiovascular,nan,"Ultrasound renal denervation for hypertension resistant to a triple medication pill (RADIANCE-HTN TRIO): a randomised, multicentre, single-blind, sham-controlled trial"
10.1016_s0140-6736(21)00763-7,LANC,2021,Cardiovascular,Phase 3,"Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): health status analysis of a randomised, double-blind, placebo-controlled, phase 3 trial"
10.1016_s0140-6736(21)00578-x,LANC,2021,Nephrology/Urology,Phase 3,"Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial"
10.1016_s0140-6736(21)00581-x,LANC,2021,Oncology,Phase 2/3,"<sup>18</sup>F-fluciclovine-PET/CT imaging versus conventional imaging alone to guide postprostatectomy salvage radiotherapy for prostate cancer (EMPIRE-1): a single centre, open-label, phase 2/3 randomised controlled trial"
10.1016_s0140-6736(21)00440-2,LANC,2021,Dermatology,Phase 2,"IL17A/F nanobody sonelokimab in patients with plaque psoriasis: a multicentre, randomised, placebo-controlled, phase 2b study"
10.1016_s0140-6736(21)00475-x,LANC,2021,Cardiovascular,nan,"Vagus nerve stimulation paired with rehabilitation for upper limb motor function after ischaemic stroke (VNS-REHAB): a randomised, blinded, pivotal, device trial"
10.1016_s0140-6736(21)00314-7,LANC,2021,Infectious Disease,Phase 3,"Efficacy and safety of dolutegravir with emtricitabine and tenofovir alafenamide fumarate or tenofovir disoproxil fumarate, and efavirenz, emtricitabine, and tenofovir disoproxil fumarate HIV antiretroviral therapy regimens started in pregnancy (IMPAACT 2010/VESTED): a multicentre, open-label, randomised, controlled, phase 3 trial"
10.1016_s0140-6736(21)00213-0,LANC,2021,Endocrinology/Metabolism,Phase 3,"Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial"
10.1016_s0140-6736(21)00152-5,LANC,2021,Oncology,Phase 2,"A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial"
10.1016_s0140-6736(21)00219-1,LANC,2021,Infectious Disease,Phase 3,"Posaconazole versus voriconazole for primary treatment of invasive aspergillosis: a phase 3, randomised, controlled, non-inferiority trial"
10.1016_s0140-6736(21)00125-2,LANC,2021,Rheumatology/Immunology,Phase 3,"Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial"
10.1016_s0140-6736(21)00126-4,LANC,2021,Rheumatology/Immunology,Phase 3,"Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial"
10.1016_s0140-6736(20)32714-8,LANC,2021,Oncology,Phase 3,"First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial"
10.1016_s0140-6736(20)32554-x,LANC,2021,Oncology,Phase 2,"Adavosertib plus gemcitabine for platinum-resistant or platinum-refractory recurrent ovarian cancer: a double-blind, randomised, placebo-controlled, phase 2 trial"
10.1016_s0140-6736(20)32514-9,LANC,2021,Endocrinology/Metabolism,nan,"A comparison of two hybrid closed-loop systems in adolescents and young adults with type 1 diabetes (FLAIR): a multicentre, randomised, crossover trial"
10.1016_s0140-6736(20)32544-7,LANC,2021,Neurology,Phase 2/3,"Oral rimegepant for preventive treatment of migraine: a phase 2/3, randomised, double-blind, placebo-controlled trial"
10.1016_s0140-6736(20)32541-1,LANC,2021,Infectious Disease,Phase 2,Safety and immunogenicity of two novel type 2 oral poliovirus vaccine candidates compared with a monovalent type 2 oral poliovirus vaccine in healthy adults: two clinical trials
10.1016_s0140-6736(20)32540-x,LANC,2021,Infectious Disease,Phase 2,Safety and immunogenicity of two novel type 2 oral poliovirus vaccine candidates compared with a monovalent type 2 oral poliovirus vaccine in children and infants: two clinical trials
10.1016_s0140-6736(20)32532-0,LANC,2020,Gastroenterology/Hepatology,nan,"First-attempt success rate of video laryngoscopy in small infants (VISI): a multicentre, randomised controlled trial"
10.1016_s0140-6736(20)32531-9,LANC,2020,Oncology,Phase 3,"Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial"
10.1016_s0140-6736(20)32338-2,LANC,2020,Cardiovascular,nan,"Advanced reperfusion strategies for patients with out-of-hospital cardiac arrest and refractory ventricular fibrillation (ARREST): a phase 2, single centre, open-label, randomised controlled trial"
10.1016_s0140-6736(20)32339-4,LANC,2020,Cardiovascular,Phase 4,"Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial"
10.1016_s0140-6736(20)32292-3,LANC,2020,Oncology,Phase 3,"Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial"
10.1016_s0140-6736(20)32014-6,LANC,2020,Infectious Disease,Phase 3,"Efficacy, immunogenicity, and safety of a plant-derived, quadrivalent, virus-like particle influenza vaccine in adults (18-64 years) and older adults (≥65 years): two multicentre, randomised phase 3 trials"
10.1016_s0140-6736(20)31953-x,LANC,2020,Oncology,Phase 3,"Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial"
10.1016_s0140-6736(20)31792-x,LANC,2020,Cardiovascular,Phase 3,"Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial"
10.1016_s0140-6736(20)30636-x,LANC,2020,Rheumatology/Immunology,Phase 4,"Continuing versus tapering glucocorticoids after achievement of low disease activity or remission in rheumatoid arthritis (SEMIRA): a double-blind, multicentre, randomised controlled trial"
10.1016_s0140-6736(20)30732-7,LANC,2020,Dermatology,Phase 3,"Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial"
10.1016_s0140-6736(20)31065-5,LANC,2020,Infectious Disease,Phase 3,"Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial"
10.1016_s0140-6736(20)30734-0,LANC,2020,Oncology,Phase 3,"Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study"
10.1016_s0140-6736(20)30631-0,LANC,2020,Cardiovascular,Phase 4,Dexmedetomidine for reduction of atrial fibrillation and delirium after cardiac surgery (DECADE): a randomised placebo-controlled trial
10.1016_s0140-6736(20)30609-7,LANC,2020,Dermatology,Phase 2,"Ruxolitinib cream for treatment of vitiligo: a randomised, controlled, phase 2 trial"
10.1016_s0140-6736(20)30934-x,LANC,2020,Oncology,Phase 3,"Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAF<sup>V600</sup> mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial"
10.1016_s0140-6736(20)31048-5,LANC,2020,Other,Phase 1,"Safety and immunogenicity of a mosquito saliva peptide-based vaccine: a randomised, placebo-controlled, double-blind, phase 1 trial"
10.1016_s0140-6736(20)30230-0,LANC,2020,Oncology,Phase 3,"Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial"
10.1016_s0140-6736(20)30564-x,LANC,2020,Rheumatology/Immunology,Phase 3,"Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial"
10.1016_s0140-6736(20)30470-0,LANC,2020,Infectious Disease,Phase 3,"Effectiveness of reactive focal mass drug administration and reactive focal vector control to reduce malaria transmission in the low malaria-endemic setting of Namibia: a cluster-randomised controlled, open-label, two-by-two factorial design trial"
10.1016_s0140-6736(20)30262-2,LANC,2020,Oncology,Phase 3,"Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial"
10.1016_s0140-6736(20)30554-7,LANC,2020,Cardiovascular,nan,"Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL HTN-OFF MED Pivotal): a multicentre, randomised, sham-controlled trial"
10.1016_s0140-6736(20)30611-5,LANC,2020,Neurology,Phase 3,"Efficacy of levetiracetam, fosphenytoin, and valproate for established status epilepticus by age group (ESETT): a double-blind, responsive-adaptive, randomised controlled trial"
10.1016_s0140-6736(20)30556-0,LANC,2020,Infectious Disease,Phase 2,"Safety and immunogenicity of a tetravalent dengue vaccine in children aged 2-17 years: a randomised, placebo-controlled, phase 2 trial"
10.1016_s0140-6736(20)30414-1,LANC,2020,Infectious Disease,Phase 3,"Efficacy of a tetravalent dengue vaccine in healthy children aged 4-16 years: a randomised, placebo-controlled, phase 3 trial"
10.1016_s0140-6736(20)30263-4,LANC,2020,Rheumatology/Immunology,Phase 3,"Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial"
10.1016_s0140-6736(20)30265-8,LANC,2020,Oncology,Phase 3,"Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFα inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial"
10.1016_s0140-6736(20)30258-0,LANC,2020,Cardiovascular,Phase 3,"Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre, double-blind, randomised controlled trial"
10.1016_s0140-6736(19)32990-3,LANC,2020,Infectious Disease,Phase 2,"Antiretroviral therapy alone versus antiretroviral therapy with a kick and kill approach, on measures of the HIV reservoir in participants with recent HIV infection (the RIVER trial): a phase 2, randomised trial"
10.1016_s0140-6736(19)33161-7,LANC,2020,Rheumatology/Immunology,Phase 2,"Bimekizumab in patients with active psoriatic arthritis: results from a 48-week, randomised, double-blind, placebo-controlled, dose-ranging phase 2b trial"
10.1016_s0140-6736(19)32973-3,LANC,2020,Gastroenterology/Hepatology,nan,"Low-dose aspirin for the prevention of preterm delivery in nulliparous women with a singleton pregnancy (ASPIRIN): a randomised, double-blind, placebo-controlled trial"
10.1016_s0140-6736(19)32956-3,LANC,2020,Oncology,Phase 3,"Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial"
10.1016_s0140-6736(19)32971-x,LANC,2020,Rheumatology/Immunology,Phase 3,"Ixekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X): a randomised, placebo-controlled trial"
10.1016_s0140-6736(19)32500-0,LANC,2019,Cardiovascular,Phase 3,"Fenfluramine hydrochloride for the treatment of seizures in Dravet syndrome: a randomised, double-blind, placebo-controlled trial"
10.1016_s0140-6736(19)33041-7,LANC,2019,Endocrinology / Metabolism,Phase 3,"Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial"
10.1016_s0140-6736(19)32556-5,LANC,2019,Oncology,Phase 3,"Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study"
10.1016_s0140-6736(19)32534-6,LANC,2019,Hematology,Phase 2,"Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2/3 trial"
10.1016_s0140-6736(19)32517-6,LANC,2019,Endocrinology / Metabolism,Phase 2,"Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial"
10.1016_s0140-6736(19)32597-8,LANC,2019,Respiratory,Phase 3,"Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial"
10.1016_s0140-6736(19)32591-7,LANC,2019,Oncology,Phase 3,"Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study"
10.1016_s0140-6736(19)32313-x,LANC,2019,Oncology,Phase 3,Recurrence of breast cancer after regional or general anaesthesia: a randomised controlled trial
10.1016_s0140-6736(19)32222-6,LANC,2019,Oncology,Phase 3,"Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial"
10.1016_s0140-6736(19)31881-1,LANC,2019,Respiratory,Phase 3,"Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials"
10.1016_s0140-6736(19)32131-2,LANC,2019,Endocrinology / Metabolism,Phase 4,"Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): a 5-year, multicentre, randomised, double-blind trial"
10.1016_s0140-6736(19)32135-x,LANC,2019,Cardiovascular,Phase 2,"Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebo-controlled trial"
10.1016_s0140-6736(19)31793-3,LANC,2019,Respiratory,Phase 2,"Sustained outcomes in oral immunotherapy for peanut allergy (POISED study): a large, randomised, double-blind, placebo-controlled, phase 2 study"
10.1016_s0140-6736(19)31344-3,LANC,2019,Ophthalmology,Phase 3,Ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW): an open-label randomised controlled trial
10.1016_s0140-6736(19)31817-3,LANC,2019,Rheumatology / Immunology,Phase 2/3,"Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial"
10.1016_s0140-6736(19)31872-0,LANC,2019,Hematology,Phase 3,"Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial"
10.1016_s0140-6736(19)31946-4,LANC,2019,Neurology,Phase 3,"Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial"
10.1016_s0140-6736(19)31773-8,LANC,2019,Infectious Disease,Phase 3,"Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial"
10.1016_s0140-6736(19)31606-x,LANC,2019,Infectious Disease,Phase 3,"Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial"
10.1016_s0140-6736(19)30952-3,LANC,2019,Rheumatology / Immunology,Phase 3,"Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial"
10.1016_s0140-6736(19)31388-1,LANC,2019,Gastroenterology / Hepatology,Phase 3,"Long-term safety and efficacy of veverimer in patients with metabolic acidosis in chronic kidney disease: a multicentre, randomised, blinded, placebo-controlled, 40-week extension"
10.1016_s0140-6736(19)30764-0,LANC,2019,Oncology,Phase 3,Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial
10.1016_s0140-6736(19)31149-3,LANC,2019,Cardiovascular,Phase 3,"Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial"
10.1016_s0140-6736(19)31150-x,LANC,2019,Cardiovascular,Phase 3,"Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial"
10.1016_s0140-6736(19)31271-1,LANC,2019,Endocrinology / Metabolism,Phase 3,"Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial"
10.1016_s0140-6736(19)31279-6,LANC,2019,Infectious Disease,Phase 1,"The safety and immunogenicity of two novel live attenuated monovalent (serotype 2) oral poliovirus vaccines in healthy adults: a double-blind, single-centre phase 1 study"
10.1016_s0140-6736(19)31240-1,LANC,2019,Oncology,Phase 3,"Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study"
10.1016_s0140-6736(19)30419-2,LANC,2019,Cardiovascular,Phase 3,"Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study"
10.1016_s0140-6736(19)30654-3,LANC,2019,Rheumatology / Immunology,Phase 3,"Burosumab versus conventional therapy in children with X-linked hypophosphataemia: a randomised, active-controlled, open-label, phase 3 trial"
10.1016_s0140-6736(19)30723-8,LANC,2019,Oncology,Phase 3,"Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial"
10.1016_s0140-6736(19)30772-x,LANC,2019,Hematology,Phase 3,"Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial"
10.1016_s0140-6736(18)32409-7,LANC,2019,Oncology,Phase 3,"Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial"
10.1016_s0140-6736(18)32224-4,LANC,2019,Infectious Disease,Phase 3,"Monthly sulfadoxine-pyrimethamine versus dihydroartemisinin-piperaquine for intermittent preventive treatment of malaria in pregnancy: a double-blind, randomised, controlled, superiority trial"
10.1016_s0140-6736(18)32321-3,LANC,2019,Infectious Disease,Phase 2/3,Efficacy and risk of harms of repeat ivermectin mass drug administrations for control of malaria (RIMDAMAL): a cluster-randomised trial
10.1016_s0140-6736(19)30297-1,LANC,2019,Hematology,nan,"Aspiration thrombectomy versus stent retriever thrombectomy as first-line approach for large vessel occlusion (COMPASS): a multicentre, randomised, open label, blinded outcome, non-inferiority trial"
10.1016_s0140-6736(18)32562-5,LANC,2019,Infectious Disease,Phase 3,"Veverimer versus placebo in patients with metabolic acidosis associated with chronic kidney disease: a multicentre, randomised, double-blind, controlled, phase 3 trial"
10.1016_s0140-6736(18)32593-5,LANC,2019,Infectious Disease,nan,Chlorhexidine versus routine bathing to prevent multidrug-resistant organisms and all-cause bloodstream infections in general medical and surgical units (ABATE Infection trial): a cluster-randomised trial
10.1016_s0140-6736(18)32485-1,LANC,2019,Neurology,Phase 4,"Neurodevelopmental outcome at 5 years of age after general anaesthesia or awake-regional anaesthesia in infancy (GAS): an international, multicentre, randomised, controlled equivalence trial"
10.1016_s0140-6736(19)30195-3,LANC,2019,Hematology,Phase 3,"Efficacy and safety of minimally invasive surgery with thrombolysis in intracerebral haemorrhage evacuation (MISTIE III): a randomised, controlled, open-label, blinded endpoint phase 3 trial"
10.1016_s0140-6736(19)30038-8,LANC,2019,Cardiovascular,Phase 3,"Intensive blood pressure reduction with intravenous thrombolysis therapy for acute ischaemic stroke (ENCHANTED): an international, randomised, open-label, blinded-endpoint, phase 3 trial"
10.1016_s0140-6736(18)31785-9,LANC,2019,Endocrinology / Metabolism,Phase 2,"Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial"
10.1016_s0140-6736(18)33003-4,LANC,2019,Oncology,Phase 3,"Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial"
10.1016_s0140-6736(18)32984-2,LANC,2019,Oncology,Phase 3,"Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial"
10.1016_s0140-6736(18)32818-6,LANC,2019,Cardiovascular,nan,"Visualization of asymptomatic atherosclerotic disease for optimum cardiovascular prevention (VIPVIZA): a pragmatic, open-label, randomised controlled trial"
10.1016_s0140-6736(18)31999-8,LANC,2019,Oncology,Phase 3,"Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study"
10.1016_s0140-6736(18)32779-x,LANC,2019,Oncology,Phase 3,"Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial"
10.1016_s0140-6736(18)32462-0,LANC,2019,Infectious Disease,Phase 3,"Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials"
10.1016_s0140-6736(18)32488-7,LANC,2019,Infectious Disease,Phase 2,"Immunogenicity, safety, and tolerability of the measles-vectored chikungunya virus vaccine MV-CHIK: a double-blind, randomised, placebo-controlled and active-controlled phase 2 trial"
10.1016_s0140-6736(18)32534-0,LANC,2018,Neurology,Phase 3,"Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study"
10.1016_s0140-6736(18)32328-6,LANC,2018,Cardiovascular,Phase 4,"Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial"
10.1016_s0140-6736(18)32260-8,LANC,2018,Endocrinology / Metabolism,Phase 2,"Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial"
10.1016_s0140-6736(18)32261-x,LANC,2018,Oncology,Phase 4,"Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial"
10.1016_s0140-6736(18)31543-5,LANC,2018,Obstetrics / Gynecology,nan,"Awareness of fetal movements and care package to reduce fetal mortality (AFFIRM): a stepped wedge, cluster-randomised trial"
10.1016_s0140-6736(18)32283-9,LANC,2018,Cardiovascular,nan,Blinded outcomes and angina assessment of coronary bioresorbable scaffolds: 30-day and 1-year results from the ABSORB IV randomised trial
10.1016_s0140-6736(18)32262-1,LANC,2018,Cardiovascular,nan,"A polymer-coated, paclitaxel-eluting stent (Eluvia) versus a polymer-free, paclitaxel-coated stent (Zilver PTX) for endovascular femoropopliteal intervention (IMPERIAL): a randomised, non-inferiority trial"
10.1016_s0140-6736(18)32167-6,LANC,2018,Infectious Disease,Phase 2,"Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double-blind, phase 2, randomised, controlled study"
10.1016_s0140-6736(18)31487-9,LANC,2018,Infectious Disease,nan,"A scalable, integrated intervention to engage people who inject drugs in HIV care and medication-assisted treatment (HPTN 074): a randomised, controlled phase 3 feasibility and efficacy study"
10.1016_s0140-6736(18)31551-4,LANC,2018,Hematology,Phase 3,"Brexanolone injection in post-partum depression: two multicentre, double-blind, randomised, placebo-controlled, phase 3 trials"
10.1016_s0140-6736(18)31923-8,LANC,2018,Cardiovascular,nan,"High-sensitivity troponin in the evaluation of patients with suspected acute coronary syndrome: a stepped-wedge, cluster-randomised controlled trial"
10.1016_s0140-6736(18)31773-2,LANC,2018,Endocrinology / Metabolism,Phase 2,"Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial"
10.1016_s0140-6736(18)31364-3,LANC,2018,Infectious Disease,Phase 1/2,"Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19)"
10.1016_s0140-6736(18)31363-1,LANC,2018,Infectious Disease,Phase 2,"Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial"
10.1016_s0140-6736(18)31553-8,LANC,2018,Hematology,Phase 2,Plasma-first resuscitation to treat haemorrhagic shock during emergency ground transportation in an urban area: a randomised trial
10.1016_s0140-6736(18)31362-x,LANC,2018,Respiratory,Phase 3,"Efficacy and safety of continuing versus withdrawing adalimumab therapy in maintaining remission in patients with non-radiographic axial spondyloarthritis (ABILITY-3): a multicentre, randomised, double-blind study"
10.1016_s0140-6736(18)30726-8,LANC,2018,Endocrinology / Metabolism,Phase 1/2,"MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: a randomised, controlled, double-blind, ascending dose and phase 2a study"
10.1016_s0140-6736(18)31116-4,LANC,2018,Cardiovascular,Phase 3,"Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial"
10.1016_s0140-6736(18)31115-2,LANC,2018,Cardiovascular,Phase 3,"Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial"
10.1016_s0140-6736(18)31257-1,LANC,2018,Oncology,Phase 3,"Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial"
10.1016_s0140-6736(18)31082-1,LANC,2018,Cardiovascular,nan,"Endovascular ultrasound renal denervation to treat hypertension (RADIANCE-HTN SOLO): a multicentre, international, single-blind, randomised, sham-controlled trial"
10.1016_s0140-6736(18)30951-6,LANC,2018,Cardiovascular,nan,Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial
10.1016_s0140-6736(18)30474-4,LANC,2018,Endocrinology / Metabolism,Phase 2,"NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial"
10.1016_s0140-6736(17)33297-x,LANC,2018,Oncology,Phase 3,"Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial"
10.1016_s0140-6736(17)33103-3,LANC,2018,Cardiovascular,nan,"A sirolimus-eluting bioabsorbable polymer-coated stent (MiStent) versus an everolimus-eluting durable polymer stent (Xience) after percutaneous coronary intervention (DESSOLVE III): a randomised, single-blind, multicentre, non-inferiority, phase 3 trial"
10.1016_s0140-6736(17)32812-x,LANC,2018,Psychiatry / Mental Health,Phase 4,"Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial"
10.1016_s0140-6736(17)32409-1,LANC,2018,Hematology,Phase 3,"Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial"
10.1016_s0140-6736(17)32458-3,LANC,2018,Hematology,Phase 3,"Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial"
10.1016_s0140-6736(17)32146-3,LANC,2018,Cardiovascular,nan,"Enteral versus parenteral early nutrition in ventilated adults with shock: a randomised, controlled, multicentre, open-label, parallel-group study (NUTRIREA-2)"
10.1016_s0140-6736(17)32714-9,LANC,2018,Hematology,nan,"Percutaneous coronary intervention in stable angina (ORBITA): a double-blind, randomised controlled trial"
10.1016_s0140-6736(17)32365-6,LANC,2017,Oncology,Phase 3,"Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial"
10.1016_s0140-6736(17)32440-6,LANC,2017,Oncology,Phase 3,"Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial"
10.1016_s0140-6736(17)32340-1,LANC,2017,Infectious Disease,Phase 3,"Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380-1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial"
10.1016_s0140-6736(17)32299-7,LANC,2017,Infectious Disease,Phase 3,"Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial"
10.1016_s0140-6736(17)32281-x,LANC,2017,Cardiovascular,nan,"Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED): a randomised, sham-controlled, proof-of-concept trial"
10.1016_s0140-6736(17)32247-x,LANC,2017,Oncology,Phase 3,"Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial"
10.1016_s0140-6736(17)32249-3,LANC,2017,Cardiovascular,nan,"Ultrathin, bioresorbable polymer sirolimus-eluting stents versus thin, durable polymer everolimus-eluting stents in patients undergoing coronary revascularisation (BIOFLOW V): a randomised trial"
10.1016_s0140-6736(17)31917-7,LANC,2017,Infectious Disease,Phase 2,"Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial"
10.1016_s0140-6736(16)31399-x,LANC,2017,Respiratory,Phase 3,Should recommendations about starting inhaled corticosteroid treatment for mild asthma be based on symptom frequency: a post-hoc efficacy analysis of the START study
10.1016_s0140-6736(16)32389-3,LANC,2016,Oncology,Phase 3,"Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial"
10.1016_s0140-6736(16)31419-2,LANC,2016,Oncology,Phase 3,"Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study"
10.1016_s0140-6736(16)31339-3,LANC,2016,Oncology,Phase 3,"Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial"
10.1016_s0140-6736(15)01281-7,LANC,2016,Oncology,Phase 2/3,"Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial"
10.1016_s0140-6736(15)01021-1,LANC,2016,Infectious Disease,Phase 3,Prednisone versus prednisone plus ciclosporin versus prednisone plus methotrexate in new-onset juvenile dermatomyositis: a randomised trial
10.1016_s0140-6736(15)00608-x,LANC,2016,Neurology,Phase 4,"Neurodevelopmental outcome at 2 years of age after general anaesthesia and awake-regional anaesthesia in infancy (GAS): an international multicentre, randomised controlled trial"
10.1016_s0140-6736(15)60995-3,LANC,2015,Oncology,Phase 3,"Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial"
10.1001_jama.2025.26967,JAMA,2026,Other,nan,Electronic Health Record Intervention and Deprescribing for Older Adults: A Randomized Clinical Trial
10.1001_jama.2025.23988,JAMA,2026,Gastroenterology/Hepatology,nan,Minor Papillotomy for Treatment of Idiopathic Acute Pancreatitis With Pancreas Divisum: A Randomized Clinical Trial
10.1001_jama.2025.21990,JAMA,2026,Musculoskeletal/Pain,Phase 3,Spinal Manipulation and Clinician-Supported Biopsychosocial Self-Management for Acute Back Pain: The PACBACK Randomized Clinical Trial
10.1001_jama.2025.21738,JAMA,2026,Infectious Disease,Phase 2,Valacyclovir Treatment of Early Symptomatic Alzheimer Disease: The VALAD Randomized Clinical Trial
10.1001_jama.2025.24384,JAMA,2026,Surgery/Critical Care,nan,Effect of Automated Closed-Loop Ventilation vs Protocolized Conventional Ventilation on Ventilator-Free Days in Critically Ill Adults: A Randomized Clinical Trial
10.1001_jama.2025.23373,JAMA,2026,Respiratory,nan,Intraoperative Driving Pressure-Guided High PEEP vs Standard Low PEEP for Postoperative Pulmonary Complications
10.1001_jama.2025.21112,JAMA,2026,Cardiovascular,nan,DASH-Patterned Groceries and Effects on Blood Pressure: The GoFresh Randomized Clinical Trial
10.1001_jama.2025.20620,JAMA,2026,Other,Phase 3,Efficacy and Safety of Oral PCSK9 Inhibitor Enlicitide in Adults With Heterozygous Familial Hypercholesterolemia: A Randomized Clinical Trial
10.1001_jama.2025.21056,JAMA,2026,Cardiovascular,nan,Caffeinated Coffee Consumption or Abstinence to Reduce Atrial Fibrillation: The DECAF Randomized Clinical Trial
10.1001_jama.2025.21358,JAMA,2026,Cardiovascular,Phase 3,Metformin to Improve Walking Performance in Lower Extremity Peripheral Artery Disease: The PERMET Randomized Clinical Trial
10.1001_jama.2025.20841,JAMA,2025,Cardiovascular,nan,Liberal or Restrictive Postoperative Transfusion in Patients at High Cardiac Risk: The TOP Randomized Clinical Trial
10.1001_jama.2025.19563,JAMA,2025,Endocrinology/Metabolism,nan,An AI-Powered Lifestyle Intervention vs Human Coaching in the Diabetes Prevention Program: A Randomized Clinical Trial
10.1001_jama.2025.18168,JAMA,2025,Hematology,Phase 3,Eltrombopag for Newly Diagnosed Pediatric Immune Thrombocytopenia Requiring Treatment: The PINES Randomized Clinical Trial
10.1001_jama.2025.17281,JAMA,2025,Oncology,nan,A Direct-to-Patient Digital Health Program for Lung Cancer Screening: A Randomized Clinical Trial
10.1001_jama.2025.16450,JAMA,2025,Respiratory,Phase 3,Early Intratracheal Budesonide to Reduce Bronchopulmonary Dysplasia in Extremely Preterm Infants: The Budesonide in Babies (BiB) Randomized Clinical Trial
10.1001_jama.2025.13481,JAMA,2025,Neurology,Phase 2,Single Treatment With MM120 (Lysergide) in Generalized Anxiety Disorder: A Randomized Clinical Trial
10.1001_jama.2025.6681,JAMA,2025,Cardiovascular,Phase 2,Add-On Treatment With Zilebesiran for Inadequately Controlled Hypertension: The KARDIA-2 Randomized Clinical Trial
10.1001_jama.2025.7200,JAMA,2025,Surgery/Critical Care,Phase 3,Dexmedetomidine- or Clonidine-Based Sedation Compared With Propofol in Critically Ill Patients: The A2B Randomized Clinical Trial
10.1001_jama.2025.5791,JAMA,2025,Pediatrics,Phase 3,Extended Caffeine for Apnea in Moderately Preterm Infants: The MoCHA Randomized Clinical Trial
10.1001_jama.2025.3810,JAMA,2025,Gastroenterology/Hepatology,Phase 4,Varenicline for Youth Nicotine Vaping Cessation: A Randomized Clinical Trial
10.1001_jama.2025.1483,JAMA,2025,Oncology,Phase 3,Atezolizumab in High-Risk Locally Advanced Squamous Cell Carcinoma of the Head and Neck: A Randomized Clinical Trial
10.1001_jama.2025.1604,JAMA,2025,Neurology,Phase 3,High-Dose Vitamin D in Clinically Isolated Syndrome Typical of Multiple Sclerosis: The D-Lay MS Randomized Clinical Trial
10.1001_jama.2024.25845,JAMA,2025,Neurology,nan,Palliative Care Program for Community-Dwelling Individuals With Dementia and Caregivers: The IN-PEACE Randomized Clinical Trial
10.1001_jama.2024.25056,JAMA,2025,Neurology,nan,"Health System, Community-Based, or Usual Dementia Care for Persons With Dementia and Caregivers: The D-CARE Randomized Clinical Trial"
10.1001_jama.2024.23696,JAMA,2025,Other,nan,Palliative Care Initiated in the Emergency Department: A Cluster Randomized Clinical Trial
10.1001_jama.2024.26244,JAMA,2025,Infectious Disease,nan,High-Flow Nasal Oxygen vs Noninvasive Ventilation in Patients With Acute Respiratory Failure: The RENOVATE Randomized Clinical Trial
10.1001_jama.2024.21739,JAMA,2025,Cardiovascular,nan,Personalized Patient Data and Behavioral Nudges to Improve Adherence to Chronic Cardiovascular Medications: A Randomized Pragmatic Trial
10.1001_jama.2024.24017,JAMA,2025,Cardiovascular,Phase 2,Oral Muvalaplin for Lowering of Lipoprotein(a): A Randomized Clinical Trial
10.1001_jama.2024.21957,JAMA,2024,Cardiovascular,Phase 2,Zerlasiran-A Small-Interfering RNA Targeting Lipoprotein(a): A Phase 2 Randomized Clinical Trial
10.1001_jama.2024.19585,JAMA,2024,Oncology,nan,Symptom Screening Linked to Care Pathways for Pediatric Patients With Cancer: A Randomized Clinical Trial
10.1001_jama.2024.22362,JAMA,2024,Endocrinology/Metabolism,nan,A Digital Health Behavior Intervention to Prevent Childhood Obesity: The Greenlight Plus Randomized Clinical Trial
10.1001_jama.2024.22718,JAMA,2024,Nephrology/Urology,nan,"Early, Individualized Recommendations for Hospitalized Patients With Acute Kidney Injury: A Randomized Clinical Trial"
10.1001_jama.2024.20651,JAMA,2024,Surgery/Critical Care,nan,Effect of Tele-ICU on Clinical Outcomes of Critically Ill Patients: The TELESCOPE Randomized Clinical Trial
10.1001_jama.2024.14887,JAMA,2024,Oncology,nan,Screening for Helicobacter pylori to Prevent Gastric Cancer: A Pragmatic Randomized Clinical Trial
10.1001_jama.2024.14745,JAMA,2024,Cardiovascular,nan,Fever Prevention in Patients With Acute Vascular Brain Injury: The INTREPID Randomized Clinical Trial
10.1001_jama.2024.11463,JAMA,2024,Cardiovascular,Phase 3,Edetate Disodium-Based Chelation for Patients With a Previous Myocardial Infarction and Diabetes: TACT2 Randomized Clinical Trial
10.1001_jama.2024.11057,JAMA,2024,Gastroenterology/Hepatology,nan,A Vaping Cessation Text Message Program for Adolescent E-Cigarette Users: A Randomized Clinical Trial
10.1001_jama.2024.12414,JAMA,2024,Gastroenterology/Hepatology,Phase 2/3,Risankizumab for Ulcerative Colitis: Two Randomized Clinical Trials
10.1001_jama.2024.9779,JAMA,2024,Infectious Disease,nan,Continuous vs Intermittent β-Lactam Antibiotic Infusions in Critically Ill Patients With Sepsis: The BLING III Randomized Clinical Trial
10.1001_jama.2024.9217,JAMA,2024,Endocrinology/Metabolism,Phase 3,Tirzepatide for Weight Reduction in Chinese Adults With Obesity: The SURMOUNT-CN Randomized Clinical Trial
10.1001_jama.2024.8772,JAMA,2024,Infectious Disease,Phase 2,Acetaminophen for Prevention and Treatment of Organ Dysfunction in Critically Ill Patients With Sepsis: The ASTER Randomized Clinical Trial
10.1001_jama.2024.8693,JAMA,2024,Respiratory,Phase 3,Pamrevlumab for Idiopathic Pulmonary Fibrosis: The ZEPHYRUS-1 Randomized Clinical Trial
10.1001_jama.2024.4783,JAMA,2024,Oncology,Phase 3,Ponatinib vs Imatinib in Frontline Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Randomized Clinical Trial
10.1001_jama.2024.4183,JAMA,2024,Other,Phase 4,Smoking Cessation After Initial Treatment Failure With Varenicline or Nicotine Replacement: A Randomized Clinical Trial
10.1001_jama.2024.4840,JAMA,2024,Oncology,Phase 3,Aspirin vs Placebo as Adjuvant Therapy for Breast Cancer: The Alliance A011502 Randomized Trial
10.1001_jama.2024.6248,JAMA,2024,Infectious Disease,nan,Stewardship Prompts to Improve Antibiotic Selection for Pneumonia: The INSPIRE Randomized Clinical Trial
10.1001_jama.2024.6259,JAMA,2024,Infectious Disease,nan,Stewardship Prompts to Improve Antibiotic Selection for Urinary Tract Infection: The INSPIRE Randomized Clinical Trial
10.1001_jama.2024.2452,JAMA,2024,Infectious Disease,nan,Integrated Hepatitis C-Opioid Use Disorder Care Through Facilitated Telemedicine: A Randomized Trial
10.1001_jama.2024.1215,JAMA,2024,Oncology,Phase 1/2,Aspirin for Metabolic Dysfunction-Associated Steatotic Liver Disease Without Cirrhosis: A Randomized Clinical Trial
10.1001_jama.2024.0762,JAMA,2024,Other,nan,Video Laryngoscopy vs Direct Laryngoscopy for Endotracheal Intubation in the Operating Room: A Cluster Randomized Clinical Trial
10.1001_jama.2023.27393,JAMA,2024,Infectious Disease,Phase 4,Mass Azithromycin Distribution to Prevent Child Mortality in Burkina Faso: The CHAT Randomized Clinical Trial
10.1001_jama.2023.24035,JAMA,2024,Cardiovascular,nan,"Nurse and Social Worker Palliative Telecare Team and Quality of Life in Patients With COPD, Heart Failure, or Interstitial Lung Disease: The ADAPT Randomized Clinical Trial"
10.1001_jama.2023.24945,JAMA,2024,Endocrinology/Metabolism,Phase 3,Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial
10.1001_jama.2023.22949,JAMA,2023,Endocrinology/Metabolism,Phase 3,Metformin Plus Insulin for Preexisting Diabetes or Gestational Diabetes in Early Pregnancy: The MOMPOD Randomized Clinical Trial
10.1001_jama.2023.22114,JAMA,2023,Respiratory,nan,Adenotonsillectomy for Snoring and Mild Sleep Apnea in Children: A Randomized Clinical Trial
10.1001_jama.2023.20181,JAMA,2023,Oncology,Phase 3,Toripalimab Plus Chemotherapy for Recurrent or Metastatic Nasopharyngeal Carcinoma: The JUPITER-02 Randomized Clinical Trial
10.1001_jama.2023.21471,JAMA,2023,Oncology,nan,Strategies to Increase Cervical Cancer Screening With Mailed Human Papillomavirus Self-Sampling Kits: A Randomized Clinical Trial
10.1001_jama.2023.19597,JAMA,2023,Cardiovascular,nan,"Effects of the Million Hearts Model on Myocardial Infarctions, Strokes, and Medicare Spending: A Randomized Clinical Trial"
10.1001_jama.2023.17219,JAMA,2023,Infectious Disease,Phase 4,Nasal Iodophor Antiseptic vs Nasal Mupirocin Antibiotic in the Setting of Chlorhexidine Bathing to Prevent Infections in Adult ICUs: A Randomized Clinical Trial
10.1001_jama.2023.18755,JAMA,2023,Oncology,nan,A Multilevel Primary Care Intervention to Improve Follow-Up of Overdue Abnormal Cancer Screening Test Results: A Cluster Randomized Clinical Trial
10.1001_jama.2023.16893,JAMA,2023,Cardiovascular,nan,Remote Ischemic Conditioning for Acute Stroke: The RESIST Randomized Clinical Trial
10.1001_jama.2023.20294,JAMA,2023,Endocrinology/Metabolism,Phase 3,Tirzepatide vs Insulin Lispro Added to Basal Insulin in Type 2 Diabetes: The SURPASS-6 Randomized Clinical Trial
10.1001_jama.2023.19869,JAMA,2023,Endocrinology/Metabolism,Phase 3,Early Metformin in Gestational Diabetes: A Randomized Clinical Trial
10.1001_jama.2023.14330,JAMA,2023,Cardiovascular,Phase 2,Blood Pressure Management After Endovascular Therapy for Acute Ischemic Stroke: The BEST-II Randomized Clinical Trial
10.1001_jama.2023.12317,JAMA,2023,Obstetrics/Gynecology,Phase 4,Perioperative Vaginal Estrogen as Adjunct to Native Tissue Vaginal Apical Prolapse Repair: A Randomized Clinical Trial
10.1001_jama.2023.11887,JAMA,2023,Oncology,Phase 2,Atorvastatin for Anthracycline-Associated Cardiac Dysfunction: The STOP-CA Randomized Clinical Trial
10.1001_jama.2023.10812,JAMA,2023,Gastroenterology/Hepatology,Phase 3,Cervical Pessary for Prevention of Preterm Birth in Individuals With a Short Cervix: The TOPS Randomized Clinical Trial
10.1001_jama.2023.10854,JAMA,2023,Infectious Disease,Phase 3,Identifying Children Likely to Benefit From Antibiotics for Acute Sinusitis: A Randomized Clinical Trial
10.1001_jama.2023.10042,JAMA,2023,Other,Phase 3,Cytisinicline for Smoking Cessation: A Randomized Clinical Trial
10.1001_jama.2023.11313,JAMA,2023,Endocrinology/Metabolism,Phase 3,Once-Weekly Insulin Icodec vs Once-Daily Insulin Degludec in Adults With Insulin-Naive Type 2 Diabetes: The ONWARDS 3 Randomized Clinical Trial
10.1001_jama.2023.8061,JAMA,2023,Endocrinology/Metabolism,nan,Family-Based Behavioral Treatment for Childhood Obesity Implemented in Pediatric Primary Care: A Randomized Clinical Trial
10.1001_jama.2023.7843,JAMA,2023,Oncology,nan,Direct Oral Anticoagulants vs Low-Molecular-Weight Heparin and Recurrent VTE in Patients With Cancer: A Randomized Clinical Trial
10.1001_jama.2023.7197,JAMA,2023,Pediatrics,nan,Community Health Workers in Early Childhood Well-Child Care for Medicaid-Insured Children: A Randomized Clinical Trial
10.1001_jama.2023.4428,JAMA,2023,Oncology,Phase 3,"Panitumumab vs Bevacizumab Added to Standard First-line Chemotherapy and Overall Survival Among Patients With RAS Wild-type, Left-Sided Metastatic Colorectal Cancer: A Randomized Clinical Trial"
10.1001_jama.2023.4314,JAMA,2023,Infectious Disease,Phase 2,"VE303, a Defined Bacterial Consortium, for Prevention of Recurrent Clostridioides difficile Infection: A Randomized Clinical Trial"
10.1001_jama.2023.1936,JAMA,2023,Obstetrics/Gynecology,nan,Early vs Interval Postpartum Intrauterine Device Placement: A Randomized Clinical Trial
10.1001_jama.2022.24388,JAMA,2023,Infectious Disease,Phase 3,Effect of Intrapartum Azithromycin vs Placebo on Neonatal Sepsis and Death: A Randomized Clinical Trial
10.1001_jama.2023.2854,JAMA,2023,Cardiovascular,nan,Coordinated Care to Optimize Cardiovascular Preventive Therapies in Type 2 Diabetes: A Randomized Clinical Trial
10.1001_jama.2022.23924,JAMA,2023,Cardiovascular,Phase 3,Effect of Torsemide vs Furosemide After Discharge on All-Cause Mortality in Patients Hospitalized With Heart Failure: The TRANSFORM-HF Randomized Clinical Trial
10.1001_jama.2022.21820,JAMA,2022,Infectious Disease,nan,Effect of a Community Health Worker-Delivered Personal Sound Amplification Device on Self-Perceived Communication Function in Older Adults With Hearing Loss: A Randomized Clinical Trial
10.1001_jama.2022.22625,JAMA,2022,Musculoskeletal/Pain,nan,Effect of a Biopsychosocial Intervention or Postural Therapy on Disability and Health Care Spending Among Patients With Acute and Subacute Spine Pain: The SPINE CARE Randomized Clinical Trial
10.1001_jama.2022.21177,JAMA,2022,Endocrinology/Metabolism,nan,Effect of a Remotely Delivered Self-directed Behavioral Intervention on Body Weight and Physical Health Status Among Adults With Obesity: The D-ELITE Randomized Clinical Trial
10.1001_jama.2022.21680,JAMA,2022,Other,nan,Effects of Mindfulness Training and Exercise on Cognitive Function in Older Adults: A Randomized Clinical Trial
10.1001_jama.2022.21893,JAMA,2022,Endocrinology/Metabolism,nan,Effect of Diet and Exercise on Knee Pain in Patients With Osteoarthritis and Overweight or Obesity: A Randomized Clinical Trial
10.1001_jama.2022.18590,JAMA,2022,Infectious Disease,Phase 3,Effect of Ivermectin vs Placebo on Time to Sustained Recovery in Outpatients With Mild to Moderate COVID-19: A Randomized Clinical Trial
10.1001_jama.2022.17735,JAMA,2022,Respiratory,Phase 1,Effect of Paroxetine or Quetiapine Combined With Oxycodone vs Oxycodone Alone on Ventilation During Hypercapnia: A Randomized Clinical Trial
10.1001_jama.2022.16797,JAMA,2022,Cardiovascular,nan,Effect of Telmisartan on Walking Performance in Patients With Lower Extremity Peripheral Artery Disease: The TELEX Randomized Clinical Trial
10.1001_jama.2022.16464,JAMA,2022,Oncology,Phase 3,Effect of First-Line Serplulimab vs Placebo Added to Chemotherapy on Survival in Patients With Extensive-Stage Small Cell Lung Cancer: The ASTRUM-005 Randomized Clinical Trial
10.1001_jama.2022.16197,JAMA,2022,Cardiovascular,nan,Five-Year Outcomes in Patients With Fully Magnetically Levitated vs Axial-Flow Left Ventricular Assist Devices in the MOMENTUM 3 Randomized Trial
10.1001_jama.2022.10564,JAMA,2022,Hematology,Phase 3,Effect of Intravitreal Aflibercept vs Laser Photocoagulation on Treatment Success of Retinopathy of Prematurity: The FIREFLEYE Randomized Clinical Trial
10.1001_jama.2022.11016,JAMA,2022,Cardiovascular,Phase 3,Effect of Omecamtiv Mecarbil on Exercise Capacity in Chronic Heart Failure With Reduced Ejection Fraction: The METEORIC-HF Randomized Clinical Trial
10.1001_jama.2022.9805,JAMA,2022,Psychiatry/Mental Health,nan,Effect of Pharmacogenomic Testing for Drug-Gene Interactions on Medication Selection and Remission of Symptoms in Major Depressive Disorder: The PRIME Care Randomized Clinical Trial
10.1001_jama.2022.9703,JAMA,2022,Obstetrics/Gynecology,nan,Effect of an Intensive Nurse Home Visiting Program on Adverse Birth Outcomes in a Medicaid-Eligible Population: A Randomized Clinical Trial
10.1001_jama.2022.8274,JAMA,2022,Other,Phase 4,Effect of Varenicline Added to Counseling on Smoking Cessation Among African American Daily Smokers: The Kick It at Swope IV Randomized Clinical Trial
10.1001_jama.2022.9265,JAMA,2022,Oncology,nan,Effect of Electronic Symptom Monitoring on Patient-Reported Outcomes Among Patients With Metastatic Cancer: A Randomized Clinical Trial
10.1001_jama.2022.6147,JAMA,2022,Oncology,Phase 3,Effect of Metformin vs Placebo on Invasive Disease-Free Survival in Patients With Breast Cancer: The MA.32 Randomized Clinical Trial
10.1001_jama.2022.4315,JAMA,2022,Neurology,Phase 3,Effect of Different Corticosteroid Dosing Regimens on Clinical Outcomes in Boys With Duchenne Muscular Dystrophy: A Randomized Clinical Trial
10.1001_jama.2022.2832,JAMA,2022,Infectious Disease,Phase 2/3,Effect of Sotrovimab on Hospitalization or Death Among High-risk Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial
10.1001_jama.2022.0799,JAMA,2022,Psychiatry/Mental Health,Phase 3,Effect of Sublingual Dexmedetomidine vs Placebo on Acute Agitation Associated With Bipolar Disorder: A Randomized Clinical Trial
10.1001_jama.2022.1025,JAMA,2022,Cardiovascular,nan,"Effect of Intra-arrest Transport, Extracorporeal Cardiopulmonary Resuscitation, and Immediate Invasive Assessment and Treatment on Functional Neurologic Outcome in Refractory Out-of-Hospital Cardiac Arrest: A Randomized Clinical Trial"
10.1001_jama.2022.0423,JAMA,2022,Psychiatry/Mental Health,nan,Effect of Offering Care Management or Online Dialectical Behavior Therapy Skills Training vs Usual Care on Self-harm Among Adult Outpatients With Suicidal Ideation: A Randomized Clinical Trial
10.1001_jama.2022.1645,JAMA,2022,Cardiovascular,Phase 2/3,Effect of Intra-arterial Alteplase vs Placebo Following Successful Thrombectomy on Functional Outcomes in Patients With Large Vessel Occlusion Acute Ischemic Stroke: The CHOICE Randomized Clinical Trial
10.1001_jama.2022.0078,JAMA,2022,Endocrinology/Metabolism,Phase 3,Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial
10.1001_jama.2021.23605,JAMA,2022,Infectious Disease,Phase 4,Effect of P2Y12 Inhibitors on Survival Free of Organ Support Among Non-Critically Ill Hospitalized Patients With COVID-19: A Randomized Clinical Trial
10.1001_jama.2021.24939,JAMA,2022,Infectious Disease,Phase 3,Effect of Subcutaneous Casirivimab and Imdevimab Antibody Combination vs Placebo on Development of Symptomatic COVID-19 in Early Asymptomatic SARS-CoV-2 Infection: A Randomized Clinical Trial
10.1001_jama.2021.23182,JAMA,2022,Hematology,Phase 3,Effect of Anticoagulant Therapy for 6 Weeks vs 3 Months on Recurrence and Bleeding Events in Patients Younger Than 21 Years of Age With Provoked Venous Thromboembolism: The Kids-DOTT Randomized Clinical Trial
10.1001_jama.2021.23619,JAMA,2022,Endocrinology/Metabolism,Phase 3,Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial
10.1001_jama.2021.22596,JAMA,2022,Oncology,nan,Effect of a Community-Based Medical Oncology Depression Screening Program on Behavioral Health Referrals Among Patients With Breast Cancer: A Randomized Clinical Trial
10.1001_jama.2021.22647,JAMA,2022,Surgery/Critical Care,nan,Effect of Regional vs General Anesthesia on Incidence of Postoperative Delirium in Older Patients Undergoing Hip Fracture Surgery: The RAGA Randomized Trial
10.1001_jama.2021.21187,JAMA,2021,Oncology,Phase 3,Effect of Long-term Supplementation With Marine Omega-3 Fatty Acids vs Placebo on Risk of Depression or Clinically Relevant Depressive Symptoms and on Change in Mood Scores: A Randomized Clinical Trial
10.1001_jama.2021.20929,JAMA,2021,Other,Phase 2,Effect of Intravenous or Intraosseous Calcium vs Saline on Return of Spontaneous Circulation in Adults With Out-of-Hospital Cardiac Arrest: A Randomized Clinical Trial
10.1001_jama.2021.18463,JAMA,2021,Cardiovascular,Phase 3,Effect of Sacubitril/Valsartan vs Standard Medical Therapies on Plasma NT-proBNP Concentration and Submaximal Exercise Capacity in Patients With Heart Failure and Preserved Ejection Fraction: The PARALLAX Randomized Clinical Trial
10.1001_jama.2021.15333,JAMA,2021,Rheumatology/Immunology,Phase 4,Effects of Combined Varenicline With Nicotine Patch and of Extended Treatment Duration on Smoking Cessation: A Randomized Clinical Trial
10.1001_jama.2021.15703,JAMA,2021,Cardiovascular,nan,Effect of Moderate vs Mild Therapeutic Hypothermia on Mortality and Neurologic Outcomes in Comatose Survivors of Out-of-Hospital Cardiac Arrest: The CAPITAL CHILL Randomized Clinical Trial
10.1001_jama.2021.17272,JAMA,2021,Infectious Disease,Phase 3,Effect of Antithrombotic Therapy on Clinical Outcomes in Outpatients With Clinically Stable Symptomatic COVID-19: The ACTIV-4B Randomized Clinical Trial
10.1001_jama.2021.14846,JAMA,2021,Respiratory,nan,Effect of a Pulmonary Embolism Diagnostic Strategy on Clinical Outcomes in Patients Hospitalized for COPD Exacerbation: A Randomized Clinical Trial
10.1001_jama.2021.16628,JAMA,2021,Cardiovascular,Phase 2/3,Effect of Vasopressin and Methylprednisolone vs Placebo on Return of Spontaneous Circulation in Patients With In-Hospital Cardiac Arrest: A Randomized Clinical Trial
10.1001_jama.2021.11559,JAMA,2021,Respiratory,nan,Effect of School Integrated Pest Management or Classroom Air Filter Purifiers on Asthma Symptoms in Students With Active Asthma: A Randomized Clinical Trial
10.1001_jama.2021.10207,JAMA,2021,Neurology,Phase 3,Effect of Urate-Elevating Inosine on Early Parkinson Disease Progression: The SURE-PD3 Randomized Clinical Trial
10.1001_jama.2021.13374,JAMA,2021,Respiratory,Phase 3,Effect of Lower Tidal Volume Ventilation Facilitated by Extracorporeal Carbon Dioxide Removal vs Standard Care Ventilation on 90-Day Mortality in Patients With Acute Hypoxemic Respiratory Failure: The REST Randomized Clinical Trial
10.1001_jama.2021.10767,JAMA,2021,Cardiovascular,Phase 3,Effect of an Active vs Expectant Management Strategy on Successful Resolution of Pregnancy Among Patients With a Persisting Pregnancy of Unknown Location: The ACT or NOT Randomized Clinical Trial
10.1001_jama.2021.9899,JAMA,2021,Infectious Disease,nan,Effect of 7 vs 14 Days of Antibiotic Therapy on Resolution of Symptoms Among Afebrile Men With Urinary Tract Infection: A Randomized Clinical Trial
10.1001_jama.2021.9508,JAMA,2021,Infectious Disease,Phase 3,Effect of Canakinumab vs Placebo on Survival Without Invasive Mechanical Ventilation in Patients Hospitalized With Severe COVID-19: A Randomized Clinical Trial
10.1001_jama.2021.11517,JAMA,2021,Infectious Disease,Phase 3,Effect of Oral Azithromycin vs Placebo on COVID-19 Symptoms in Outpatients With SARS-CoV-2 Infection: A Randomized Clinical Trial
10.1001_jama.2021.9199,JAMA,2021,Other,Phase 1,Effect of Oral Ranitidine on Urinary Excretion of N-Nitrosodimethylamine (NDMA): A Randomized Clinical Trial
10.1001_jama.2021.7665,JAMA,2021,Neurology,Phase 3,Effects of Intravenous Eptinezumab vs Placebo on Headache Pain and Most Bothersome Symptom When Initiated During a Migraine Attack: A Randomized Clinical Trial
10.1001_jama.2021.8828,JAMA,2021,Infectious Disease,Phase 3,Effect of Bamlanivimab vs Placebo on Incidence of COVID-19 Among Residents and Staff of Skilled Nursing and Assisted Living Facilities: A Randomized Clinical Trial
10.1001_jama.2021.6128,JAMA,2021,Cardiovascular,nan,Effect of Implantable vs Prolonged External Electrocardiographic Monitoring on Atrial Fibrillation Detection in Patients With Ischemic Stroke: The PER DIEM Randomized Clinical Trial
10.1001_jama.2021.6470,JAMA,2021,Cardiovascular,nan,Effect of Long-term Continuous Cardiac Monitoring vs Usual Care on Detection of Atrial Fibrillation in Patients With Stroke Attributed to Large- or Small-Vessel Disease: The STROKE-AF Randomized Clinical Trial
10.1001_jama.2021.4956,JAMA,2021,Infectious Disease,Phase 3,Effect of Antimicrobial Therapy on Respiratory Hospitalization or Death in Adults With Idiopathic Pulmonary Fibrosis: The CleanUP-IPF Randomized Clinical Trial
10.1001_jama.2021.2454,JAMA,2021,Oncology,Phase 3,Effect of Celecoxib vs Placebo Added to Standard Adjuvant Therapy on Disease-Free Survival Among Patients With Stage III Colon Cancer: The CALGB/SWOG 80702 (Alliance) Randomized Clinical Trial
10.1001_jama.2021.2536,JAMA,2021,Cardiovascular,nan,Effect of Low-Intensity vs High-Intensity Home-Based Walking Exercise on Walk Distance in Patients With Peripheral Artery Disease: The LITE Randomized Clinical Trial
10.1001_jama.2021.3224,JAMA,2021,Endocrinology/Metabolism,Phase 3,Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial
10.1001_jama.2021.1489,JAMA,2021,Oncology,Phase 3,Effect of Marine Omega-3 Fatty Acid and Vitamin D Supplementation on Incident Atrial Fibrillation: A Randomized Clinical Trial
10.1001_jama.2021.3645,JAMA,2021,Infectious Disease,Phase 1/2,Immunogenicity of the Ad26.COV2.S Vaccine for COVID-19
10.1001_jama.2021.1233,JAMA,2021,Rheumatology/Immunology,nan,Effect of Ventral vs Dorsal Spinal Surgery on Patient-Reported Physical Functioning in Patients With Cervical Spondylotic Myelopathy: A Randomized Clinical Trial
10.1001_jama.2021.0987,JAMA,2021,Oncology,Phase 3,Effect of Blinatumomab vs Chemotherapy on Event-Free Survival Among Children With High-risk First-Relapse B-Cell Acute Lymphoblastic Leukemia: A Randomized Clinical Trial
10.1001_jama.2021.0669,JAMA,2021,Oncology,Phase 3,"Effect of Postreinduction Therapy Consolidation With Blinatumomab vs Chemotherapy on Disease-Free Survival in Children, Adolescents, and Young Adults With First Relapse of B-Cell Acute Lymphoblastic Leukemia: A Randomized Clinical Trial"
10.1001_jama.2021.1831,JAMA,2021,Endocrinology/Metabolism,Phase 3,Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial
10.1001_jama.2020.24505,JAMA,2021,Infectious Disease,Phase 3,"Effect of Vitamin C, Thiamine, and Hydrocortisone on Ventilator- and Vasopressor-Free Days in Patients With Sepsis: The VICTAS Randomized Clinical Trial"
10.1001_jama.2020.25855,JAMA,2021,Endocrinology/Metabolism,nan,Effect of Behavioral Therapy With In-Clinic or Telephone Group Visits vs In-Clinic Individual Visits on Weight Loss Among Patients With Obesity in Rural Clinical Practice: A Randomized Clinical Trial
10.1001_jama.2021.0202,JAMA,2021,Infectious Disease,Phase 2/3,Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial
10.1001_jama.2020.24326,JAMA,2021,Cardiovascular,Phase 2/3,Effect of Out-of-Hospital Sodium Nitrite on Survival to Hospital Admission After Cardiac Arrest: A Randomized Clinical Trial
10.1001_jama.2020.23649,JAMA,2021,Cardiovascular,Phase 4,Effect of High-Dose Trivalent vs Standard-Dose Quadrivalent Influenza Vaccine on Mortality or Cardiopulmonary Hospitalization in Patients With High-risk Cardiovascular Disease: A Randomized Clinical Trial
10.1001_jama.2020.23138,JAMA,2020,Cardiovascular,Phase 4,Effect of Digoxin vs Bisoprolol for Heart Rate Control in Atrial Fibrillation on Patient-Reported Quality of Life: The RATE-AF Randomized Clinical Trial
10.1001_jama.2020.23027,JAMA,2020,Endocrinology/Metabolism,Phase 2/3,Effect of Intravitreous Aflibercept vs Vitrectomy With Panretinal Photocoagulation on Visual Acuity in Patients With Vitreous Hemorrhage From Proliferative Diabetic Retinopathy: A Randomized Clinical Trial
10.1001_jama.2020.23517,JAMA,2020,Infectious Disease,nan,Effect of a Lower vs Higher Positive End-Expiratory Pressure Strategy on Ventilator-Free Days in ICU Patients Without ARDS: A Randomized Clinical Trial
10.1001_jama.2020.22258,JAMA,2020,Cardiovascular,Phase 3,Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events in Patients at High Cardiovascular Risk: The STRENGTH Randomized Clinical Trial
10.1001_jama.2020.22760,JAMA,2020,Infectious Disease,Phase 2,Fluvoxamine vs Placebo and Clinical Deterioration in Outpatients With Symptomatic COVID-19: A Randomized Clinical Trial
10.1001_jama.2020.22240,JAMA,2020,Infectious Disease,Phase 3,Effect of Hydroxychloroquine on Clinical Status at 14 Days in Hospitalized Patients With COVID-19: A Randomized Clinical Trial
10.1001_jama.2020.18977,JAMA,2020,Cardiovascular,nan,Effect of an Online Weight Management Program Integrated With Population Health Management on Weight Change: A Randomized Clinical Trial
10.1001_jama.2020.16195,JAMA,2020,Cardiovascular,Phase 3,Effect of Catheter Ablation With Vein of Marshall Ethanol Infusion vs Catheter Ablation Alone on Persistent Atrial Fibrillation: The VENUS Randomized Clinical Trial
10.1001_jama.2020.16641,JAMA,2020,Cardiovascular,Phase 2,Effect of Praliciguat on Peak Rate of Oxygen Consumption in Patients With Heart Failure With Preserved Ejection Fraction: The CAPACITY HFpEF Randomized Clinical Trial
10.1001_jama.2020.15922,JAMA,2020,Cardiovascular,Phase 2,Effect of Vericiguat vs Placebo on Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction: The VITALITY-HFpEF Randomized Clinical Trial
10.1001_jama.2020.14581,JAMA,2020,Oncology,nan,Effect of Sustained Smoking Cessation Counseling and Provision of Medication vs Shorter-term Counseling and Medication Advice on Smoking Abstinence in Patients Recently Diagnosed With Cancer: A Randomized Clinical Trial
10.1001_jama.2020.13361,JAMA,2020,Infectious Disease,nan,Effect of Prophylactic Negative Pressure Wound Therapy vs Standard Wound Dressing on Surgical-Site Infection in Obese Women After Cesarean Delivery: A Randomized Clinical Trial
10.1001_jama.2020.8958,JAMA,2020,Surgery/Critical Care,Phase 2,Effect of Out-of-Hospital Tranexamic Acid vs Placebo on 6-Month Functional Neurologic Outcomes in Patients With Moderate or Severe Traumatic Brain Injury
10.1001_jama.2020.17021,JAMA,2020,Infectious Disease,Phase 3,Effect of Dexamethasone on Days Alive and Ventilator-Free in Patients With Moderate or Severe Acute Respiratory Distress Syndrome and COVID-19: The CoDEX Randomized Clinical Trial
10.1001_jama.2020.16761,JAMA,2020,Infectious Disease,Phase 3,Effect of Hydrocortisone on 21-Day Mortality or Respiratory Support Among Critically Ill Patients With COVID-19: A Randomized Clinical Trial
10.1001_jama.2020.12443,JAMA,2020,Cardiovascular,Phase 4,Effect of Genotype-Guided Oral P2Y12 Inhibitor Selection vs Conventional Clopidogrel Therapy on Ischemic Outcomes After Percutaneous Coronary Intervention: The TAILOR-PCI Randomized Clinical Trial
10.1001_jama.2020.12384,JAMA,2020,Respiratory,Phase 2,Effect of Vitamin D3 Supplementation on Severe Asthma Exacerbations in Children With Asthma and Low Vitamin D Levels: The VDKA Randomized Clinical Trial
10.1001_jama.2020.16349,JAMA,2020,Infectious Disease,Phase 3,Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial
10.1001_jama.2020.11946,JAMA,2020,Infectious Disease,Phase 2/3,"Effect of Ascorbic Acid, Corticosteroids, and Thiamine on Organ Injury in Septic Shock: The ACTS Randomized Clinical Trial"
10.1001_jama.2020.11747,JAMA,2020,Cardiovascular,nan,"Effect of a Collaborative Care Model on Depressive Symptoms and Glycated Hemoglobin, Blood Pressure, and Serum Cholesterol Among Patients With Depression and Diabetes in India: The INDEPENDENT Randomized Clinical Trial"
10.1001_jama.2020.10834,JAMA,2020,Pediatrics,nan,"Effect of High Add Power, Medium Add Power, or Single-Vision Contact Lenses on Myopia Progression in Children: The BLINK Randomized Clinical Trial"
10.1001_jama.2020.10224,JAMA,2020,Oncology,Phase 3,Effect of Long-term Vitamin D3 Supplementation vs Placebo on Risk of Depression or Clinically Relevant Depressive Symptoms and on Change in Mood Scores: A Randomized Clinical Trial
10.1001_jama.2020.10009,JAMA,2020,Surgery/Critical Care,Phase 3,Effect of Intravenous Acetaminophen on Postoperative Hypoxemia After Abdominal Surgery: The FACTOR Randomized Clinical Trial
10.1001_jama.2020.5230,JAMA,2020,Cardiovascular,Phase 2,Effect of Doxycycline on Aneurysm Growth Among Patients With Small Infrarenal Abdominal Aortic Aneurysms: A Randomized Clinical Trial
10.1001_jama.2020.3138,JAMA,2020,Infectious Disease,Phase 4,Effect of Preemptive Therapy vs Antiviral Prophylaxis on Cytomegalovirus Disease in Seronegative Liver Transplant Recipients With Seropositive Donors: A Randomized Clinical Trial
10.1001_jama.2020.2477,JAMA,2020,Infectious Disease,Phase 2,Effect of a Chikungunya Virus-Like Particle Vaccine on Safety and Tolerability Outcomes: A Randomized Clinical Trial
10.1001_jama.2020.1707,JAMA,2020,Oncology,Phase 3,Effect of Doxorubicin Plus Olaratumab vs Doxorubicin Plus Placebo on Survival in Patients With Advanced Soft Tissue Sarcomas: The ANNOUNCE Randomized Clinical Trial
10.1001_jama.2020.1906,JAMA,2020,Cardiovascular,Phase 3,Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes
10.1001_jama.2020.3308,JAMA,2020,Cardiovascular,Phase 3,Effect of Apabetalone Added to Standard Therapy on Major Adverse Cardiovascular Events in Patients With Recent Acute Coronary Syndrome and Type 2 Diabetes: A Randomized Clinical Trial
10.1001_jama.2020.0572,JAMA,2020,Oncology,nan,Comparison of Abbreviated Breast MRI vs Digital Breast Tomosynthesis for Breast Cancer Detection Among Women With Dense Breasts Undergoing Screening
10.1001_jama.2019.22525,JAMA,2020,Respiratory,Phase 3,Effect of Intravenous Interferon β-1a on Death and Days Free From Mechanical Ventilation Among Patients With Moderate to Severe Acute Respiratory Distress Syndrome: A Randomized Clinical Trial
10.1001_jama.2019.22450,JAMA,2020,Neurology,Phase 3,Effects of Iron Isomaltoside vs Ferric Carboxymaltose on Hypophosphatemia in Iron-Deficiency Anemia: Two Randomized Clinical Trials
10.1001_jama.2019.20747,JAMA,2020,Dermatology,Phase 1,Effect of Sunscreen Application on Plasma Concentration of Sunscreen Active Ingredients: A Randomized Clinical Trial
10.1001_jama.2019.20207,JAMA,2020,Oncology,Phase 3,Effect of a Behavioral Intervention to Increase Vegetable Consumption on Cancer Progression Among Men With Early-Stage Prostate Cancer: The MEAL Randomized Clinical Trial
10.1001_jama.2019.18714,JAMA,2020,Obstetrics/Gynecology,nan,Effect of Folic Acid and Zinc Supplementation in Men on Semen Quality and Live Birth Among Couples Undergoing Infertility Treatment: A Randomized Clinical Trial
10.1001_jama.2019.20785,JAMA,2020,Infectious Disease,nan,Effect of Treating Parents Colonized With Staphylococcus aureus on Transmission to Neonates in the Intensive Care Unit: A Randomized Clinical Trial
10.1001_jama.2019.17478,JAMA,2019,Hematology,Phase 3,Effect of Fresh vs Standard-issue Red Blood Cell Transfusions on Multiple Organ Dysfunction Syndrome in Critically Ill Pediatric Patients: A Randomized Clinical Trial
10.1001_jama.2019.16711,JAMA,2019,Neurology,Phase 3,Effect of Ubrogepant vs Placebo on Pain and the Most Bothersome Associated Symptom in the Acute Treatment of Migraine: The ACHIEVE II Randomized Clinical Trial
10.1001_jama.2019.16585,JAMA,2019,Cardiovascular,Phase 3,Effect of Bempedoic Acid vs Placebo Added to Maximally Tolerated Statins on Low-Density Lipoprotein Cholesterol in Patients at High Risk for Cardiovascular Disease: The CLEAR Wisdom Randomized Clinical Trial
10.1001_jama.2019.17380,JAMA,2019,Hematology,nan,Effect of Vitamin D and Omega-3 Fatty Acid Supplementation on Kidney Function in Patients With Type 2 Diabetes: A Randomized Clinical Trial
10.1001_jama.2019.15702,JAMA,2019,Oncology,Phase 3,Effect of Caspofungin vs Fluconazole Prophylaxis on Invasive Fungal Disease Among Children and Young Adults With Acute Myeloid Leukemia: A Randomized Clinical Trial
10.1001_jama.2019.14969,JAMA,2019,Oncology,nan,Effect of Cryotherapy vs Loop Electrosurgical Excision Procedure on Cervical Disease Recurrence Among Women With HIV and High-Grade Cervical Lesions in Kenya: A Randomized Clinical Trial
10.1001_jama.2019.14735,JAMA,2019,Musculoskeletal / Pain,Phase 2,Effect of Intra-Articular Sprifermin vs Placebo on Femorotibial Joint Cartilage Thickness in Patients With Osteoarthritis: The FORWARD Randomized Clinical Trial
10.1001_jama.2019.11825,JAMA,2019,Respiratory,Phase 2,Effect of Vitamin C Infusion on Organ Failure and Biomarkers of Inflammation and Vascular Injury in Patients With Sepsis and Severe Acute Respiratory Failure: The CITRIS-ALI Randomized Clinical Trial
10.1001_jama.2019.12812,JAMA,2019,Obstetrics / Gynecology,nan,Effect of Vaginal Mesh Hysteropexy vs Vaginal Hysterectomy With Uterosacral Ligament Suspension on Treatment Failure in Women With Uterovaginal Prolapse: A Randomized Clinical Trial
10.1001_jama.2019.12467,JAMA,2019,Nephrology / Urology,Phase 3,Effect of Behavioral and Pelvic Floor Muscle Therapy Combined With Surgery vs Surgery Alone on Incontinence Symptoms Among Women With Mixed Urinary Incontinence: The ESTEEM Randomized Clinical Trial
10.1001_jama.2019.12964,JAMA,2019,Infectious Disease,nan,Effect of a Multicomponent Home-Based Physical Therapy Intervention on Ambulation After Hip Fracture in Older Adults: The CAP Randomized Clinical Trial
10.1001_jama.2019.12618,JAMA,2019,Gastroenterology / Hepatology,Phase 3,Effect of Corticosteroid-Sparing Treatment With Mycophenolate Mofetil vs Methotrexate on Inflammation in Patients With Uveitis: A Randomized Clinical Trial
10.1001_jama.2019.11645,JAMA,2019,Respiratory,nan,N95 Respirators vs Medical Masks for Preventing Influenza Among Health Care Personnel: A Randomized Clinical Trial
10.1001_jama.2019.11642,JAMA,2019,Oncology,Phase 3,Effect of Tandem Autologous Stem Cell Transplant vs Single Transplant on Event-Free Survival in Patients With High-Risk Neuroblastoma: A Randomized Clinical Trial
10.1001_jama.2019.10517,JAMA,2019,Endocrinology / Metabolism,Phase 4,Effect of Continuing Olanzapine vs Placebo on Relapse Among Patients With Psychotic Depression in Remission: The STOP-PD II Randomized Clinical Trial
10.1001_jama.2019.10551,JAMA,2019,Cardiovascular,nan,Association of Intensive vs Standard Blood Pressure Control With Cerebral White Matter Lesions
10.1001_jama.2019.9346,JAMA,2019,Cardiovascular,Phase 3,Intensive vs Standard Treatment of Hyperglycemia and Functional Outcome in Patients With Acute Ischemic Stroke: The SHINE Randomized Clinical Trial
10.1001_jama.2019.9055,JAMA,2019,Hematology,Phase 3,Effect of Filgotinib vs Placebo on Clinical Response in Patients With Moderate to Severe Rheumatoid Arthritis Refractory to Disease-Modifying Antirheumatic Drug Therapy: The FINCH 2 Randomized Clinical Trial
10.1001_jama.2019.8044,JAMA,2019,Musculoskeletal / Pain,Phase 3,"Effect of Tanezumab on Joint Pain, Physical Function, and Patient Global Assessment of Osteoarthritis Among Patients With Osteoarthritis of the Hip or Knee: A Randomized Clinical Trial"
10.1001_jama.2019.6717,JAMA,2019,Cardiovascular,Phase 2,Effect of Neladenoson Bialanate on Exercise Capacity Among Patients With Heart Failure With Preserved Ejection Fraction: A Randomized Clinical Trial
10.1001_jama.2019.5358,JAMA,2019,Hematology,Phase 3,Effect of a Recombinant Human Soluble Thrombomodulin on Mortality in Patients With Sepsis-Associated Coagulopathy: The SCARLET Randomized Clinical Trial
10.1001_jama.2019.3698,JAMA,2019,Other,nan,Effect of Restriction of the Number of Concurrently Open Records in an Electronic Health Record on Wrong-Patient Order Errors: A Randomized Clinical Trial
10.1001_jama.2019.4973,JAMA,2019,Cardiovascular,Phase 4,Effect of Aclidinium Bromide on Major Cardiovascular Events and Exacerbations in High-Risk Patients With Chronic Obstructive Pulmonary Disease: The ASCENT-COPD Randomized Clinical Trial
10.1001_jama.2019.5586,JAMA,2019,Dermatology,Phase 1,Effect of Sunscreen Application Under Maximal Use Conditions on Plasma Concentration of Sunscreen Active Ingredients: A Randomized Clinical Trial
10.1001_jama.2019.5790,JAMA,2019,Cardiovascular,Phase 3,Effect of Initial Management With Aflibercept vs Laser Photocoagulation vs Observation on Vision Loss Among Patients With Diabetic Macular Edema Involving the Center of the Macula and Good Visual Acuity: A Randomized Clinical Trial
10.1001_jama.2019.3307,JAMA,2019,Other,nan,Effect of a Workplace Wellness Program on Employee Health and Economic Outcomes: A Randomized Clinical Trial
10.1001_jama.2019.2402,JAMA,2019,Oncology,Phase 2,Effect of High-Dose vs Standard-Dose Vitamin D3 Supplementation on Progression-Free Survival Among Patients With Advanced or Metastatic Colorectal Cancer: The SUNSHINE Randomized Clinical Trial
10.1001_jama.2019.2341,JAMA,2019,Oncology,Phase 2,Intramyocardial Injection of Mesenchymal Precursor Cells and Successful Temporary Weaning From Left Ventricular Assist Device Support in Patients With Advanced Heart Failure: A Randomized Clinical Trial
10.1001_jama.2019.1660,JAMA,2019,Cardiovascular,nan,Effect of Sustained Inflations vs Intermittent Positive Pressure Ventilation on Bronchopulmonary Dysplasia or Death Among Extremely Preterm Infants: The SAIL Randomized Clinical Trial
10.1001_jama.2019.2942,JAMA,2019,Endocrinology / Metabolism,Phase 3,Effect of Additional Oral Semaglutide vs Sitagliptin on Glycated Hemoglobin in Adults With Type 2 Diabetes Uncontrolled With Metformin Alone or With Sulfonylurea: The PIONEER 3 Randomized Clinical Trial
10.1001_jama.2019.0693,JAMA,2019,Hematology,nan,"Effect of Catheter Ablation vs Antiarrhythmic Drug Therapy on Mortality, Stroke, Bleeding, and Cardiac Arrest Among Patients With Atrial Fibrillation: The CABANA Randomized Clinical Trial"
10.1001_jama.2019.0692,JAMA,2019,Cardiovascular,nan,Effect of Catheter Ablation vs Medical Therapy on Quality of Life Among Patients With Atrial Fibrillation: The CABANA Randomized Clinical Trial
10.1001_jama.2019.0557,JAMA,2019,Endocrinology / Metabolism,nan,Effect of Integrated Behavioral Weight Loss Treatment and Problem-Solving Therapy on Body Mass Index and Depressive Symptoms Among Patients With Obesity and Depression: The RAINBOW Randomized Clinical Trial
10.1001_jama.2019.1113,JAMA,2019,Rheumatology / Immunology,Phase 3,Effect of Epicutaneous Immunotherapy vs Placebo on Reaction to Peanut Protein Ingestion Among Children With Peanut Allergy: The PEPITES Randomized Clinical Trial
10.1001_jama.2019.0234,JAMA,2019,Cardiovascular,Phase 4,Effect of Intravenous Acetaminophen vs Placebo Combined With Propofol or Dexmedetomidine on Postoperative Delirium Among Older Patients Following Cardiac Surgery: The DEXACET Randomized Clinical Trial
10.1001_jama.2019.0071,JAMA,2019,Infectious Disease,nan,Effect of a Resuscitation Strategy Targeting Peripheral Perfusion Status vs Serum Lactate Levels on 28-Day Mortality Among Patients With Septic Shock: The ANDROMEDA-SHOCK Randomized Clinical Trial
10.1001_jama.2018.22005,JAMA,2019,Cardiovascular,nan,Effect of Electroencephalography-Guided Anesthetic Administration on Postoperative Delirium Among Older Adults Undergoing Major Surgery: The ENGAGES Randomized Clinical Trial
10.1001_jama.2018.21442,JAMA,2019,Cardiovascular,nan,Effect of Intensive vs Standard Blood Pressure Control on Probable Dementia: A Randomized Clinical Trial
10.1001_jama.2018.20579,JAMA,2019,Endocrinology / Metabolism,nan,Effect of a Low Free Sugar Diet vs Usual Diet on Nonalcoholic Fatty Liver Disease in Adolescent Boys: A Randomized Clinical Trial
10.1001_jama.2018.19791,JAMA,2019,Cardiovascular,Phase 4,Effect of Medication Co-payment Vouchers on P2Y12 Inhibitor Use and Major Adverse Cardiovascular Events Among Patients With Myocardial Infarction: The ARTEMIS Randomized Clinical Trial
10.1001_jama.2018.18269,JAMA,2019,Cardiovascular,Phase 4,Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial
10.1001_jama.2018.16773,JAMA,2018,Pediatrics,Phase 3,Effect of Lanadelumab Compared With Placebo on Prevention of Hereditary Angioedema Attacks: A Randomized Clinical Trial
10.1001_jama.2018.14852,JAMA,2018,Cardiovascular,Phase 2,Effect of Inorganic Nitrite vs Placebo on Exercise Capacity Among Patients With Heart Failure With Preserved Ejection Fraction: The INDIE-HFpEF Randomized Clinical Trial
10.1001_jama.2018.14283,JAMA,2018,Infectious Disease,Phase 2,Effect of Human Recombinant Alkaline Phosphatase on 7-Day Creatinine Clearance in Patients With Sepsis-Associated Acute Kidney Injury: A Randomized Clinical Trial
10.1001_jama.2018.13308,JAMA,2018,Musculoskeletal / Pain,nan,Effect of Early Surgery vs Physical Therapy on Knee Function Among Patients With Nonobstructive Meniscal Tears: The ESCAPE Randomized Clinical Trial
10.1001_jama.2018.13155,JAMA,2018,Infectious Disease,Phase 2,Effect of Algorithm-Based Therapy vs Usual Care on Clinical Success and Serious Adverse Events in Patients with Staphylococcal Bacteremia: A Randomized Clinical Trial
10.1001_jama.2018.7044,JAMA,2018,Cardiovascular,nan,Effect of a Strategy of Initial Laryngeal Tube Insertion vs Endotracheal Intubation on 72-Hour Survival in Adults With Out-of-Hospital Cardiac Arrest: A Randomized Clinical Trial
10.1001_jama.2018.8496,JAMA,2018,Cardiovascular,Phase 3,Effect of Alteplase vs Aspirin on Functional Outcome for Patients With Acute Ischemic Stroke and Minor Nondisabling Neurologic Deficits: The PRISMS Randomized Clinical Trial
10.1001_jama.2018.8102,JAMA,2018,Cardiovascular,nan,Effect of a Home-Based Wearable Continuous ECG Monitoring Patch on Detection of Undiagnosed Atrial Fibrillation: The mSToPS Randomized Clinical Trial
10.1001_jama.2018.4657,JAMA,2018,Oncology,Phase 3,Effect of Intravesical Instillation of Gemcitabine vs Saline Immediately Following Resection of Suspected Low-Grade Non-Muscle-Invasive Bladder Cancer on Tumor Recurrence: SWOG S0337 Randomized Clinical Trial
10.1001_jama.2018.4853,JAMA,2018,Neurology,Phase 3,Effect of Fremanezumab Compared With Placebo for Prevention of Episodic Migraine: A Randomized Clinical Trial
10.1001_jama.2018.5729,JAMA,2018,Respiratory,Phase 4,Effect of Vitamin D Supplementation on Recurrent Wheezing in Black Infants Who Were Born Preterm: The D-Wheeze Randomized Clinical Trial
10.1001_jama.2018.6496,JAMA,2018,Respiratory,nan,Effect of Use of a Bougie vs Endotracheal Tube and Stylet on First-Attempt Intubation Success Among Patients With Difficult Airways Undergoing Emergency Intubation: A Randomized Clinical Trial
10.1001_jama.2018.6129,JAMA,2018,Respiratory,Phase 2,Effect of Recombinant Human Pentraxin 2 vs Placebo on Change in Forced Vital Capacity in Patients With Idiopathic Pulmonary Fibrosis: A Randomized Clinical Trial
10.1001_jama.2018.3708,JAMA,2018,Cardiovascular,Phase 2/3,Effect of Atropine With Propofol vs Atropine With Atracurium and Sufentanil on Oxygen Desaturation in Neonates Requiring Nonemergency Intubation: A Randomized Clinical Trial
10.1001_jama.2018.3197,JAMA,2018,Hematology,Phase 4,"Effect of Ticagrelor Plus Aspirin, Ticagrelor Alone, or Aspirin Alone on Saphenous Vein Graft Patency 1 Year After Coronary Artery Bypass Grafting: A Randomized Clinical Trial"
10.1001_jama.2018.0899,JAMA,2018,Musculoskeletal / Pain,nan,Effect of Opioid vs Nonopioid Medications on Pain-Related Function in Patients With Chronic Back Pain or Hip or Knee Osteoarthritis Pain: The SPACE Randomized Clinical Trial
10.1001_jama.2017.19826,JAMA,2018,Respiratory,nan,Effect of Hydrolyzed Infant Formula vs Conventional Formula on Risk of Type 1 Diabetes: The TRIGR Randomized Clinical Trial
10.1001_jama.2017.19132,JAMA,2018,Hematology,nan,Effect of Mechanically Expanded vs Self-Expanding Transcatheter Aortic Valve Replacement on Mortality and Major Adverse Clinical Events in High-Risk Patients With Aortic Stenosis: The REPRISE III Randomized Clinical Trial
10.1001_jama.2017.17437,JAMA,2017,Cardiovascular,nan,Effect of Granulocyte-Macrophage Colony-Stimulating Factor With or Without Supervised Exercise on Walking Performance in Patients With Peripheral Artery Disease: The PROPEL Randomized Clinical Trial
10.1001_jama.2017.16190,JAMA,2017,Musculoskeletal / Pain,Phase 4,Effect of a Single Dose of Oral Opioid and Nonopioid Analgesics on Acute Extremity Pain in the Emergency Department: A Randomized Clinical Trial
10.1001_jama.2017.14752,JAMA,2017,Endocrinology / Metabolism,Phase 2,Effect of Oral Semaglutide Compared With Placebo and Subcutaneous Semaglutide on Glycemic Control in Patients With Type 2 Diabetes: A Randomized Clinical Trial
10.1001_jama.2016.20939,JAMA,2017,Oncology,nan,Effect of a Scalp Cooling Device on Alopecia in Women Undergoing Chemotherapy for Breast Cancer: The SCALP Randomized Clinical Trial
10.1001_jama.2016.7050,JAMA,2016,Cardiovascular,nan,Intensive vs Standard Blood Pressure Control and Cardiovascular Disease Outcomes in Adults Aged ≥75 Years: A Randomized Clinical Trial
10.1200_jco-25-00570,JCO,2026,Oncology,Phase 3,Pembrolizumab With or Without Lenvatinib as First-Line Therapy for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Phase III LEAP-010 Study
10.1200_jco-25-01328,JCO,2026,Oncology,Phase 3,Five-Year Clinical Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Unresectable Pleural Mesothelioma in CheckMate 743
10.1200_jco-25-01808,JCO,2026,Oncology,Phase 2/3,"Axitinib and Long-Acting Octreotide in Advanced Extrapancreatic Neuroendocrine Tumors: A Randomized, Double-Blind, Placebo-Controlled, Phase III Clinical Trial (AXINET, GETNE 1107)"
10.1200_jco-25-01548,JCO,2026,Oncology,Phase 2,"Pharmacodynamics of Camizestrant Treatment in Postmenopausal Women With Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Primary Breast Cancer: Results From the Randomized, Presurgical SERENA-3 Study"
10.1200_jco-25-00826,JCO,2026,Oncology,Phase 1/2,Erdafitinib or Erdafitinib Plus Cetrelimab for Patients With Metastatic Urothelial Carcinoma and &lt;i&gt;FGFR&lt;/i&gt; Alterations: Final Results From the Phase II NORSE Study
10.1200_jco-25-01569,JCO,2026,Oncology,Phase 3,Chemoradiation ± Atezolizumab in Limited-Stage Small Cell Lung Cancer: Results of NRG Oncology/Alliance LU005
10.1200_jco-25-00203,JCO,2026,Oncology,Phase 3,Three-Year Follow-Up of Nivolumab-AVD Versus Brentuximab Vedotin-AVD in Adolescents With Advanced-Stage Classic Hodgkin Lymphoma on S1826
10.1200_jco-25-00929,JCO,2026,Oncology,Phase 2,"NCI9673 (Part B): ETCTN Randomized Phase II Study of Nivolumab With or Without Ipilimumab in Refractory, Metastatic Squamous Cell Carcinoma of the Anal Canal"
10.1200_jco-25-00872,JCO,2025,Oncology,Phase 3,TRYBECA-1: A Randomized Phase III Study of Eryaspase Combined With Chemotherapy Versus Chemotherapy as Second-Line Treatment in Patients With Advanced Pancreatic Adenocarcinoma
10.1200_jco-25-01369,JCO,2025,Oncology,Phase 2/3,US Food and Drug Administration Approval Summary: Imetelstat for Selected Patients With Low- to Intermediate-1 Risk Myelodysplastic Syndromes With Transfusion-Dependent Anemia
10.1200_jco-25-00582,JCO,2025,Oncology,Phase 3,Efficacy and Safety of Long-Term Continuous Nirogacestat Treatment in Adults With Desmoid Tumors: Results From the DeFi Trial
10.1200_jco-25-00809,JCO,2025,Hematology,Phase 3,Ruxolitinib Versus Best Available Therapy in Patients With Steroid-Refractory Acute Graft-Versus-Host Disease: Final Analysis From the Randomized Phase III REACH2 Trial
10.1200_jco-25-01957,JCO,2025,Oncology,Phase 3,Mosunetuzumab Plus Polatuzumab Vedotin in Transplant-Ineligible Refractory/Relapsed Large B-Cell Lymphoma: Primary Results of the Phase III SUNMO Trial
10.1200_jco-25-00788,JCO,2025,Oncology,Phase 1/2,Phase II Dose-Randomized Study of Sunvozertinib in Platinum-Pretreated Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor Exon 20 Insertion Mutations (WU-KONG1B)
10.1200_jco-25-00272,JCO,2025,Oncology,Phase 3,"Xevinapant or Placebo Plus Platinum-Based Chemoradiotherapy in Unresected Locally Advanced Squamous Cell Carcinoma of the Head and Neck (TrilynX): A Randomized, Phase III Study"
10.1200_jco-24-02644,JCO,2025,Oncology,Phase 2,Randomized Phase II Trial of Pazopanib Versus Placebo in Patients With Advanced Extrapancreatic Neuroendocrine Tumors (Alliance A021202)
10.1200_jco-25-00486,JCO,2025,Oncology,Phase 3,"Pembrolizumab Plus Chemotherapy Versus Chemotherapy as Perioperative Therapy in Locally Advanced Gastric and Gastroesophageal Junction Cancer: Final Analysis of the Randomized, Phase III KEYNOTE-585 Study"
10.1200_jco-25-00221,JCO,2025,Oncology,Phase 2/3,Hippocampal Avoidance During Prophylactic Cranial Irradiation for Patients With Small Cell Lung Cancer: Randomized Phase II/III Trial NRG-CC003
10.1200_jco-25-00618,JCO,2025,Oncology,Phase 2/3,"Dual Immune Check Point Blockade in &lt;i&gt;MGMT&lt;/i&gt;-Unmethylated Newly Diagnosed Glioblastoma: NRG Oncology BN007, a Randomized Phase II/III Clinical Trial"
10.1200_jco-25-00399,JCO,2025,Oncology,Phase 3,"Lisocabtagene Maraleucel Versus Standard of Care for Second-Line Relapsed/Refractory Large B-Cell Lymphoma: 3-Year Follow-Up From the Randomized, Phase III TRANSFORM Study"
10.1200_jco-24-02477,JCO,2025,Nephrology/Urology,Phase 3,Ruxolitinib in Patients With Corticosteroid-Refractory or Corticosteroid-Dependent Chronic Graft-Versus-Host Disease: 3-Year Final Analysis of the Phase III REACH3 Study
10.1200_jco-25-00378,JCO,2025,Psychiatry/Mental Health,nan,Multisite Randomized Trial of Inpatient Palliative Care Intervention for Patients Undergoing Hematopoietic Stem Cell Transplantation
10.1200_jco-24-02550,JCO,2025,Oncology,Phase 2,"Long-Term Follow-Up of E3311, an ECOG-ACRIN Cancer Research Group Phase II Trial of Transoral Surgery and Risk-Based Adjuvant Treatment in Human Papillomavirus-Initiated Oropharynx Cancer"
10.1200_jco-25-00166,JCO,2025,Oncology,Phase 3,Phase III Trial of Pirtobrutinib Versus Idelalisib/Rituximab or Bendamustine/Rituximab in Covalent Bruton Tyrosine Kinase Inhibitor-Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321)
10.1200_jco-25-00744,JCO,2025,Oncology,Phase 3,Isatuximab Subcutaneous by On-Body Injector Versus Isatuximab Intravenous Plus Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Phase III IRAKLIA Study
10.1200_jco-25-00748,JCO,2025,Oncology,Phase 3,"Lenvatinib Plus Pembrolizumab and Chemotherapy Versus Chemotherapy in Advanced Metastatic Gastroesophageal Adenocarcinoma: The Phase III, Randomized LEAP-015 Study"
10.1200_jco-25-00746,JCO,2025,Oncology,Phase 3,"Tumor Treating Fields With Gemcitabine and Nab-Paclitaxel for Locally Advanced Pancreatic Adenocarcinoma: Randomized, Open-Label, Pivotal Phase III PANOVA-3 Study"
10.1200_jco-24-01681,JCO,2025,Oncology,Phase 3,"Five-Year Survival Outcomes With Atezolizumab After Chemotherapy in Resected Stage IB-IIIA Non-Small Cell Lung Cancer (IMpower010): An Open-Label, Randomized, Phase III Trial"
10.1200_jco-24-01580,JCO,2025,Oncology,Phase 2,Randomized Phase II Study of Concurrent Versus Sequential Pembrolizumab in Combination With Chemoradiation in Locally Advanced Head and Neck Cancer
10.1200_jco-24-02818,JCO,2025,Oncology,Phase 3,Updated Overall Survival and Long-Term Safety With Ripretinib Versus Sunitinib in Patients With GI Stromal Tumor: Final Overall Survival Analysis From INTRIGUE
10.1200_jco-25-00131,JCO,2025,Oncology,Phase 2,Outcomes of Radium-223 and Stereotactic Ablative Radiotherapy Versus Stereotactic Ablative Radiotherapy for Oligometastatic Prostate Cancers: The RAVENS Phase II Randomized Trial
10.1200_jco-24-01818,JCO,2025,Oncology,Phase 3,"&lt;i&gt;NOTCH1&lt;/i&gt; Mutation and Survival Analysis of Tislelizumab in Advanced or Metastatic Esophageal Squamous Cell Carcinoma: A Biomarker Analysis From the Randomized, Phase III, RATIONALE-302 Trial"
10.1200_jco.24.00727,JCO,2025,Oncology,Phase 3,"Randomized, Open-Label, Phase III Study of Tilsotolimod in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced Refractory Melanoma (ILLUMINATE-301)"
10.1200_jco-24-01283,JCO,2025,Oncology,Phase 3,"Pembrolizumab Plus Docetaxel Versus Docetaxel for Previously Treated Metastatic Castration-Resistant Prostate Cancer: The Randomized, Double-Blind, Phase III KEYNOTE-921 Trial"
10.1200_jco-24-01829,JCO,2025,Oncology,Phase 3,Postoperative Radiotherapy ± Cetuximab for Intermediate-Risk Head and Neck Cancer
10.1200_jco-24-02239,JCO,2025,Oncology,Phase 3,Neoadjuvant Nivolumab Plus Ipilimumab Versus Chemotherapy in Resectable Lung Cancer
10.1200_jco.24.00994,JCO,2025,Oncology,Phase 3,Fulvestrant Versus Anastrozole in Endocrine Therapy-Naïve Women With Hormone Receptor-Positive Advanced Breast Cancer: Final Overall Survival in the Phase III FALCON Trial
10.1200_jco-24-01710,JCO,2025,Oncology,Phase 2,"Trastuzumab Plus Pertuzumab Versus Cetuximab Plus Irinotecan in Patients With &lt;i&gt;RAS/BRAF&lt;/i&gt; Wild-Type, HER2-Positive, Metastatic Colorectal Cancer (S1613): A Randomized Phase II Trial"
10.1200_jco.24.00921,JCO,2025,Oncology,Phase 3,Improved Patient-Reported Outcomes With Post-Transplant Cyclophosphamide: A Quality-of-Life Evaluation and 2-Year Outcomes of BMT CTN 1703
10.1200_jco.24.01121,JCO,2025,Oncology,Phase 3,"Long-Term Follow-Up and Overall Survival in NRG258, a Randomized Phase III Trial of Chemoradiation Versus Chemotherapy for Locally Advanced Endometrial Carcinoma"
10.1200_jco-24-02086,JCO,2025,Oncology,Phase 3,Abemaciclib Plus Fulvestrant in Advanced Breast Cancer After Progression on CDK4/6 Inhibition: Results From the Phase III postMONARCH Trial
10.1200_jco-24-01383,JCO,2025,Oncology,Phase 3,"SWOG S1815: A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers"
10.1200_jco.24.01124,JCO,2025,Oncology,Phase 2/3,Three-Year Overall Survival With Nivolumab Plus Relatlimab in Advanced Melanoma From RELATIVITY-047
10.1200_jco.24.00933,JCO,2025,Oncology,Phase 3,Olaparib as Treatment Versus Nonplatinum Chemotherapy in Patients With Platinum-Sensitive Relapsed Ovarian Cancer: Phase III SOLO3 Study Final Overall Survival Results
10.1200_jco-24-02265,JCO,2025,Oncology,Phase 3,Zanubrutinib Versus Bendamustine and Rituximab in Patients With Treatment-Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Median 5-Year Follow-Up of SEQUOIA
10.1200_jco.24.00342,JCO,2025,Oncology,nan,Effectiveness of a Cardiovascular Health Electronic Health Record Application for Cancer Survivors in Community Oncology Practice: Results From WF-1804CD
10.1200_jco.24.00965,JCO,2025,Oncology,nan,Randomized Controlled Trial of Acceptance and Commitment Therapy for Fatigue Interference With Functioning in Metastatic Breast Cancer
10.1200_jco.24.00529,JCO,2025,Oncology,Phase 3,"Trastuzumab Duocarmazine in Pretreated Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Breast Cancer: An Open-Label, Randomized, Phase III Trial (TULIP)"
10.1200_jco.24.00337,JCO,2025,Oncology,Phase 2,Atezolizumab Plus Chemotherapy With or Without Bevacizumab in Advanced Biliary Tract Cancer: Clinical and Biomarker Data From the Randomized Phase II IMbrave151 Trial
10.1200_jco.24.00340,JCO,2025,Oncology,Phase 3,Adjuvant Nivolumab in High-Risk Muscle-Invasive Urothelial Carcinoma: Expanded Efficacy From CheckMate 274
10.1200_jco.24.00237,JCO,2025,Oncology,Phase 3,Estimating Long-Term Survivorship Rates Among Patients With Resected Stage III/IV Melanoma: Analyses From CheckMate 238 and European Organization for Research and Treatment of Cancer 18071 Trials
10.1200_jco.24.00440,JCO,2025,Oncology,nan,Sexual Health and Quality of Life in Patients With Low-Risk Early-Stage Cervical Cancer: Results From GCIG/CCTG CX.5/SHAPE Trial Comparing Simple Versus Radical Hysterectomy
10.1200_jco.24.00773,JCO,2025,Oncology,Phase 3,"Adjuvant Nivolumab for Localized Renal Cell Carcinoma at High Risk of Recurrence After Nephrectomy: Part B of the Randomized, Placebo-Controlled, Phase III CheckMate 914 Trial"
10.1200_jco.24.00920,JCO,2025,Oncology,Phase 3,Datopotamab Deruxtecan Versus Chemotherapy in Previously Treated Inoperable/Metastatic Hormone Receptor-Positive Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer: Primary Results From TROPION-Breast01
10.1200_jco-24-01544,JCO,2025,Oncology,Phase 3,"Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-Lung01 Study"
10.1200_jco.24.00022,JCO,2024,Oncology,Phase 2,Primary Results of NRG-RTOG1106/ECOG-ACRIN 6697: A Randomized Phase II Trial of Individualized Adaptive (chemo)Radiotherapy Using Midtreatment &lt;sup&gt;18&lt;/sup&gt;F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Stage III Non-Small Cell Lung Cancer
10.1200_jco.24.00683,JCO,2024,Oncology,Phase 2/3,"Cediranib and Olaparib Combination Compared With Cediranib or Olaparib Alone, or Chemotherapy in Platinum-Resistant or Primary Platinum-Refractory Ovarian Cancer: NRG-GY005"
10.1200_jco-24-01798,JCO,2024,Oncology,Phase 3,Darolutamide in Combination With Androgen-Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer From the Phase III ARANOTE Trial
10.1200_jco.24.00767,JCO,2024,Oncology,Phase 2,"Final Overall Survival Analysis of S1500: A Randomized, Phase II Study Comparing Sunitinib With Cabozantinib, Crizotinib, and Savolitinib in Advanced Papillary Renal Cell Carcinoma"
10.1200_jco.23.02747,JCO,2024,Oncology,Phase 3,"Phase III KEYNOTE-789 Study of Pemetrexed and Platinum With or Without Pembrolizumab for Tyrosine Kinase Inhibitor‒Resistant, <i>EGFR</i>-Mutant, Metastatic Nonsquamous Non-Small Cell Lung Cancer"
10.1200_jco.24.00427,JCO,2024,Oncology,Phase 3,"US Food and Drug Administration Approval Summary: Capivasertib With Fulvestrant for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced or Metastatic Breast Cancer With <i>PIK3CA</i>/<i>AKT1</i>/<i>PTEN</i> Alterations"
10.1200_jco.23.01448,JCO,2024,Oncology,Phase 3,Outcomes With Postrecurrence Systemic Therapy Following Adjuvant Checkpoint Inhibitor Treatment for Resected Melanoma in CheckMate 238
10.1200_jco.23.02659,JCO,2024,Oncology,Phase 3,"Devimistat (CPI-613) With Modified Fluorouarcil, Oxaliplatin, Irinotecan, and Leucovorin (FFX) Versus FFX for Patients With Metastatic Adenocarcinoma of the Pancreas: The Phase III AVENGER 500 Study"
10.1200_jco.24.00048,JCO,2024,Oncology,nan,Randomized Controlled Trial of a Nurse-Led Brief Behavioral Intervention for Dyspnea in Patients With Advanced Lung Cancer
10.1200_jco.24.00038,JCO,2024,Oncology,Phase 3,Longitudinal Health-Related Quality of Life Among Patients With High-Risk Pediatric Hodgkin Lymphoma Treated on the Children's Oncology Group AHOD 1331 Study
10.1200_jco.23.02167,JCO,2024,Oncology,Phase 3,"Neoadjuvant Docetaxel, Oxaliplatin, and S-1 Plus Surgery and Adjuvant S-1 for Resectable Advanced Gastric Cancer: Updated Overall Survival Outcomes From Phase III PRODIGY"
10.1200_jco.23.02170,JCO,2024,Oncology,Phase 2,Adjuvant Trastuzumab Emtansine Versus Paclitaxel Plus Trastuzumab for Stage I Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: 5-Year Results and Correlative Analyses From ATEMPT
10.1200_jco.23.02036,JCO,2024,Oncology,Phase 3,"Randomized Phase III Study of Amcenestrant Plus Palbociclib Versus Letrozole Plus Palbociclib in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Primary Results From AMEERA-5"
10.1200_jco.24.01001,JCO,2024,Oncology,Phase 3,"Subcutaneous Versus Intravenous Amivantamab, Both in Combination With Lazertinib, in Refractory Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer: Primary Results From the Phase III PALOMA-3 Study"
10.1200_jco.24.00733,JCO,2024,Oncology,Phase 3,"Sacituzumab Govitecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer: The Randomized, Open-Label Phase III EVOKE-01 Study"
10.1200_jco.23.02082,JCO,2024,Oncology,Phase 3,Bempegaldesleukin Plus Nivolumab Versus Sunitinib or Cabozantinib in Previously Untreated Advanced Clear Cell Renal Cell Carcinoma: A Phase III Randomized Study (PIVOT-09)
10.1200_jco.23.02736,JCO,2024,Oncology,Phase 3,"Lenvatinib Plus Pembrolizumab Versus Standard of Care for Previously Treated Metastatic Colorectal Cancer: Final Analysis of the Randomized, Open-Label, Phase III LEAP-017 Study"
10.1200_jco.23.02344,JCO,2024,Oncology,Phase 3,"Phase III Randomized, Placebo-Controlled Trial of Endocrine Therapy ± 1 Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive, Early-Stage Breast Cancer"
10.1200_jco.24.00724,JCO,2024,Oncology,Phase 3,CNS Protective Effect of Selpercatinib in First-Line <i>RET</i> Fusion-Positive Advanced Non-Small Cell Lung Cancer
10.1200_jco.24.00581,JCO,2024,Oncology,Phase 3,Lorlatinib Versus Crizotinib in Patients With Advanced &lt;i&gt;ALK&lt;/i&gt;-Positive Non-Small Cell Lung Cancer: 5-Year Outcomes From the Phase III CROWN Study
10.1200_jco.23.01462,JCO,2024,Oncology,Phase 3,Patient-Reported Outcomes From the Phase III HIMALAYA Study of Tremelimumab Plus Durvalumab in Unresectable Hepatocellular Carcinoma
10.1200_jco.23.02076,JCO,2024,Oncology,Phase 1/2,Phase I and Randomized Phase II Study of Ruxolitinib With Frontline Neoadjuvant Therapy in Advanced Ovarian Cancer: An NRG Oncology Group Study
10.1200_jco.24.00144,JCO,2024,Oncology,Phase 2,Final Results of RIGHT Choice: Ribociclib Plus Endocrine Therapy Versus Combination Chemotherapy in Premenopausal Women With Clinically Aggressive Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer
10.1200_jco.23.01636,JCO,2024,Oncology,Phase 2,First-Line Nivolumab and Relatlimab Plus Chemotherapy for Gastric or Gastroesophageal Junction Adenocarcinoma: The Phase II RELATIVITY-060 Study
10.1200_jco.23.01100,JCO,2024,Oncology,Phase 3,"Phase III Randomized, Placebo-Controlled Clinical Trial of Donepezil for Treatment of Cognitive Impairment in Breast Cancer Survivors After Adjuvant Chemotherapy (WF-97116)"
10.1200_jco.23.02394,JCO,2024,Oncology,Phase 3,Elective Pelvic Lymph Node Radiation Therapy and the Risk of Death in Patients With Unfavorable-Risk Prostate Cancer: A Postrandomization Analysis
10.1200_jco.23.02110,JCO,2024,Oncology,Phase 3,"RESILIENT Part 2: A Randomized, Open-Label Phase III Study of Liposomal Irinotecan Versus Topotecan in Adults With Relapsed Small Cell Lung Cancer"
10.1200_jco.23.02166,JCO,2024,Oncology,Phase 3,CONTACT-01: A Randomized Phase III Trial of Atezolizumab + Cabozantinib Versus Docetaxel for Metastatic Non-Small Cell Lung Cancer After a Checkpoint Inhibitor and Chemotherapy
10.1200_jco.23.02330,JCO,2024,Oncology,nan,Randomized Controlled Trial of Virtually Delivered Cognitive Behavioral Therapy for Insomnia to Address Perceived Cancer-Related Cognitive Impairment in Cancer Survivors
10.1200_jco.23.01500,JCO,2024,Oncology,Phase 2,"Giredestrant for Estrogen Receptor-Positive, HER2-Negative, Previously Treated Advanced Breast Cancer: Results From the Randomized, Phase II acelERA Breast Cancer Study"
10.1200_jco.23.01544,JCO,2024,Oncology,Phase 3,"Randomized, Double-Blind Phase III Study of Pazopanib Versus Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease After Metastasectomy: ECOG-ACRIN E2810"
10.1200_jco.23.01940,JCO,2024,Oncology,Phase 2,"PACE: A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab After Progression on Cyclin-Dependent Kinase 4/6 Inhibitor and Aromatase Inhibitor for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor-Negative Metastatic Breast Cancer"
10.1200_jco.23.02474,JCO,2024,Oncology,Phase 3,Gilteritinib as Post-Transplant Maintenance for AML With Internal Tandem Duplication Mutation of <i>FLT3</i>
10.1200_jco.23.02182,JCO,2024,Oncology,Phase 3,US Food and Drug Administration Approval Summary: Talazoparib in Combination With Enzalutamide for Treatment of Patients With Homologous Recombination Repair Gene-Mutated Metastatic Castration-Resistant Prostate Cancer
10.1200_jco.23.02355,JCO,2024,Oncology,Phase 3,Pembrolizumab Versus Placebo as Adjuvant Therapy in Resected Stage IIB or IIC Melanoma: Final Analysis of Distant Metastasis-Free Survival in the Phase III KEYNOTE-716 Study
10.1200_jco.23.01409,JCO,2024,Oncology,Phase 3,Final Results From the Randomized Phase III ASCENT Clinical Trial in Metastatic Triple-Negative Breast Cancer and Association of Outcomes by Human Epidermal Growth Factor Receptor 2 and Trophoblast Cell Surface Antigen 2 Expression
10.1200_jco.23.01601,JCO,2024,Oncology,Phase 3,"First-Line Nivolumab Plus Chemotherapy for Advanced Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma: 3-Year Follow-Up of the Phase III CheckMate 649 Trial"
10.1200_jco.23.02112,JCO,2024,Oncology,Phase 3,"US Food and Drug Administration Approval Summary: Elacestrant for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, <i>ESR1</i>-Mutated Advanced or Metastatic Breast Cancer"
10.1200_jco.23.01214,JCO,2024,Oncology,Phase 3,"Patient-Reported Outcomes in OlympiA: A Phase III, Randomized, Placebo-Controlled Trial of Adjuvant Olaparib in g<i>BRCA1/2</i> Mutations and High-Risk Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer"
10.1200_jco.23.01017,JCO,2024,Oncology,Phase 3,Nivolumab Plus Chemotherapy in Epidermal Growth Factor Receptor-Mutated Metastatic Non-Small-Cell Lung Cancer After Disease Progression on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: Final Results of CheckMate 722
10.1200_jco.23.00137,JCO,2024,Oncology,Phase 3,Overall Survival With Palbociclib Plus Letrozole in Advanced Breast Cancer
10.1200_jco.23.00795,JCO,2024,Oncology,Phase 3,"Gemcitabine and Paclitaxel Versus Gemcitabine Alone After 5-Fluorouracil, Oxaliplatin, and Irinotecan in Metastatic Pancreatic Adenocarcinoma: A Randomized Phase III PRODIGE 65-UCGI 36-GEMPAX UNICANCER Study"
10.1200_jco.23.01569,JCO,2024,Oncology,Phase 3,"Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study"
10.1200_jco.23.01868,JCO,2024,Oncology,Phase 3,FDA Approval Summary: Olaparib in Combination With Abiraterone for Treatment of Patients With <i>BRCA</i>-Mutated Metastatic Castration-Resistant Prostate Cancer
10.1200_jco.23.00838,JCO,2024,Oncology,Phase 3,Minimal Residual Disease Status Predicts Outcome in Patients With Previously Untreated Follicular Lymphoma: A Prospective Analysis of the Phase III GALLIUM Study
10.1200_jco.23.02219,JCO,2024,Oncology,Phase 3,CNS Efficacy of Osimertinib With or Without Chemotherapy in Epidermal Growth Factor Receptor-Mutated Advanced Non-Small-Cell Lung Cancer
10.1200_jco.23.00980,JCO,2024,Oncology,Phase 3,Canakinumab Versus Placebo in Combination With First-Line Pembrolizumab Plus Chemotherapy for Advanced Non-Small-Cell Lung Cancer: Results From the CANOPY-1 Trial
10.1200_jco.23.01363,JCO,2024,Oncology,Phase 3,SKYSCRAPER-02: Tiragolumab in Combination With Atezolizumab Plus Chemotherapy in Untreated Extensive-Stage Small-Cell Lung Cancer
10.1200_jco.22.02644,JCO,2024,Oncology,Phase 3,Adjuvant Hyperthermic Intraperitoneal Chemotherapy in Patients With Locally Advanced Colon Cancer (COLOPEC): 5-Year Results of a Randomized Multicenter Trial
10.1200_jco.23.02132,JCO,2024,Oncology,Phase 3,Durvalumab Plus Carboplatin/Paclitaxel Followed by Maintenance Durvalumab With or Without Olaparib as First-Line Treatment for Advanced Endometrial Cancer: The Phase III DUO-E Trial
10.1200_jco.23.00910,JCO,2024,Oncology,Phase 3,"Canakinumab as Adjuvant Therapy in Patients With Completely Resected Non-Small-Cell Lung Cancer: Results From the CANOPY-A Double-Blind, Randomized Clinical Trial"
10.1200_jco.23.00753,JCO,2024,Oncology,Phase 1/2,"Prophylactic Radiation Therapy Versus Standard of Care for Patients With High-Risk Asymptomatic Bone Metastases: A Multicenter, Randomized Phase II Clinical Trial"
10.1200_jco.23.00309,JCO,2024,Oncology,nan,Effect of a Community Health Worker-Led Intervention Among Low-Income and Minoritized Patients With Cancer: A Randomized Clinical Trial
10.1200_jco.23.00985,JCO,2023,Oncology,nan,Stereotactic Body Radiation Therapy and Abiraterone Acetate for Patients Affected by Oligometastatic Castrate-Resistant Prostate Cancer: A Randomized Phase II Trial (ARTO)
10.1200_jco.23.00493,JCO,2023,Oncology,Phase 2,Inaugural Results of the Individualized Screening Trial of Innovative Glioblastoma Therapy: A Phase II Platform Trial for Newly Diagnosed Glioblastoma Using Bayesian Adaptive Randomization
10.1200_jco.23.00170,JCO,2023,Oncology,Phase 3,Health-Related Quality of Life With Nivolumab Plus Chemotherapy Versus Chemotherapy in Patients With Advanced Gastric/Gastroesophageal Junction Cancer or Esophageal Adenocarcinoma From CheckMate 649
10.1200_jco.23.00296,JCO,2023,Oncology,Phase 3,Effect of Metformin Versus Placebo on New Primary Cancers in Canadian Cancer Trials Group MA.32: A Secondary Analysis of a Phase III Randomized Double-Blind Trial in Early Breast Cancer
10.1200_jco.23.01361,JCO,2023,Oncology,Phase 2,"Trastuzumab Deruxtecan in Patients With <i>HER2</i>-Mutant Metastatic Non-Small-Cell Lung Cancer: Primary Results From the Randomized, Phase II DESTINY-Lung02 Trial"
10.1200_jco.23.00172,JCO,2023,Oncology,Phase 3,"Bempegaldesleukin Plus Nivolumab in Untreated Advanced Melanoma: The Open-Label, Phase III PIVOT IO 001 Trial Results"
10.1200_jco.22.02630,JCO,2023,Oncology,Phase 3,Nimotuzumab Plus Gemcitabine for K-Ras Wild-Type Locally Advanced or Metastatic Pancreatic Cancer
10.1200_jco.23.00126,JCO,2023,Oncology,Phase 3,Impact of BMI in Patients With Early Hormone Receptor-Positive Breast Cancer Receiving Endocrine Therapy With or Without Palbociclib in the PALLAS Trial
10.1200_jco.23.00045,JCO,2023,Oncology,Phase 2/3,Outcomes After Preoperative Chemoradiation With or Without Pazopanib in Non-Rhabdomyosarcoma Soft Tissue Sarcoma: A Report From Children's Oncology Group and NRG Oncology
10.1200_jco.23.00775,JCO,2023,Oncology,Phase 2,ROSEWOOD: A Phase II Randomized Study of Zanubrutinib Plus Obinutuzumab Versus Obinutuzumab Monotherapy in Patients With Relapsed or Refractory Follicular Lymphoma
10.1200_jco.22.02830,JCO,2023,Other,Phase 3,Zanubrutinib Versus Ibrutinib in Symptomatic Waldenström Macroglobulinemia: Final Analysis From the Randomized Phase III ASPEN Study
10.1200_jco.23.00355,JCO,2023,Oncology,nan,Cluster Randomized Pragmatic Clinical Trial Testing Behavioral Economic Implementation Strategies to Improve Tobacco Treatment for Patients With Cancer Who Smoke
10.1200_jco.23.00515,JCO,2023,Oncology,Phase 3,Lazertinib Versus Gefitinib as First-Line Treatment in Patients With <i>EGFR</i>-Mutated Advanced Non-Small-Cell Lung Cancer: Results From LASER301
10.1200_jco.22.02624,JCO,2023,Oncology,Phase 2,"Relacorilant + Nab-Paclitaxel in Patients With Recurrent, Platinum-Resistant Ovarian Cancer: A Three-Arm, Randomized, Controlled, Open-Label Phase II Study"
10.1200_jco.22.02746,JCO,2023,Oncology,Phase 2,"AMEERA-3: Randomized Phase II Study of Amcenestrant (Oral Selective Estrogen Receptor Degrader) Versus Standard Endocrine Monotherapy in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer"
10.1200_jco.22.01856,JCO,2023,Oncology,Phase 3,Effect of Brachytherapy With External Beam Radiation Therapy Versus Brachytherapy Alone for Intermediate-Risk Prostate Cancer: NRG Oncology RTOG 0232 Randomized Clinical Trial
10.1200_jco.23.00233,JCO,2023,Oncology,Phase 3,"Pembrolizumab Plus Olaparib for Patients With Previously Treated and Biomarker-Unselected Metastatic Castration-Resistant Prostate Cancer: The Randomized, Open-Label, Phase III KEYLYNK-010 Trial"
10.1200_jco.23.00903,JCO,2023,Oncology,Phase 2/3,Patient-Reported Outcomes During and After Treatment for Locally Advanced Rectal Cancer in the PROSPECT Trial (Alliance N1048)
10.1200_jco.22.02200,JCO,2023,Oncology,Phase 3,"Children's Oncology Group AALL1331: Phase III Trial of Blinatumomab in Children, Adolescents, and Young Adults With Low-Risk B-Cell ALL in First Relapse"
10.1200_jco.22.02366,JCO,2023,Oncology,Phase 2,Randomized Double-Blind Phase II Trial of Fecal Microbiota Transplantation Versus Placebo in Allogeneic Hematopoietic Cell Transplantation and AML
10.1200_jco.22.01777,JCO,2023,Oncology,Phase 2,Phase II Randomized Trial of Lenalidomide in Children With Pilocytic Astrocytomas and Optic Pathway Gliomas: A Report From the Children's Oncology Group
10.1200_jco.22.01792,JCO,2023,Oncology,Phase 3,Avelumab First-Line Maintenance for Advanced Urothelial Carcinoma: Results From the JAVELIN Bladder 100 Trial After ≥2 Years of Follow-Up
10.1200_jco.22.02152,JCO,2023,Oncology,Phase 3,Lenvatinib Plus Pembrolizumab in Previously Treated Advanced Endometrial Cancer: Updated Efficacy and Safety From the Randomized Phase III Study 309/KEYNOTE-775
10.1200_jco.22.02394,JCO,2023,Oncology,Phase 3,Randomized Phase III Study of Enzalutamide Compared With Enzalutamide Plus Abiraterone for Metastatic Castration-Resistant Prostate Cancer (Alliance A031201 Trial)
10.1200_jco.22.01994,JCO,2023,Oncology,Phase 2,"Randomized Phase II Trial of Ficlatuzumab With or Without Cetuximab in Pan-Refractory, Recurrent/Metastatic Head and Neck Cancer"
10.1200_jco.22.01649,JCO,2023,Oncology,Phase 3,Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer
10.1200_jco.22.01989,JCO,2023,Oncology,Phase 3,Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non-Small-Cell Lung Cancer: 5-Year Outcomes From the Phase 3 KEYNOTE-189 Study
10.1200_jco.23.00041,JCO,2023,Oncology,Phase 3,Darolutamide Plus Androgen-Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer by Disease Volume and Risk Subgroups in the Phase III ARASENS Trial
10.1200_jco.22.00751,JCO,2023,Oncology,nan,Improving Uptake of Cancer Genetic Risk Assessment in a Remote Tailored Risk Communication and Navigation Intervention: Large Effect Size but Room to Grow
10.1200_jco.22.02447,JCO,2023,Oncology,Phase 3,US Food and Drug Administration Approval Summary: Fam-Trastuzumab Deruxtecan-nxki for Human Epidermal Growth Factor Receptor 2-Low Unresectable or Metastatic Breast Cancer
10.1200_jco.22.01990,JCO,2023,Oncology,Phase 3,Pembrolizumab Plus Chemotherapy in Squamous Non-Small-Cell Lung Cancer: 5-Year Update of the Phase III KEYNOTE-407 Study
10.1200_jco.22.02186,JCO,2023,Oncology,Phase 3,Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non-Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial
10.1200_jco.22.01285,JCO,2023,Oncology,Phase 1,"A First-in-Human Phase I Study of Milademetan, an MDM2 Inhibitor, in Patients With Advanced Liposarcoma, Solid Tumors, or Lymphomas"
10.1200_jco.22.01815,JCO,2023,Oncology,Phase 3,Randomized Phase III Trial of Ganitumab With Interval-Compressed Chemotherapy for Patients With Newly Diagnosed Metastatic Ewing Sarcoma: A Report From the Children's Oncology Group
10.1200_jco.22.01359,JCO,2023,Oncology,Phase 3,High-Dose Once-Daily Thoracic Radiotherapy in Limited-Stage Small-Cell Lung Cancer: CALGB 30610 (Alliance)/RTOG 0538
10.1200_jco.22.00509,JCO,2023,Pediatrics,Phase 3,Ibrutinib for First-Line Treatment of Chronic Graft-Versus-Host Disease: Results From the Randomized Phase III iNTEGRATE Study
10.1200_jco.22.00996,JCO,2023,Oncology,Phase 2,Phase IIa Study of SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma
10.1200_jco.22.01064,JCO,2023,Oncology,Phase 3,Adjuvant Exemestane With Ovarian Suppression in Premenopausal Breast Cancer: Long-Term Follow-Up of the Combined TEXT and SOFT Trials
10.1200_jco.22.00972,JCO,2023,Oncology,Phase 1/2,Nivolumab Plus Cabozantinib With or Without Ipilimumab for Advanced Hepatocellular Carcinoma: Results From Cohort 6 of the CheckMate 040 Trial
10.1200_jco.22.01065,JCO,2023,Oncology,Phase 3,Adjuvant Endocrine Therapy in Premenopausal Breast Cancer: 12-Year Results From SOFT
10.1200_jco.22.00332,JCO,2023,Oncology,Phase 3,Nivolumab Plus Ipilimumab Versus EXTREME Regimen as First-Line Treatment for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck: The Final Results of CheckMate 651
10.1200_jco.22.00620,JCO,2023,Oncology,Phase 3,"Pembrolizumab Versus Placebo as Second-Line Therapy in Patients From Asia With Advanced Hepatocellular Carcinoma: A Randomized, Double-Blind, Phase III Trial"
10.1200_jco.22.00510,JCO,2023,Oncology,Phase 3,Zanubrutinib Versus Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: Interim Analysis of a Randomized Phase III Trial
10.1200_jco.22.01662,JCO,2023,Oncology,Phase 2,Phase II Randomized Study of Salvage Radiation Therapy Plus Enzalutamide or Placebo for High-Risk Prostate-Specific Antigen Recurrent Prostate Cancer After Radical Prostatectomy: The SALV-ENZA Trial
10.1200_jco.22.01637,JCO,2023,Oncology,Phase 3,Potential Mediators of Oxaliplatin-Induced Peripheral Neuropathy From Adjuvant Therapy in Stage III Colon Cancer: Findings From CALGB (Alliance)/SWOG 80702
10.1200_jco.22.00738,JCO,2023,Oncology,nan,Effects of a Geriatric Assessment Intervention on Patient-Reported Symptomatic Toxicity in Older Adults With Advanced Cancer
10.1200_jco.21.02937,JCO,2023,Oncology,Phase 3,Margetuximab Versus Trastuzumab in Patients With Previously Treated HER2-Positive Advanced Breast Cancer (SOPHIA): Final Overall Survival Results From a Randomized Phase 3 Trial
10.1200_jco.22.00975,JCO,2023,Oncology,Phase 3,Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non-Small-Cell Lung Cancer: The Phase III POSEIDON Study
10.1200_jco.21.02885,JCO,2023,Oncology,Phase 3,Five-Year Outcomes With Pembrolizumab Versus Chemotherapy as First-Line Therapy in Patients With Non-Small-Cell Lung Cancer and Programmed Death Ligand-1 Tumor Proportion Score ≥ 1% in the KEYNOTE-042 Study
10.1200_jco.22.00164,JCO,2023,Oncology,Phase 2,NRG Oncology/RTOG1205: A Randomized Phase II Trial of Concurrent Bevacizumab and Reirradiation Versus Bevacizumab Alone as Treatment for Recurrent Glioblastoma
10.1200_jco.22.01013,JCO,2023,Oncology,Phase 2,Randomized Study of Temozolomide or Temozolomide and Capecitabine in Patients With Advanced Pancreatic Neuroendocrine Tumors (ECOG-ACRIN E2211)
10.1200_jco.21.02947,JCO,2023,Oncology,Phase 2,Randomized Trial of Olaparib With or Without Cediranib for Metastatic Castration-Resistant Prostate Cancer: The Results From National Cancer Institute 9984
10.1200_jco.21.02303,JCO,2023,Oncology,Phase 2/3,FORT-1: Phase II/III Study of Rogaratinib Versus Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Carcinoma Selected Based on <i>FGFR1</i>/<i>3</i> mRNA Expression
10.1200_jco.22.01258,JCO,2023,Oncology,nan,A Pragmatic Cluster-Randomized Trial of a Standing Order Entry Intervention for Colony-Stimulating Factor Use Among Patients at Intermediate Risk for Febrile Neutropenia
10.1200_jco.22.01503,JCO,2023,Oncology,Phase 3,Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non-Small-Cell Lung Cancer in CheckMate 227
10.1200_jco.21.02508,JCO,2023,Oncology,Phase 3,Pembrolizumab With or Without Chemotherapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Updated Results of the Phase III KEYNOTE-048 Study
10.1200_jco.22.01763,JCO,2023,Oncology,Phase 3,Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced <i>BRAF</i>-Mutant Melanoma: The DREAMseq Trial-ECOG-ACRIN EA6134
10.1200_jco.22.00533,JCO,2023,Oncology,Phase 3,Adjuvant Therapy of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Patients With Resected Stage IIIB-D or Stage IV Melanoma (CheckMate 915)
10.1200_jco.22.01549,JCO,2023,Oncology,Phase 3,Overall Survival With Maintenance Olaparib at a 7-Year Follow-Up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial
10.1200_jco.22.00343,JCO,2023,Oncology,Phase 3,"Randomized, Double-Blind, Placebo-Controlled, Global Phase III Trial of Talimogene Laherparepvec Combined With Pembrolizumab for Advanced Melanoma"
10.1200_jco.21.02815,JCO,2023,Oncology,Phase 2,Elotuzumab Plus Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma: Final Overall Survival Analysis From the Randomized Phase II ELOQUENT-3 Trial
10.1200_jco.22.00205,JCO,2023,Oncology,Phase 2,"Durvalumab Plus Olaparib in Previously Untreated, Platinum-Ineligible Patients With Metastatic Urothelial Carcinoma: A Multicenter, Randomized, Phase II Trial (BAYOU)"
10.1200_jco.22.01002,JCO,2022,Oncology,Phase 3,Sacituzumab Govitecan in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer
10.1200_jco.22.00294,JCO,2022,Oncology,Phase 3,"Ripretinib Versus Sunitinib in Patients With Advanced Gastrointestinal Stromal Tumor After Treatment With Imatinib (INTRIGUE): A Randomized, Open-Label, Phase III Trial"
10.1200_jco.21.01604,JCO,2022,Oncology,Phase 3,Overall Survival Results From the POLO Trial: A Phase III Study of Active Maintenance Olaparib Versus Placebo for Germline BRCA-Mutated Metastatic Pancreatic Cancer
10.1200_jco.21.02772,JCO,2022,Oncology,Phase 3,Atezolizumab With Neoadjuvant Anti-Human Epidermal Growth Factor Receptor 2 Therapy and Chemotherapy in Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: Primary Results of the Randomized Phase III IMpassion050 Trial
10.1200_jco.22.00146,JCO,2022,Oncology,Phase 3,Phase III Randomized Trial of Maintenance Taxanes Versus Surveillance in Women With Advanced Ovarian/Tubal/Peritoneal Cancer: A Gynecologic Oncology Group 0212:NRG Oncology Study
10.1200_jco.22.01003,JCO,2022,Oncology,Phase 3,"A Randomized, Phase III Trial to Evaluate Rucaparib Monotherapy as Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer (ATHENA-MONO/GOG-3020/ENGOT-ov45)"
10.1200_jco.21.02278,JCO,2022,Oncology,Phase 3,Post Hoc Analysis of Lorlatinib Intracranial Efficacy and Safety in Patients With <i>ALK</i>-Positive Advanced Non-Small-Cell Lung Cancer From the Phase III CROWN Study
10.1200_jco.22.00338,JCO,2022,Oncology,Phase 3,"Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial"
10.1200_jco.21.02641,JCO,2022,Oncology,Phase 3,AENEAS: A Randomized Phase III Trial of Aumolertinib Versus Gefitinib as First-Line Therapy for Locally Advanced or MetastaticNon-Small-Cell Lung Cancer With <i>EGFR</i> Exon 19 Deletion or L858R Mutations
10.1200_jco.21.02628,JCO,2022,Oncology,Phase 3,Final Analysis of 3 Versus 6 Months of Adjuvant Oxaliplatin and Fluoropyrimidine-Based Therapy in Patients With Stage III Colon Cancer: The Randomized Phase III ACHIEVE Trial
10.1200_jco.22.00227,JCO,2022,Oncology,Phase 2,"COAST: An Open-Label, Phase II, Multidrug Platform Study of Durvalumab Alone or in Combination With Oleclumab or Monalizumab in Patients With Unresectable, Stage III Non-Small-Cell Lung Cancer"
10.1200_jco.21.02517,JCO,2022,Oncology,Phase 3,"Orteronel for Metastatic Hormone-Sensitive Prostate Cancer: A Multicenter, Randomized, Open-Label Phase III Trial (SWOG-1216)"
10.1200_jco.21.01926,JCO,2022,Oncology,Phase 3,Tislelizumab Versus Chemotherapy as Second-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma (RATIONALE-302): A Randomized Phase III Study
10.1200_jco.22.00193,JCO,2022,Oncology,Phase 3,Improved Survival With Enzalutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer
10.1200_jco.21.01829,JCO,2022,Oncology,Phase 2/3,"Selinexor in Advanced, Metastatic Dedifferentiated Liposarcoma: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial"
10.1200_jco.21.02198,JCO,2022,Oncology,Phase 3,Pembrolizumab Alone or With Chemotherapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma in KEYNOTE-048: Subgroup Analysis by Programmed Death Ligand-1 Combined Positive Score
10.1200_jco.21.02011,JCO,2022,Oncology,Phase 3,"Olaparib With or Without Cediranib Versus Platinum-Based Chemotherapy in Recurrent Platinum-Sensitive Ovarian Cancer (NRG-GY004): A Randomized, Open-Label, Phase III Trial"
10.1200_jco.21.02678,JCO,2022,Oncology,Phase 3,Children's Oncology Group Trial AALL1231: A Phase III Clinical Trial Testing Bortezomib in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia and Lymphoma
10.1200_jco.21.00714,JCO,2022,Oncology,Phase 3,"Selumetinib Plus Adjuvant Radioactive Iodine in Patients With High-Risk Differentiated Thyroid Cancer: A Phase III, Randomized, Placebo-Controlled Trial (ASTRA)"
10.1200_jco.21.01308,JCO,2022,Oncology,Phase 3,Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer
10.1200_jco.21.01601,JCO,2022,Oncology,Phase 3,Randomized Phase III Trial Evaluating Spartalizumab Plus Dabrafenib and Trametinib for <i>BRAF</i> V600-Mutant Unresectable or Metastatic Melanoma
10.1200_jco.21.02050,JCO,2022,Oncology,Phase 3,Randomized Phase III Trial of Paclitaxel and Carboplatin Versus Paclitaxel and Ifosfamide in Patients With Carcinosarcoma of the Uterus or Ovary: An NRG Oncology Trial
10.1200_jco.21.02006,JCO,2022,Oncology,nan,Early Local Therapy for the Primary Site in De Novo Stage IV Breast Cancer: Results of a Randomized Clinical Trial (EA2108)
10.1200_jco.21.01918,JCO,2022,Oncology,Phase 3,Treatment Exposure and Discontinuation in the PALbociclib CoLlaborative Adjuvant Study of Palbociclib With Adjuvant Endocrine Therapy for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer (PALLAS/AFT-05/ABCSG-42/BIG-14-03)
10.1200_jco.21.01657,JCO,2022,Oncology,Phase 2,"BRE12-158: A Postneoadjuvant, Randomized Phase II Trial of Personalized Therapy Versus Treatment of Physician's Choice for Patients With Residual Triple-Negative Breast Cancer"
10.1200_jco.21.00896,JCO,2022,Oncology,Phase 3,Trastuzumab Emtansine Plus Pertuzumab Versus Taxane Plus Trastuzumab Plus Pertuzumab After Anthracycline for High-Risk Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: The Phase III KAITLIN Study
10.1200_jco.21.01473,JCO,2022,Oncology,Phase 2,Randomized Controlled Phase II Evaluation of Two Dose Levels of Bupropion Versus Placebo for Sexual Desire in Female Cancer Survivors: NRG-CC004
10.1200_jco.21.02554,JCO,2022,Oncology,Phase 3,Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03)
10.1200_jco.21.02293,JCO,2022,Oncology,Phase 3,Randomized Phase III BMT CTN Trial of Calcineurin Inhibitor-Free Chronic Graft-Versus-Host Disease Interventions in Myeloablative Hematopoietic Cell Transplantation for Hematologic Malignancies
10.1200_jco.21.00601,JCO,2022,Oncology,Phase 3,Impact of Pembrolizumab Versus Chemotherapy as Second-Line Therapy for Advanced Esophageal Cancer on Health-Related Quality of Life in KEYNOTE-181
10.1200_jco.21.00838,JCO,2022,Oncology,Phase 3,Ibrutinib Plus Rituximab Versus Placebo Plus Rituximab for Waldenström's Macroglobulinemia: Final Analysis From the Randomized Phase III iNNOVATE Study
10.1200_jco.20.03452,JCO,2022,Oncology,Phase 2,Phase II Randomized Study of CMB305 and Atezolizumab Compared With Atezolizumab Alone in Soft-Tissue Sarcomas Expressing NY-ESO-1
10.1200_jco.21.01181,JCO,2021,Oncology,Phase 3,Minimal Residual Disease Dynamics after Venetoclax-Obinutuzumab Treatment: Extended Off-Treatment Follow-up From the Randomized CLL14 Study
10.1200_jco.21.00358,JCO,2021,Oncology,Phase 3,Phase III Trial Adding Vincristine-Topotecan-Cyclophosphamide to the Initial Treatment of Patients With Nonmetastatic Ewing Sarcoma: A Children's Oncology Group Report
10.1200_jco.21.00807,JCO,2021,Oncology,Phase 2,Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia: Primary Analysis Results From the Minimal Residual Disease Cohort of the Randomized Phase II CAPTIVATE Study
10.1200_jco.21.01839,JCO,2021,Oncology,nan,"Radioembolization With Chemotherapy for Colorectal Liver Metastases: A Randomized, Open-Label, International, Multicenter, Phase III Trial"
10.1200_jco.21.00279,JCO,2021,Oncology,nan,Targeting Depressive Symptoms in Younger Breast Cancer Survivors: The Pathways to Wellness Randomized Controlled Trial of Mindfulness Meditation and Survivorship Education
10.1200_jco.21.00944,JCO,2021,Oncology,Phase 3,E2112: Randomized Phase III Trial of Endocrine Therapy Plus Entinostat or Placebo in Hormone Receptor-Positive Advanced Breast Cancer. A Trial of the ECOG-ACRIN Cancer Research Group
10.1200_jco.21.00217,JCO,2021,Oncology,Phase 1,"Avapritinib Versus Regorafenib in Locally Advanced Unresectable or Metastatic GI Stromal Tumor: A Randomized, Open-Label Phase III Study"
10.1200_jco.21.01210,JCO,2021,Oncology,Phase 3,Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial
10.1200_jco.20.03555,JCO,2021,Oncology,Phase 2,"Safety, Efficacy, and Pharmacodynamics of Tremelimumab Plus Durvalumab for Patients With Unresectable Hepatocellular Carcinoma: Randomized Expansion of a Phase I/II Study"
10.1200_jco.20.03329,JCO,2021,Oncology,Phase 2,Randomized Phase II Trial Evaluating Two Sequential Treatments in First Line of Metastatic Pancreatic Cancer: Results of the PANOPTIMOX-PRODIGE 35 Trial
10.1200_jco.21.00703,JCO,2021,Oncology,Phase 2,"Randomized Phase II Trial of MIBG Versus MIBG, Vincristine, and Irinotecan Versus MIBG and Vorinostat for Patients With Relapsed or Refractory Neuroblastoma: A Report From NANT Consortium"
10.1200_jco.20.03692,JCO,2021,Oncology,Phase 2,Efficacy and Toxicity of Pegaspargase and Calaspargase Pegol in Childhood Acute Lymphoblastic Leukemia: Results of DFCI 11-001
10.1200_jco.21.00596,JCO,2021,Oncology,Phase 3,Radiation and Androgen Deprivation Therapy With or Without Docetaxel in the Management of Nonmetastatic Unfavorable-Risk Prostate Cancer: A Prospective Randomized Trial
10.1200_jco.20.02864,JCO,2021,Other,Phase 2,"Randomized, Single-Blind, Multicenter Phase II Study of Two Doses of Imetelstat in Relapsed or Refractory Myelofibrosis"
10.1200_jco.20.02914,JCO,2021,Oncology,Phase 3,"PRODIGY: A Phase III Study of Neoadjuvant Docetaxel, Oxaliplatin, and S-1 Plus Surgery and Adjuvant S-1 Versus Surgery and Adjuvant S-1 for Resectable Advanced Gastric Cancer"
10.1200_jco.21.00972,JCO,2021,Oncology,Phase 3,"Final Overall Survival Analysis of the TOURMALINE-MM1 Phase III Trial of Ixazomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma"
10.1200_jco.21.00976,JCO,2021,Oncology,Phase 3,Randomized Phase III Postoperative Trial of Platinum-Based Chemotherapy Versus Capecitabine in Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy: ECOG-ACRIN EA1131
10.1200_jco.20.03398,JCO,2021,Oncology,Phase 2,Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT): A Randomized Clinical Trial
10.1200_jco.21.00286,JCO,2021,Oncology,Phase 3,Randomized Phase III Trial of Gemcitabine and Cisplatin With Bevacizumab or Placebo in Patients With Advanced Urothelial Carcinoma: Results of CALGB 90601 (Alliance)
10.1200_jco.20.03488,JCO,2021,Oncology,Phase 3,"Apalutamide in Patients With Metastatic Castration-Sensitive Prostate Cancer: Final Survival Analysis of the Randomized, Double-Blind, Phase III TITAN Study"
10.1200_jco.21.00306,JCO,2021,Oncology,Phase 3,"Atezolizumab, Bevacizumab, and Chemotherapy for Newly Diagnosed Stage III or IV Ovarian Cancer: Placebo-Controlled Randomized Phase III Trial (IMagyn050/GOG 3015/ENGOT-OV39)"
10.1200_jco.21.00174,JCO,2021,Oncology,Phase 3,Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50
10.1200_jco.20.03639,JCO,2021,Oncology,Phase 3,Palbociclib for Residual High-Risk Invasive HR-Positive and HER2-Negative Early Breast Cancer-The Penelope-B Trial
10.1200_jco.20.02977,JCO,2021,Oncology,Phase 3,Correlative Biomarker Analysis of Intrinsic Subtypes and Efficacy Across the MONALEESA Phase III Studies
10.1200_jco.20.02619,JCO,2021,Oncology,Phase 3,"Phase III, Randomized, Placebo-Controlled Trial of CC-486 (Oral Azacitidine) in Patients With Lower-Risk Myelodysplastic Syndromes"
10.1200_jco.20.02212,JCO,2021,Oncology,Phase 3,Nivolumab and Ipilimumab as Maintenance Therapy in Extensive-Disease Small-Cell Lung Cancer: CheckMate 451
10.1200_jco.20.01366,JCO,2021,Oncology,Phase 3,ROBUST: A Phase III Study of Lenalidomide Plus R-CHOP Versus Placebo Plus R-CHOP in Previously Untreated Patients With ABC-Type Diffuse Large B-Cell Lymphoma
10.1200_jco.20.02759,JCO,2021,Oncology,Phase 2,TRANSFORMER: A Randomized Phase II Study Comparing Bipolar Androgen Therapy Versus Enzalutamide in Asymptomatic Men With Castration-Resistant Metastatic Prostate Cancer
10.1200_jco.20.02232,JCO,2021,Oncology,Phase 3,Randomized Phase III Study of FOLFOX Alone or With Pegilodecakin as Second-Line Therapy in Patients With Metastatic Pancreatic Cancer That Progressed After Gemcitabine (SEQUOIA)
10.1200_jco.20.03579,JCO,2021,Oncology,Phase 3,"Pembrolizumab Plus Ipilimumab or Placebo for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%: Randomized, Double-Blind Phase III KEYNOTE-598 Study"
10.1200_jco.20.03128,JCO,2021,Oncology,Phase 2,Reduced-Dose Radiation Therapy for HPV-Associated Oropharyngeal Carcinoma (NRG Oncology HN002)
10.1200_jco.20.02088,JCO,2021,Oncology,Phase 3,Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated <i>BRAF</i> V600E-Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study
10.1200_jco.20.01691,JCO,2021,Oncology,Phase 3,Lenalidomide-Epoetin Alfa Versus Lenalidomide Monotherapy in Myelodysplastic Syndromes Refractory to Recombinant Erythropoietin
10.1200_jco.20.01055,JCO,2021,Oncology,Phase 3,"Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133)"
10.1200_jco.20.00494,JCO,2021,Oncology,Phase 3,Excellent Outcomes With Reduced Frequency of Vincristine and Dexamethasone Pulses in Standard-Risk B-Lymphoblastic Leukemia: Results From Children's Oncology Group AALL0932
10.1200_jco.20.01994,JCO,2021,Oncology,Phase 2,Randomized Trial of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF-Mutant Metastatic Colorectal Cancer (SWOG S1406)
10.1200_jco.20.01370,JCO,2021,Oncology,Phase 3,Health-Related Quality of Life in Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma: Findings From the Phase III MAIA Trial
10.1200_jco.20.00892,JCO,2021,Oncology,Phase 3,Phase III Trial of Avelumab Maintenance After First-Line Induction Chemotherapy Versus Continuation of Chemotherapy in Patients With Gastric Cancers: Results From JAVELIN Gastric 100
10.1200_jco.20.00290,JCO,2021,Oncology,Phase 2,Randomized Phase II Trial of Nivolumab With Stereotactic Body Radiotherapy Versus Nivolumab Alone in Metastatic Head and Neck Squamous Cell Carcinoma
10.1200_jco.20.01888,JCO,2020,Oncology,Phase 3,Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer
10.1200_jco.20.01149,JCO,2020,Oncology,Phase 2/3,Randomized Trial of Afatinib Plus Cetuximab Versus Afatinib Alone for First-Line Treatment of <i>EGFR</i>-Mutant Non-Small-Cell Lung Cancer: Final Results From SWOG S1403
10.1200_jco.20.02060,JCO,2020,Oncology,Phase 3,Ixazomib as Postinduction Maintenance for Patients With Newly Diagnosed Multiple Myeloma Not Undergoing Autologous Stem Cell Transplantation: The Phase III TOURMALINE-MM4 Trial
10.1200_jco.20.00948,JCO,2020,Oncology,Phase 3,Venetoclax Plus Rituximab in Relapsed Chronic Lymphocytic Leukemia: 4-Year Results and Evaluation of Impact of Genomic Complexity and Gene Mutations From the MURANO Phase III Study
10.1200_jco.20.02514,JCO,2020,Oncology,Phase 3,"Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE)"
10.1200_jco.20.02110,JCO,2020,Oncology,Phase 3,Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial
10.1200_jco.20.00256,JCO,2020,Oncology,Phase 3,Children's Oncology Group AALL0434: A Phase III Randomized Clinical Trial Testing Nelarabine in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia
10.1200_jco.20.00505,JCO,2020,Oncology,Phase 3,Brigatinib Versus Crizotinib in Advanced ALK Inhibitor-Naive ALK-Positive Non-Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial
10.1200_jco.20.00315,JCO,2020,Oncology,Phase 3,"Cancer and Leukemia Group B 90203 (Alliance): Radical Prostatectomy With or Without Neoadjuvant Chemohormonal Therapy in Localized, High-Risk Prostate Cancer"
10.1200_jco.20.00147,JCO,2020,Oncology,Phase 3,Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With ≥ 2 HER2-Directed Regimens: Phase III NALA Trial
10.1200_jco.20.00531,JCO,2020,Oncology,Phase 3,Successful Outcomes of Newly Diagnosed T Lymphoblastic Lymphoma: Results From Children's Oncology Group AALL0434
10.1200_jco.19.02892,JCO,2020,Oncology,Phase 3,Impact of Intrathecal Triple Therapy Versus Intrathecal Methotrexate on Disease-Free Survival for High-Risk B-Lymphoblastic Leukemia: Children's Oncology Group Study AALL1131
10.1200_jco.20.00793,JCO,2020,Oncology,Phase 3,"Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study"
10.1200_jco.20.00775,JCO,2020,Oncology,Phase 2,Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial
10.1200_jco.19.03355,JCO,2020,Oncology,Phase 3,"ASCEND: Phase III, Randomized Trial of Acalabrutinib Versus Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia"
10.1200_jco.19.03158,JCO,2020,Oncology,Phase 3,Safety and Patient-Reported Outcomes of Atezolizumab Plus Chemotherapy With or Without Bevacizumab Versus Bevacizumab Plus Chemotherapy in Non-Small-Cell Lung Cancer
10.1200_jco.19.03091,JCO,2020,Oncology,Phase 2,Randomized Double-Blind Phase II Study of Maintenance Pembrolizumab Versus Placebo After First-Line Chemotherapy in Patients With Metastatic Urothelial Cancer
10.1200_jco.19.03136,JCO,2020,Oncology,Phase 3,Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer
10.1200_jco.19.02250,JCO,2020,Oncology,Phase 2,Randomized Phase II Study of First-Line Cladribine With Concurrent or Delayed Rituximab in Patients With Hairy Cell Leukemia
10.1200_jco.19.03292,JCO,2020,Oncology,Phase 2,TBCRC 031: Randomized Phase II Study of Neoadjuvant Cisplatin Versus Doxorubicin-Cyclophosphamide in Germline <i>BRCA</i> Carriers With HER2-Negative Breast Cancer (the INFORM trial)
10.1200_jco.19.02446,JCO,2020,Oncology,Phase 2/3,"Long-Term Outcomes and Retreatment Among Patients With Previously Treated, Programmed Death-Ligand 1‒Positive, Advanced Non‒Small-Cell Lung Cancer in the KEYNOTE-010 Study"
10.1200_jco.19.02745,JCO,2020,Oncology,Phase 3,Olaparib Versus Nonplatinum Chemotherapy in Patients With Platinum-Sensitive Relapsed Ovarian Cancer and a Germline BRCA1/2 Mutation (SOLO3): A Randomized Phase III Trial
10.1200_jco.19.02767,JCO,2020,Oncology,Phase 3,Hippocampal Avoidance During Whole-Brain Radiotherapy Plus Memantine for Patients With Brain Metastases: Phase III Trial NRG Oncology CC001
10.1200_jco.19.01455,JCO,2020,Oncology,Phase 3,NSABP B-47/NRG Oncology Phase III Randomized Trial Comparing Adjuvant Chemotherapy With or Without Trastuzumab in High-Risk Invasive Breast Cancer Negative for HER2 by FISH and With IHC 1+ or 2
10.1200_jco.19.01348,JCO,2020,Oncology,Phase 3,Health-Related Quality of Life With Carboplatin-Paclitaxel or nab-Paclitaxel With or Without Pembrolizumab in Patients With Metastatic Squamous Non-Small-Cell Lung Cancer
10.1200_jco.19.00172,JCO,2020,Oncology,Phase 1/2,Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
10.1200_jco.19.01740,JCO,2020,Oncology,Phase 3,Randomized Trial of Lenalidomide Versus Observation in Smoldering Multiple Myeloma
10.1200_jco.19.01701,JCO,2019,Oncology,Phase 2,"Phase II Trial of a DNA Vaccine Encoding Prostatic Acid Phosphatase (pTVG-HP [MVI-816]) in Patients With Progressive, Nonmetastatic, Castration-Sensitive Prostate Cancer"
10.1200_jco.19.00555,JCO,2019,Oncology,Phase 3,Phase III Randomized Trial of Chemotherapy With or Without Bevacizumab in Patients With Recurrent or Metastatic Head and Neck Cancer
10.1200_jco.19.01507,JCO,2019,Oncology,Phase 3,"Phase IIb, Randomized, Double-Blind Trial of GC4419 Versus Placebo to Reduce Severe Oral Mucositis Due to Concurrent Radiotherapy and Cisplatin For Head and Neck Cancer"
10.1200_jco.18.01931,JCO,2019,Oncology,Phase 2,Romiplostim Treatment of Chemotherapy-Induced Thrombocytopenia
10.1200_jco.19.00269,JCO,2019,Oncology,Phase 1/2,Phase II Trial of Cediranib in Combination With Cisplatin and Pemetrexed in Chemotherapy-Naïve Patients With Unresectable Malignant Pleural Mesothelioma (SWOG S0905)
10.1200_jco.19.01006,JCO,2019,Oncology,Phase 3,"Pemetrexed, Bevacizumab, or the Combination As Maintenance Therapy for Advanced Nonsquamous Non-Small-Cell Lung Cancer: ECOG-ACRIN 5508"
10.1200_jco.19.00799,JCO,2019,Oncology,Phase 3,"ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer"
10.1200_jco.19.00327,JCO,2019,Oncology,Phase 3,"Clofarabine Can Replace Anthracyclines and Etoposide in Remission Induction Therapy for Childhood Acute Myeloid Leukemia: The AML08 Multicenter, Randomized Phase III Trial"
10.1200_jco.18.02238,JCO,2019,Oncology,Phase 3,Niraparib Maintenance Therapy in Patients With Recurrent Ovarian Cancer After a Partial Response to the Last Platinum-Based Chemotherapy in the ENGOT-OV16/NOVA Trial
10.1200_jco.19.00538,JCO,2019,Oncology,Phase 1/2,Nivolumab Alone and With Ipilimumab in Previously Treated Metastatic Urothelial Carcinoma: CheckMate 032 Nivolumab 1 mg/kg Plus Ipilimumab 3 mg/kg Expansion Cohort Results
10.1200_jco.18.02374,JCO,2019,Oncology,Phase 2,Randomized Double-Blind Phase II Study of Regorafenib in Patients With Metastatic Osteosarcoma
10.1200_jco.19.00066,JCO,2019,Oncology,Phase 2,"Seven-Year Follow-Up Analysis of Adjuvant Paclitaxel and Trastuzumab Trial for Node-Negative, Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer"
10.1200_jco.18.01994,JCO,2019,Oncology,Phase 3,Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303
10.1200_jco.18.01770,JCO,2019,Oncology,nan,"Self-Management in Long-Term Prostate Cancer Survivors: A Randomized, Controlled Trial"
10.1200_jco.18.02403,JCO,2019,Oncology,Phase 3,"Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non-Germinal Center B-Cell Diffuse Large B-Cell Lymphoma"
10.1200_jco.19.00010,JCO,2019,Oncology,Phase 3,AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma
10.1200_jco.18.02459,JCO,2019,Oncology,Phase 3,"Binimetinib, Encorafenib, and Cetuximab Triplet Therapy for Patients With <i>BRAF</i> V600E-Mutant Metastatic Colorectal Cancer: Safety Lead-In Results From the Phase III BEACON Colorectal Cancer Study"
10.1200_jco.18.02031,JCO,2019,Oncology,Phase 3,Phase III Trial of PROSTVAC in Asymptomatic or Minimally Symptomatic Metastatic Castration-Resistant Prostate Cancer
10.1200_jco.18.01295,JCO,2019,Oncology,Phase 1/2,Phase IB/II Randomized Study of FOLFIRINOX Plus Pegylated Recombinant Human Hyaluronidase Versus FOLFIRINOX Alone in Patients With Metastatic Pancreatic Adenocarcinoma: SWOG S1313
10.1200_jco.18.01777,JCO,2019,Oncology,Phase 2,Evaluation of Intense Androgen Deprivation Before Prostatectomy: A Randomized Phase II Trial of Enzalutamide and Leuprolide With or Without Abiraterone
10.1200_jco.18.01998,JCO,2019,Oncology,Phase 3,Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma: Results From the Phase IIIb/IV CheckMate 511 Trial
10.1200_jco.18.00925,JCO,2019,Oncology,Phase 3,Cyclin E1 Expression and Palbociclib Efficacy in Previously Treated Hormone Receptor-Positive Metastatic Breast Cancer
10.1200_jco.18.00296,JCO,2019,Oncology,Phase 2,Neoadjuvant Degarelix Versus Triptorelin in Premenopausal Patients Who Receive Letrozole for Locally Advanced Endocrine-Responsive Breast Cancer: A Randomized Phase II Trial
10.1200_jco.18.01580,JCO,2019,Oncology,Phase 3,Fixed Duration of Venetoclax-Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Eradicates Minimal Residual Disease and Prolongs Survival: Post-Treatment Follow-Up of the MURANO Phase III Study
10.1200_jco.18.01219,JCO,2018,Oncology,Phase 3,Longer Follow-Up Confirms Relapse-Free Survival Benefit With Adjuvant Dabrafenib Plus Trametinib in Patients With Resected <i>BRAF</i> V600-Mutant Stage III Melanoma
10.1200_jco.2018.77.7250,JCO,2018,Oncology,Phase 3,Improved Survival for Children and Young Adults With T-Lineage Acute Lymphoblastic Leukemia: Results From the Children's Oncology Group AALL0434 Methotrexate Randomization
10.1200_jco.2018.77.9363,JCO,2018,Oncology,Phase 3,CNS Efficacy of Osimertinib in Patients With T790M-Positive Advanced Non-Small-Cell Lung Cancer: Data From a Randomized Phase III Trial (AURA3)
10.1200_jco.2018.79.2028,JCO,2018,Oncology,Phase 3,Double-Blind Phase III Trial of Adjuvant Chemotherapy With and Without Bevacizumab in Patients With Lymph Node-Positive and High-Risk Lymph Node-Negative Breast Cancer (E5103)
10.1200_jco.2018.78.9909,JCO,2018,Oncology,Phase 3,"Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3"
10.1200_jco.2017.76.8960,JCO,2018,Oncology,Phase 3,Immunochemotherapy With Obinutuzumab or Rituximab for Previously Untreated Follicular Lymphoma in the GALLIUM Study: Influence of Chemotherapy on Efficacy and Safety
10.1200_jco.2017.77.5841,JCO,2018,Oncology,Phase 1/2,Exploratory Analysis of Brigatinib Activity in Patients With Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer and Brain Metastases in Two Clinical Trials
10.1200_jco.2017.77.2293,JCO,2018,Oncology,Phase 3,Patient-Reported Symptoms and Impact of Treatment With Osimertinib Versus Chemotherapy in Advanced Non-Small-Cell Lung Cancer: The AURA3 Trial
10.1200_jco.2017.76.9331,JCO,2018,Oncology,Phase 2,"Randomized Phase II Trial of Fulvestrant Plus Everolimus or Placebo in Postmenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer Resistant to Aromatase Inhibitor Therapy: Results of PrE0102"
10.1200_jco.2017.76.4126,JCO,2018,Oncology,Phase 3,Phase III Intergroup Trial of Adjuvant Androgen Deprivation With or Without Mitoxantrone Plus Prednisone in Patients With High-Risk Prostate Cancer After Radical Prostatectomy: SWOG S9921
10.1200_jco.2017.76.4381,JCO,2018,Oncology,Phase 2,Prospective International Randomized Phase II Study of Low-Dose Abiraterone With Food Versus Standard Dose Abiraterone In Castration-Resistant Prostate Cancer
10.1200_jco.2017.76.5966,JCO,2018,Oncology,Phase 2,Randomized Phase II Trial of Carboplatin-Paclitaxel Versus Carboplatin-Paclitaxel-Trastuzumab in Uterine Serous Carcinomas That Overexpress Human Epidermal Growth Factor Receptor 2/neu
10.1200_jco.2017.74.0720,JCO,2018,Oncology,Phase 2,Bayesian Adaptive Randomization Trial of Passive Scattering Proton Therapy and Intensity-Modulated Photon Radiotherapy for Locally Advanced Non-Small-Cell Lung Cancer
10.1200_jco.2017.75.6270,JCO,2018,Oncology,Phase 1,Durable Complete Response After Discontinuation of Pembrolizumab in Patients With Metastatic Melanoma
10.1200_jco.2017.75.7310,JCO,2018,Oncology,Phase 2,Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012
10.1200_jco.2017.74.9564,JCO,2018,Oncology,Phase 2,"HALO 202: Randomized Phase II Study of PEGPH20 Plus Nab-Paclitaxel/Gemcitabine Versus Nab-Paclitaxel/Gemcitabine in Patients With Untreated, Metastatic Pancreatic Ductal Adenocarcinoma"
10.1200_jco.2017.74.6651,JCO,2018,Oncology,Phase 3,"Randomized, Multicenter, Placebo-Controlled Clinical Trial of Duloxetine Versus Placebo for Aromatase Inhibitor-Associated Arthralgias in Early-Stage Breast Cancer: SWOG S1202"
10.1200_jco.2017.73.7585,JCO,2017,Oncology,Phase 3,MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy
10.1200_jco.2016.67.3061,JCO,2016,Oncology,Phase 3,Plasma ESR1 Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast Cancer
10.1200_jco.2015.64.8675,JCO,2016,Oncology,Phase 3,Adjuvant Tamoxifen Plus Ovarian Function Suppression Versus Tamoxifen Alone in Premenopausal Women With Early Breast Cancer: Patient-Reported Outcomes in the Suppression of Ovarian Function Trial
10.1200_jco.2015.64.0821,JCO,2016,Oncology,Phase 2,Randomized Trial of Hepatic Artery Embolization for Hepatocellular Carcinoma Using Doxorubicin-Eluting Microspheres Compared With Embolization With Microspheres Alone
10.1200_jco.2015.60.7465,JCO,2015,Oncology,Phase 2,"Randomized Multicenter Phase II Study of Modified  Docetaxel, Cisplatin, and Fluorouracil (DCF) Versus DCF  Plus Growth Factor Support in Patients With Metastatic  Gastric Adenocarcinoma: A Study of the US Gastric  Cancer Consortium"
10.1200_jco.2015.61.5831,JCO,2015,Oncology,Phase 3,Fulvestrant 500 mg Versus Anastrozole 1 mg for the First-Line Treatment of Advanced Breast Cancer: Overall Survival Analysis From the Phase II FIRST Study